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   CHAPTER 1 
General introduction
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General introduction  
Advances in treatment options for multiple sclerosis (MS) provide patients with new 
opportunities to delay disease progression. As the number of treatment options increases, 
choosing the right disease-modifying drug (DMD) for an individual patient, i.e. a DMD that 
fits with the patient’s preferences and needs, becomes more and more difficult. Therefore, 
there is a need for patients to be actively involved in their healthcare. This dissertation 
describes the development of a web-based patient decision aid for choosing the optimal 
DMD treatment – an aid to facilitate shared decision making between patients with MS and 
the healthcare professional. This chapter provides a general introduction into the topic. 
First, the pathology of MS and its different disease courses are described, followed by a 
description of the consequences of MS on patients’ health and quality of life. Second, 
pharmacological treatment options for MS management are explained, and the importance 
of appropriate long-term use of the treatments for patients’ health outcomes. Third, this 
chapter highlights the importance of incorporating preference-sensitive decisions into a 
shared decision making process for MS treatment, and how patient decision aids could 
support this process. Finally, the role of intervention appraisal for making decisions on 
policy with regard to the implementation of new interventions, such as patient decision 
aids, is explained. 
Burden of multiple sclerosis 
MS is a progressive disease of the central nervous system. The central nervous system, 
which includes an extensive and complex network of neurons, processes information 
obtained from sensory neurons and sends signals via motor neurons to impel action in the 
body. Signals are transmitted in neurons through axons, which often are covered with a 
myelin sheet to enable quick transmission of signals. In MS, inflammatory processes trigger 
demyelination of the neurons’ axons. As a consequence, lesions or plaques occur typically 
in the white and grey matter of the central nervous system. As disease duration increases, 
the ability of the myelin sheets to recuperate decreases, resulting in permanent damage to 
the central nervous system. Demyelination obstructs the efficient conduction of pulses 
across neurons, leading to all sorts of symptoms, such as impaired motor functions and 
cognitive capabilities, depending on the location of the lesions [1]. The cause of MS is still 
unknown, but genetic and environmental factors are believed to play a role [2].  
 
Four disease courses can be distinguished in MS [3]. About 89% of MS patients in the 
Netherlands have the relapsing-remitting (RRMS) disease course at on set [4]. RRMS is 
characterized by a recurrent pattern of relapses and remissions. A relapse is an exacerbation 
of MS symptoms, which can emerge slowly over time or more suddenly. A relapse can last 
from 24 hours up to a couple of months and is followed by a stable period, called remission. 
Depending on the disease severity, multiple relapses may occur, and the patient’s central 
nervous system may be less and less able to recover, resulting in an accumulation of 
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disabilities [3, 5]. The majority of patients with RRMS at onset will transition to secondary 
progressive MS (SPMS) over time. SPMS is characterized by progressive deterioration in 
abilities. If a progressive disease course has not been preceded by relapses and remissions, 
patients have primary progressive MS [3]. Clinically isolated syndrome (CIS) is considered 
the fourth disease course. CIS patients have experienced a single event resembling a relapse 
in MS, but have yet to meet the criteria of dissemination in time and in place for clinically 
definite MS [3, 6].  
  
Most recent numbers show that 2.3 million people are diagnosed with MS worldwide [4]. 
Prevalence is higher in North America, Europe and Australia. In the Netherlands, the 
prevalence is 88 per 100,000 people, representing about 15,000 Dutch people, and each 
year another 5 per 100,000 people will receive the diagnosis of MS [4]. More women than 
men are affected by MS, at a ratio of 2:1, and MS manifests itself most often in young 
adulthood [4]. Physical, cognitive or mental symptoms, such as impairment in mobility, in 
bladder function, sensory issues, fatigue, reduced information processing, memory 
impairment, and depression [7, 8], disrupt the person’s daily life and the ability to 
participate in social and occupational activities. This transpires in a time when people 
generally are establishing a life for themselves: making a career, establishing relationships 
and having children. MS patients’ quality of life is significantly reduced in comparison with 
that of healthy people, with most pronounced differences found in the physical domains 
and in patients’ social functioning [9]. Moreover, patients with MS have been reported to 
have an excess risk of mortality [10]. MS thus affects patients’ quantity of life and their 
quality of life at onset and in the following years, making it a considerable burdens for the 
patient and his/her social environment.  
 
Due to impaired physical, cognitive and social functioning, patients with MS need 
specialized healthcare and a considerable proportion of patients are less or not able to work 
[11-13], which contributes to a large economic burden. In the Netherlands, the healthcare 
cost of MS came to 206.8 million Euros in 2015, 45% of this was for hospital and specialist 
care and 35% for medication [14]. Severe MS is related with higher costs, including costs for 
the healthcare sector and for patients and their family [11, 13]. The average total costs per 
patient per year are €27,400 higher for patients with severe MS in comparison with mild 
MS, with the latter coming to an average of €23,100 total costs per year. This difference in 
costs is mainly driven by more use of community services and informal care [13]. A relapse 
in RRMS patients costs €2,977 due to increased use of medical care, informal care, 
consultations and investments [11]. Accordingly, reducing relapses and disease progression 
is important for reducing the burden of MS on people’s daily functioning, their quality of 
life and the societal expenditure.  
 
1
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Treatment options 
No cure is yet available for MS. Nevertheless several pharmacological and non-
pharmacological treatments, such as lifestyle interventions, rehabilitation and physical 
therapy, can manage MS symptoms. As from 1995, disease-modifying drugs (DMDs) have 
become available for the treatment of RRMS (Figure 1). The first DMDs to receive market 
authorization by the European Medicines Agency were interferons (interferon beta-1b, 
interferon beta-1a IM, interferon beta-1a SC) and glatiramer acetate [15]. These 
immunomodulators are aimed at decreasing the inflammatory processes that destroy the 
myelin sheets around the axons, and are administered by self-injection once or multiple 
times a week. These DMDs have shown to be effective in reducing the annualised relapse 
rate in RRMS patients ranging from a hazard ratio of 0.66 to 0.87 in comparison with placebo 
[16], and consequently reducing disease progression as fewer disabilities accumulate from 
the residual symptoms of relapses [16]. Aside from RRMS, these DMDs are also prescribed 
for the treatment of CIS and secondary progressive MS with ongoing relapse activity [15, 
17].  
 
In 2006, natalizumab was granted market authorization, which was the first 
immunosuppressant drug for RRMS, administered via intravenous infusion once per month. 
Natalizumab was found to be more effective than interferons and glatiramere acetate [16]. 
However, with the increase in the probability of reducing relapses came an increase in the 
risk of severely disabling or life-threatening side effects. Therefore, natalizumab is labelled 
for use only for those patients with highly active MS not responding to treatment with at 
least one of the other DMDs or for those patients with rapidly developing MS, and it is also 
classified as second-line treatment [17]. Interferons and glatiramer acetate were 
considered first-line treatments [17]. Each of these DMDs has their advantages and 
disadvantages: they have been shown to be only partially effective, have been associated 
with burdensome common or severe side effects, and/or have administration regimens 
generally considered burdensome by patients [18].  
 
Since 2011, the options for first-line and second-line treatment have been increasing 
rapidly. Orally administered DMDs (fingolimod, teriflunomide and dimethyl fumarate), 
other infusion-administered DMDs (alemtuzumab, cladribine and ocrelizumab) as well as 
one other self-injectable DMD with a decreased administration frequency in comparison 
with other injectable DMDs (peginterferon-1a) have become available, resulting in a total 
of twelve DMDs currently available in the Netherlands for RRMS (Figure 1).  
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Treatment options for MS are still fast evolving, with a number of new treatments in the 
pipeline for RRMS, but also specifically for the progressive MS courses [18, 19]. Recently, 
ocrelizumab has been authorized for the treatment of primary progressive MS (Figure 1). 
Moreover, new evidence is continuously becoming available about current DMDs, resulting 
in changes in the treatment mix. For example, daclizumab, authorized in 2016, was 
withdrawn in 2018 after post-authorisation evidence showed a serious risk of fatal immune 
reactions. Because of new insights into the risks of severe side effects, alemtuzumab has 
recently been classified as third-line DMD, only indicated for those patients with highly 
active MS not responding to at least two other DMDs or when treatment with any of the 
other DMDs is contra-indicated [17].  
Patients’ persistence and adherence to MS treatment 
DMD treatment requires long-term persistence and adherence for the DMD to have its 
optimal effects. Treatment persistence is defined as “the duration of time from initiation to 
discontinuation of therapy”, while adherence is defined as “the extent to which a patient 
acts in accordance with the prescribed interval, and dose of a dosing regimen” [20]. 
Treatment persistence and treatment adherence are, however, problematic. 
 
Retrospective and prospective real-world studies in MS show that reported discontinuation 
rates in the first year after initiating DMD treatment range between 12% and 32% for 
injectable DMDs [21-26] and 10% to 44% for orally administered DMDs [21, 24, 25, 27-35], 
and percentages increase as treatment duration increases [23, 36]. Of the people who 
persist with DMD treatment for up to one year, reported rates for optimal adherence range 
from 82% to 53% of patients [21, 22, 25, 31, 37, 38]. Non-adherence was found to be 
associated with higher relapse rates and more severe relapses [39]. Known reasons for 
discontinuation are a lack of efficacy [24, 32, 40, 41], intolerance of side effects or serious 
adverse events [24, 32, 33, 40, 41] and inconvenience [24, 40]. Forgetfulness [42-47], being 
tired of taking the drug or anxiety of self-injections [42, 43, 45-47], side effects [42, 43, 45, 
47], inconvenient dosing schedule that does not fit with daily life [42, 45, 47], the perception 
that not every dose is needed [43, 45] and treatment dissatisfaction [47] have been 
reported reasons for missing doses. Addressing reasons for discontinuation and non-
adherence before the patient starts using a DMD could improve persistence and adherence 
rates. This could be established by ensuring that the patient has realistic expectations 
regarding the effectiveness of the DMD and the burden of taking the treatment, and by 
supporting patients in choosing an appropriate DMD.  
Preference-sensitive treatment decision making 
Choosing a DMD for the treatment of RRMS is a preference-sensitive decision, meaning that 
there is no dominant choice in terms of effects and burden, and the choice may depend on 
what the patient prefers in the treatment. Although a patient’s eligibility for DMDs depends 
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on the clinical presentation of the disease and their response to earlier treatment, most 
patients have two or more options, including the option to not start a DMD treatment. 
DMDs differ from each other to lesser or greater extent according to a number of 
characteristics. Second-line DMDs are generally more effective than first-line DMDs, but 
also have less favourable risk profiles for serious adverse events. The administration 
regimen in terms of methods – i.e. injectable, orally or per intravenous infusion – and 
frequency, and the burden of common side effects can differ between DMDs as well. 
Therefore, characteristics of one DMD can be conflicting according to the preferences of a 
patient: a trade-off between the level of effectiveness, the risk of severe side effects, 
burden of common side effects, administration regimen and other characteristics needs to 
be considered. What is most important in the treatment decision may differ from patient 
to patient. Studies have shown that patients’ preferences for DMD characteristics can vary, 
for example in relation to prior experience with DMDs [48, 49], the degree of disability 
experienced [48], disease duration [49] and age [50].   
 
The importance of involving the patient’s preferences into the treatment decision is now 
widely recognized and has been highlighted in international recommendations for 
treatment of MS [51, 52]. Shared decision making is an approach to making healthcare 
decisions by involving the patient in the decision making process [53]. Shared decision 
making is defined as “an approach where clinicians and patients make decisions together 
using the best available evidence. Patients are encouraged to think about the available 
screening, treatment, or management options and the likely benefits and harms of each so 
that they can communicate their preferences and help select the best course of action for 
them” [53]. However, involving patients in shared decision making requires effort from both 
the physician and the patient.  
 
Patient decision aids are increasingly being used to support patients and physicians in 
achieving a shared decision. Patient decision aids contain information about treatment 
options and a value elicitation tool, and empower patients to be involved in a shared 
decision making process with their healthcare provider [54, 55]. Patient decision aids have 
been reported to positively influence decisional conflict, patients’ knowledge about 
treatment options, patient’s participation in decision making, and the match of patient’s 
preferences to treatment options (24). By developing informed preferences and choosing a 
treatment option aligned with these preferences, patients may have more realistic 
expectations of the chosen treatment, resulting in higher satisfaction and improved 
treatment adherence and persistence. Stalmeier theorizes that patient decision aids have – 
besides their primary aim of improving patient-physician communication, patient education 
and patient involvement in the decision for treatment – secondary effects for adherence by 
helping the patient to develop a more pronounced and persistent attitude towards the 
chosen treatment [56]. To date, evidence for the effect of a patient decision aid on 
persistence and adherence is limited [57], with only some studies finding results supporting 
1
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the effect of a patient decision aid on adherence in treatment and screening decisions other 
than for MS [58-60]. 
 
As patient decision aids inform the patient’s preferences and thus affect the treatment 
decision, the tool must be reliable and valid. Accordingly, the adequate development and 
quality of a patient decision aid is important. Working in a collaboration, expert researchers 
in the field of shared decision making and patient decision aid development have composed 
the International Patient Decision Aid Standards (IPDAS). The IPDAS provide a framework 
consisting of several stages (Figure 2) for user-centred development and testing of a patient 
decision aid. The initial steps are to define the scope of the patient decision aid and to 
establish a steering group consisting of experts, such as healthcare professionals, patients 
and experts in the development of patient decision aids. During the design steps of the 
patient decision aid, the first step is to elicit which information needs to be included for 
patients to participate in the decision making process. Both the patients’ and the healthcare 
professionals’ perspectives should be queried. Second, the format and the delivery of the 
patient decision aid should be planned. Third, the clinical evidence for the different 
treatment options should be reviewed and synthesized. Using the data collected in the 
previous steps, the fourth step is to develop a prototype of the patient decision aid. In the 
pilot testing a new patient decision aid, first, an alpha test should be conducted to assess 
the comprehensibility and usability. Second, in a beta pilot test, feasibility of 
implementation should be evaluated in a real-world setting by patients and healthcare 
professionals actually using the patient decision aid in clinical decision making. The aim of 
the IPDAS’ framework is to ensure the quality of patient decision aids and of the 
implementation of shared decision making supported by patient decision aids in clinical 
practice [61].  
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Figure 2. Steps for the systematic development of patient decision aids according to the 
International Patient Decision Aid Standards (IPDAS) in relation to the chapters of this 
dissertation. Figure adapted from Coulter et al. [61]. 
Patient decision aids for MS 
Reviews of patient decision aids for healthcare decisions [62] and information provision 
specifically for MS patients [63] identified only one study reporting on the evaluation of a 
German paper-based patient decision aid for DMDs for MS [64]. Three additional patient 
decision aids for DMDs for MS could be identified. These English patient decision aids focus 
either on just a part of the decision (whether to start DMD treatment or not) [65], consider 
only first-line treatment [66], or do not explicitly match the patient’s preferences with the 
available DMDs [67]. The recently published paper about a Canadian patient decision aid 
matching the patient’s preferences with the available first-line DMDs [66] suggests that 
1
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more prescriptive rather than descriptive patient decision aids could be appropriate in 
complex decisions with many options and many conflicting characteristics [68]. Instead of 
verbally describing the performance of treatment options and relying on an interpersonal 
process for weighting the treatment options according to their performance and according 
to the patient’s preferences, these prescriptive (or analytical) patient decision aids use 
numerical representations of the performance of treatment options for relevant 
characteristics. Similarly to the descriptive (or verbal) patient decision aids, the analytic 
patient decision aids elicit the patient’s preferences for the treatment characteristics, but 
also translates these preferences into a numerical weight. Ultimately, the analytic patient 
decision aid combines the numerical performances and the numerical weights to provide a 
ranking of treatment options best matching the patient’s preferences. In such a way, this 
type of patient decision aid provides another “opinion” which should be discussed during 
the patient’s consultation with the healthcare professional, and could thus be considered 
as being a more prescriptive approach in supporting the shared decision making process 
[68]. At the start of the project described in this thesis, such a prescriptive tool was not yet 
available, nor is such a tool available now for first-line and second-line DMDs or appropriate 
for the Dutch patient population. 
Economic appraisal of new interventions 
The implementation of shared decision making supported by a patient decision aid in clinical 
practice means investing healthcare budgets, but it has the possibility to limit future health 
costs because of improved health outcomes resulting from improved adherence and 
persistence. Due to limited healthcare budgets, policy makers need to decide whether the 
financial investment is worthwhile, considering the beneficial effects of implementing 
shared decision making supported by a patient decision aid. This is most important because 
funds can be spent only once. Accordingly, investing in shared decision making has 
opportunity costs, meaning that less or no funds might be available for implementation of 
other technologies. Through health technology assessment, a technology (an intervention 
in the broadest sense, for example a drug, medical device, public health program or patient 
decision aid) is appraised according to a number of aspects, such as safety, efficacy, 
feasibility, ethical consequences and cost-effectiveness. Assessing the cost-effectiveness of 
shared decision making means answering the question of whether the additional costs are 
acceptable in order to achieve the additional benefits of the intervention. Information 
about the cost-effectiveness of particular interventions plays an increasingly important role 
in reimbursement and implementation decisions [69]. 
Objectives of this thesis 
The aim of this thesis is two-fold. The first aim is to develop and user-test a patient decision 
aid about DMDs for MS to ultimately support shared decision making between the patient 
and her/his neurologist and MS nurse. The following specific objectives were addressed: 
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1. To assess which information about the DMD options is needed to make a 
treatment decision from the patients’ and healthcare professionals’ perspectives. 
2. To develop a prototype of the patient decision aid that incorporates the 
informational needs of the patient. 
3. To assess the comprehensibility, usability and acceptability of the patient decision 
aid with patients and healthcare professionals 
The second aim was to inform the design of web-based health services and research for MS 
and, specifically, the potential cost-effectiveness of shared decision making for MS. The 
following specific objectives were addressed:  
1. To evaluate whether shared decision making, whether or not supported by a 
patient decision aid, for DMDs for MS could potentially be cost-effective, and 
which parameters would most affect the cost-effectiveness.  
2. To evaluate whether a difference in frequency and length of questionnaires 
affects patients’ adherence to online self-assessment in direct-to-patient 
research. 
Outline of the thesis 
As the objective of this thesis was two-fold, the thesis is divided into two parts. 
 
Part I describes the studies conducted to systematically develop an online patient decision 
aid about DMDs for MS according to the six stages recommended by the IPDAS.  
 
Chapters 2 and 3 describe the assessment of informational needs in the decision about 
DMDs according to patients (Chapter 2) and according to healthcare professionals (Chapter 
3). In Chapter 2, after an initial exploratory phase of literature review and consultation with 
healthcare professionals, the characteristics of DMDs that need to be described in the 
patient decision aid for patients to make an informed decision are identified using focus 
groups, with a nominal group technique with patients. Chapter 3 describes how the relative 
importance of the DMD characteristics according to MS patients was quantified using a 
best-worst scaling survey. This survey was conducted with neurologists and MS nurses to 
assess the relative importance of DMD characteristics according to their experience. The 
perspectives of neurologists and nurses were compared with each other, and the overall 
healthcare professionals’ perspective was compared with the MS patients’ perspective to 
evaluate whether there were any discrepancies.  
 
Chapter 4 describes the entire systematic development of the patient decision aid for DMDs 
for MS. This chapter includes defining the scope of the patient decision aid, assessing the 
decisional needs, determining the format and delivery system of the patient decision aid, 
reviewing the literature for the best available evidence, developing the prototype and alpha 
pilot testing the prototype with patients and healthcare professionals in an iterative 
process.  
1
141878 Ingrid Kremer BNW.indd   17 19-02-20   09:49
C H A P T E R  1  
18 
 
Part II explores how web-based health services and research for MS can be optimized and 
the potential cost-effectiveness of shared decision making in MS.  
 
Chapter 5 evaluates the potential cost-effectiveness of shared decision making in DMDs for 
MS using a decision analytical modeling approach. A transition state model was developed 
to simulate the expected effect of shared decision making on treatment initiation, 
treatment persistence and treatment adherence, and the further consequences for health 
outcomes, quality-adjusted life years and costs. The study informs which parameters are of 
importance in assessing the cost-effectiveness of shared decision making and should be 
measured in further trial-based research.  
 
Chapter 6 investigates MS patients’ adherence to a self-assessment schedule with low-
frequency long questionnaires versus a high-frequency short questionnaire. In direct-to-
patient research, this study informs how self-assessment schedules could be designed to 
optimize patients’ response and minimize missing data.  
 
Finally, Chapter 7 provides a discussion of the main findings in this dissertation, as well as a 
discussion of the main methodological considerations of this thesis and implications for 
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Abstract  
Objectives. Understanding the preferences of patients with multiple sclerosis (MS) for 
disease-modifying drugs and involving these patients in clinical decision making can 
improve the concordance between medical decisions and patient values and may, 
subsequently, improve adherence to disease-modifying drugs. This study aims first to 
identify which characteristics - or attributes - of disease-modifying drugs influence patients’ 
decisions about these treatments and second to quantify the attributes' relative importance 
among patients. 
Methods. First, three focus groups of relapsing-remitting MS patients were formed to 
compile a preliminary list of attributes using a nominal group technique. Based on this 
qualitative research, a survey with several choice tasks (best-worst scaling) was developed 
to prioritize attributes, asking a larger patient group to choose the most and least important 
attributes. The attributes' mean relative importance scores (RIS) were calculated. 
Results. Nineteen patients reported 34 attributes during the focus groups and 185 patients 
evaluated the importance of the attributes in the survey. The effect on disease progression 
received the highest RIS (RIS = 9.64, 95% confidence interval: [9.48-9.81]), followed by 
quality of life (RIS = 9.21 [9.00-9.42]), relapse rate (RIS = 7.76 [7.39-8.13]), severity of side 
effects (RIS = 7.63 [7.33-7.94]) and relapse severity (RIS = 7.39 [7.06-7.73]). Subgroup 
analyses showed heterogeneity in preference of patients. For example, side effect related 
attributes were statistically more important for patients who had no experience in using 
disease-modifying drugs compared to experienced patients (p < .001).  
Conclusions. This study shows that, on average, patients valued effectiveness and 
unwanted effects as most important. Clinicians should be aware of the average preferences 
but also that attributes of disease-modifying drugs are valued differently by different 
patients. Person-centred clinical decision making would be needed and requires eliciting 
individual preferences. 
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Introduction 
Multiple sclerosis (MS) is a demyelinating and degenerative disease of the central nervous 
system causing physical and cognitive disabilities. MS occurs as different disease courses 
[1]. Relapsing-remitting MS (RRMS) is characterized by recurring exacerbations of MS 
symptoms (relapses) that recover partially or completely (remission) [1]. Between relapses, 
the disease remains stable. Progressive types of MS are characterized by a continuous 
increase in disability over time, either from the onset of MS (primary progressive MS) or 
conversion of RRMS to secondary progressive MS [1]. When a central nervous system 
demyelinating event has occurred that is isolated in time and compatible with the possible 
future development of MS, clinically isolated syndrome (CIS) is diagnosed [2]. Thirteen 
different disease-modifying drugs (DMDs) are currently available in the United States and 
in Europe to reduce the relapse rate and disease progression for patients with RRMS and 
new DMDs are still being developed. Some of these DMDs are also indicated for the 
treatment of CIS [3-5]. Adherence to DMD treatment is problematic, however, ranging from 
41% to 88% of doses taken as prescribed [6], and non-adherence is associated with an 
increased relapse rate [7]. 
DMDs differ in their effectiveness, unwanted effects and other characteristics or attributes 
[3, 5]. For patients diagnosed with RRMS or CIS, a decision needs to be made between the 
options the patient has, including the option of no DMD treatment. Decision making can be 
difficult because it requires comparing different DMD treatment options according to their 
specific characteristics or attributes.  
Patients with MS have been reported to prefer being actively involved in the decision 
making about DMDs [8]. Therefore, it is important to inform and involve patients in the 
decision to start or not start taking a DMD, and, in case of starting, it is important to choose 
the type of DMD that best suits the patient’s preferences and situation. In the shared 
decision making approach, the decision is made through a joint process between the 
physician and the patient. This entails informing the patient about treatment options and 
deliberation with the physician about which treatment would best fit the patient’s 
preferences [9]. Understanding which DMD attributes are important according to patients 
may therefore contribute to the tailoring of information for patients in clinical practice and 
may support the clinical decision making process. Effective support of the shared decision 
making process could improve patient satisfaction and treatment adherence [10]. 
Preference research is often used to elicit patients’ preferences for treatment options, i.e. 
to determine which attributes of the treatment options are important for patients in 
decision making. Patients are asked to state which treatment or treatment attribute they 
prefer in hypothetical trade-offs between two or more treatments or attributes [11]. Some 
preference studies have been conducted on MS patients’ preferences for DMD treatments 
[12-18] but, to the best of our knowledge, no study has attempted to identify among 
patients the full range of attributes of DMDs in general – regardless of the specific type or 
administration mode of the DMD – that may be of importance in decision making. 
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Therefore, important attributes of DMDs for decision making between all available DMDs 
may have been omitted in the exercises for prioritization of the attributes.  
The current study aimed to use thorough research methodologies for evaluating patients’ 
preferences for the full spectrum of DMD attributes that are of importance in the decision 
about DMD treatment. More specifically, the study’s objective was twofold. The first 
objective was to identify the range of DMD attributes that influence the decision from the 
patients’ perspective. The second objective was to quantify the relative importance of the 
identified attributes among a large group of patients. 
Methods 
Consecutive studies were conducted (Fig 1). First, an exploratory literature review and 
telephone interviews with healthcare professionals were performed to identify DMD 
attributes that may be of importance for decision making in DMD treatment. A full 
description of the methods used and results of this exploratory phase is provided in S1 and 
S2 (supplementary information). Next, patient focus groups using a nominal group 
technique were formed to identify attributes and to verify any additional attributes that 
were derived from the exploratory phase. A nominal group technique, as developed by 
Delbecq and Van de Ven [19, 20], is a structured method for guiding a group discussion to 
generate and prioritize ideas for a specific question. The RATS guideline [21] was used for 
reporting the methods and results of the nominal group technique, when appropriate. 
Finally, a best-worst scaling was conducted to prioritize the attributes according to a patient 
sample much larger than the number of patients that participated in the focus groups. A 
best-worst scaling is a specific method for conducting preference research. Respondents 
are asked to complete a series of choice tasks in which they have to choose the most and 
least important attributes from a selection of 4 or 5 attributes from a master list of 
attributes [22]. The advantage of the best-worst scaling over other stated preference 
research is the ability to acquire patients’ preferences for a large number of attributes, 
regardless of the levels of the attributes. As the best-worst scaling was administered online, 
design and results of the best-worst scaling were presented according to the Checklist for 
Reporting Results of Internet E-Surveys [23]. The protocols of both the focus groups and the 
best-worst scaling were submitted to the Medical Ethics Committee of the Academic 
Hospital Maastricht and Maastricht University, the Netherlands (nr. 14-4-172). The 
committee concluded that the study did not qualify for a review according to the Dutch 
Medical Research Involving Human Subjects Act of 1998 and provided a positive decision 
for conducting the study. The study was performed in agreement with the ethical standards 
laid down in the 1964 Declaration of Helsinki and its later amendments. All participants gave 
their written informed consent before participating in the studies. 
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Figure 1. Consecutive process of studies 
Patient population  
Both for the focus groups with nominal group technique and the survey with the best-worst 
scaling, patients were considered eligible for participation if they were diagnosed with 
RRMS or CIS, were 18 years or older, and were willing and able to participate. For the focus 
groups an additional criterion was that the participant had experience with making a 
decision about DMD treatment or had experience with taking DMDs. Potential participants 
were recruited through advertisements on websites, social media or mailing lists of MS 
patient organizations.  
Patients interested in participating in the focus groups were asked to contact one of the 
researchers (I.K.) by phone or e-mail. Based on the respondents’ place of residence, three 
locations dispersed over the Netherlands were selected: a hospital in Nijmegen (the eastern 
part of the Netherlands) and community centres in Nieuwegein (the middle of the 
Netherlands) and Roermond (the southern part of the Netherlands). Patients who fulfilled 
the inclusion criteria and were able to travel to one of the selected locations were sent an 
information leaflet about the study and a consent form by mail. After a week, the patients 
were contacted by the first author to answer any of their questions and to register their 
participation. After participation in the focus group, each respondent received a 50 Euro gift 
card to compensate for any travel expenses and the time invested. Patients willing to 
participate in the best-worst scaling were redirected to the online questionnaire by means 
of a link in the advertisement or in the e-mail. After providing information about the 
purpose and content of the survey, the patients were informed that by filling out the 
questionnaire, they gave consent to the use of their answers in the study. To prevent the 
same person filling out multiple questionnaires, cookies were placed on their browser when 
they submitted their questionnaire. The recruitment method did not allow us to identify 
which patients did not choose to participate in the best-worst scaling or the focus groups. 
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Focus group with nominal group technique 
Design 
Focus groups were performed by applying the nominal group technique. The structured 
method of a nominal group technique ensures that every participant’s perspective is 
included and allows for differences in perspectives [19, 20]. A nominal group technique is 
therefore particularly suitable for identifying the full range of important DMD attributes and 
has already been used in other studies, e.g. to identify attributes of osteoporotic 
medications [24]. Two researchers were present at each focus group to facilitate the group 
discussion (IK) and to take notes (IvdK). The nominal group technique consisted of four 
steps. First, the participants were asked to individually answer the following question: 
“What characteristics of DMDs do you feel are important to consider when having to make 
a decision about DMD treatment?” Second, the participants took turns in reporting 
attributes until all attributes generated were written down on a flip-over by the facilitator. 
This ensured that every participant’s opinion was elicited, and that they participated in the 
discussion. Third, the discussion was intended to come to an agreement within the group 
about the meaning and scope of each attribute. The participant that reported the attribute 
often provided the first description. Other participants were given the opportunity to react 
to this description. If the descriptions were different or had a broad scope an attribute was 
split into multiple attributes. If multiple attributes were similar in their meaning, these 
attributes were combined. This was done upon agreement of the participants. In the second 
and third focus group, the discussion was followed by asking for the participants’ opinions 
about any additional attributes derived from the exploratory phase and whether these 
attributes should be included. Participants were entirely free to accept or reject the 
additional attributes. In the final step of each nominal group technique, participants were 
asked to select the 10 most important attributes from the list of attributes compiled and 
rank the top 5. After the third focus group, it was checked whether data saturation had been 
reached, i.e. whether any new attributes emerged that had not already been derived from 
the previous focus groups or the exploratory phase. Responses during the nominal group 
technique were recorded on audio tape so that attribute descriptions could be transcribed 
correctly and these tapes were erased afterwards. The anonymity of the respondents was 
ensured in the transcriptions.  
Analyses 
An overall list of important DMD attributes for decision making according to patients was 
created by comparing the attribute definitions from the three groups to each other. If from 
the transcripts of the discussions it appeared that attributes had similar descriptions across 
the focus groups, then these attributes were combined. The frequency with which 
participants included the attributes in their top 10 and top 5 was calculated. The attributes 
in the top 5 were awarded points, from 5 points for the most important attribute to 1 point 
for the least important one. Per attribute, the mean importance score was calculated by 
dividing the total points awarded per attribute by the total number of patients participating 
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in all focus groups. Based on the mean importance score and calculated frequencies, an 
initial ranking of attributes was made from most to least important. Attributes that were 
not included in any of the participants’ top 10 of most important attributes were excluded 
from the best-worst scaling. 
Best-worst scaling
Design
Based on the results of the focus groups, a best-worst scaling was developed and converted 
to an online questionnaire of 3 pages with 6 questions each, and also contained 2 pages 
with 4 or 5 questions about the respondent’s demographic and disease characteristics. All 
questions had to be filled out before the respondents could proceed to the next page or 
submit the questionnaire, but respondents were able to go back to change their answers 
before submission. A “don’t know” option was provided for the appropriate demographic 
questions. Responses were registered automatically. No data were collected that could be 
referred back to the identity of the respondent (e.g. IP-address). The best-worst scaling 
consisted of 17 unique choice tasks. Each choice task presented five attributes of the full 
attribute list as derived from the focus groups. Each respondent was asked to select the 
most and least important attributes for decision making about DMD treatment. The 
attributes selected by the respondent represent the attributes that are furthest apart on 
the importance scale for the individual patient [22]. Additionally, patients were provided 
the opportunity to list any important DMD attributes that in their opinion were not included 
in the best-worst scaling. Fig 2 provides an example of a choice task. 
Figure 2. Example of a choice task in the best-worst scaling
A fractional design was created for the best-worst scaling with Sawtooth SSI Web version 
8.2.0. This software creates the most efficient design, characterized by orthogonality (the 
frequency of an attribute paired with other attributes is equal for all attributes), balance 
(the frequency of attributes occurring in the best-worst scaling is equal), and positional 
frequency (the frequency of attributes on the 1st to 5th position in the choice task is equal) 
and determines which attributes are presented to the respondent in each choice task. Four 
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best-worst scaling versions were created. Each attribute was presented 12 or 13 times, was 
combined at least once with every other attribute and appeared 2 to 4 times in each 
position in the choice tasks. Respondents randomly received 1 of the 4 best-worst scaling 
versions. The questionnaire was pilot-tested among researchers (N=3) and MS patients 
(N=3) prior to the start of the study, which resulted in minor revisions of the instructions. 
The questionnaire was not found to be too cognitively burdensome to patients. 
 
Analyses 
Questionnaires were filled out from 12 May 2015 to 5 June 2015. Only completed best-
worst scaling questionnaires were included in the analyses. Descriptive statistics were used 
to present demographic and disease characteristics of the respondents. Hierarchical Bayes 
analysis was performed with Sawtooth SSI Web version 8.2.0 to estimate the mean relative 
importance score per attribute. The raw score, which was obtained with an iterative process 
of estimating individual utility scores based on the sample means, was rescaled to a 
probability score on a ratio scale. This score represents the attribute’s relative importance 
for decision making about DMD treatment according to the respondent. The relative 
importance scores of all attributes combined for an individual respondent sum up to 100 
[25]. A mean overall relative importance score was calculated per attribute with its 95% 
confidence interval. Based on the mean scores, attributes were ranked from most to least 
important for decision making in DMD treatment. Attributes with a score of 3.7 were 
regarded as of average importance (100 points divided by 27 attributes). In lack of 
consensus on the minimal important difference in relative importance scores, if confidence 
intervals of two consecutive ranked attributes did not overlap, we considered them to be 
of different importance in the decision about DMDs.  
The quality of the responses was checked based on the individual’s fit statistic, i.e. if 
responses had a fit statistic below 0.247, these were excluded from analyses because this 
indicates purely random responses to the choice tasks [26]. Subgroup analyses on gender, 
age, education, disease duration, relapse rate, experience with DMD, and current and prior 
DMDs taken were conducted to explore whether patients’ preferences for DMD attributes 
differ according to demographic characteristics, disease characteristics or DMD experience. 
Subgroups for continuous data (age, disease duration) were made according to the median. 
For categorical data, subgroups were made based on relevance for comparison (e.g. DMD-
naive vs. DMD-experienced). Difference in importance scores between subgroups were 
statistically tested with an independent t-test for parametric data and the Mann-Whitney 
test for non-parametric data using SPSS for Windows version 20. An alpha of .05 and a 
Bonferroni-adjusted alpha of .0019 (for 27 comparisons) were used to assess whether 
differences in RIS of attributes between subgroups were statistically significant. 
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Table 1 presents the characteristics of the patients that participated in the focus groups and 
the best-worst scaling. Three focus groups with a total of 19 RRMS patients took place. Each 
group consisted of male and female participants ranging in age, educational level and 
experience with DMD use. Age was approximately normally distributed with a mean of 46.8 
(±8.8) years old. Thirteen (68.4%) patients had prior experience with making a decision 
about DMDs and six (31.6%) were considering or reconsidering their DMD options at the 
time of the focus groups.  
Of the 286 people who accessed the survey via the provided link, 193 respondents (67.5%) 
started the best-worst scaling exercise and met the inclusion criteria. Of these respondents, 
185 people (95.9%) completed the best-worst scaling exercise. The majority of the 
respondents who completed the best-worst scaling exercise were female (86.5%); this is 
somewhat higher than the Dutch MS population of 72% [27]. Of the respondents, 54.1% 
had completed a higher vocational education or university education. Mean age was 42.1 
(±9.6) years, which was approximately normally distributed, and almost all patients 
reported a diagnosis of RRMS (98.4%). Twenty-seven (14.6%) patients reported having no 
experience with using DMDs and 131 (70.8%) respondents were currently taking a DMD. 
Focus group with nominal group technique 
Data saturation was reached in the third focus group because no new attributes emerged. 
Combining the attribute lists from the three focus groups resulted in 34 DMD attributes 
that, according to the patients, were important in decision making about DMD treatment. 
Based on the mean importance scores, participants in the focus groups regarded the type 
of side effects as most important, followed by effect on disease progression, method of 
administration, effect on relapse rate, safety and insurance coverage. Seven attributes were 
not included in the top 10 by any of the participants (adherence rate, availability of the DMD 
in the Netherlands, brand recognition, issuance of DMD, wash-out requirements, shelf life 
and legal liability). For descriptions of all DMD attributes, their ranking and mean 
importance scores, we refer to the data in S3 (supplementary information). 
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Table 1. Patient characteristics: nominal group technique (N=19) and best-worst scaling 
(N=185) 





Women n (%)  15 (78.9) 160 (86.5) 
Age, mean ± SD (years)  46.8 ± 8.8 42.1 ± 9.6 
Educational level n (%)    
 Lower 7 (36.8) 72 (38.9) 
 Higher 12 (63.2) 113 (61.1) 
Employed    
 Yes 8 (42.1%) 90 (48.6%) 
 No 11 (57.9%) 95 (51.4%) 
Diagnosis    
 RRMS n (%) 19 (100) 182 (98.4) 
 CIS n (%) 0 (0) 3 (1.6) 
Duration of diagnosis, mean ± SD (years)  9.5 ± 8.4 6.4 ± 5.9 
Relapse rate previous year, n (%)   (N=17) (N=172) 
 0 7 (41.2) 63 (36.6) 
  10 (58.8) 109 (63.4) 
Currently taking DMD n (%)  15 (78.9) 131 (70.8) 
Previously taken DMD n (%)  10 (52.6) 86 (46.5) 
Number of prior taken DMD n (%)  (N=19) (N=184) 
 1 6 (31.6) 43 (23.4) 
 2 2 (10.5) 35 (19.0) 
 3 2 (10.5) 5 (2.7) 
 4 0 (0) 3 (1.6) 
CIS, clinically isolated syndrome; DMD, disease-modifying drug; RRMS, relapsing-remitting multiple sclerosis; SD, 
standard deviation. 
Best-worst scaling 
The best-worst scaling survey included 27 attributes. From the list of 34 attributes identified 
in the focus groups, seven attributes were excluded because they were not included in the 
top 10 by any of the participants in the focus groups. All respondents had a fit statistic higher 
than 0.247 and were therefore all included in the analysis. Hierarchical Bayes analysis 
showed that attributes related to effectiveness and unwanted effects were most important 
for decision making according to patients. Table 2 presents the group average relative 
importance scores of all 27 attributes with their 95% confidence intervals ranked from most 
to least important for decision making in DMD treatment. The effect on disease progression 
was ranked as the most important attribute with a RIS of 9.6 (95% CI 9.5 – 9.8). The effect 
on quality of life, defined as the overall increase in the well-being of a patient as a result of 
the DMD, was ranked second (RIS 9.2; 95% CI 9.0 – 9.4), followed by effect on the relapse 
rate (RIS 7.8; 95% CI 7.4 – 8.1), and severity of side effects (RIS 7.6; 95% CI 7.3 – 7.9). The 
severity of side effects scored higher than safety issues, i.e. common side effects were found 
to be of more influence on the treatment decision than risks of life threatening or severely 
disabling consequences. The most important attribute not related to beneficial or 
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unwanted effects was influence on life style (RIS 5.3; 95% CI 4.9 – 5.7) but this attribute was 
only half as important as the number one ranked attribute, effect on disease progression. 
Other convenience issues with taking DMDs were valued far less: the RIS for administration 
method, administration frequency and required monitoring were 1.6 (95% CI 1.2 – 2.0), 0.7 
(95% CI 0.5 – 0.9) and 0.6 (95% CI 0.4 – 0.7) respectively. Rankings of attributes as derived 
from the focus groups deviate from these results. The convenience issues mentioned 
previously were all ranked in the top 10, while the effect on quality of life, plaque 
development and severity of side effects were of less importance. 
One MS patient reported “effect of the DMD on pregnancy or child” as an additional 
attribute that was not already included in the best-worst scaling. Other attributes that were 
reported, such as effect of the DMD on mental well-being and family members, and feelings 
of depression or anxiety, were captured in or had considerable overlap with other 
attributes.  
Subgroup analyses showed deviations from the overall importance scores for patients with 
certain characteristics. As is presented in Fig 3, patients who had never used a DMD (n=27) 
valued duration, type and severity of side effects significantly higher than did patients who 
had DMD experience (n=157) (respectively U=946, z=-4.59, p<.001; t (182) =4.36, p<.001; 
U=863, z=-4.92, p<.001). The patients in this last group had higher relative importance 
scores for the effectiveness of the DMD on the relapse rate, relapse severity, plaque 
development and life expectancy compared with DMD-naive patients (respectively U=1196, 
z=-3.61, p<.001; U=1312, z=-3.16, p=.001; U=1585, z=-2.09, p=.038; U=1549, z=-2.23, 
p=.026). For attributes of which the relative importance score did not significantly differ 
between DMD-naive and DMD-experienced patients, the results of the analyses are 
provided in S4 (supplementary information). 
Similar differences in the importance of attributes were found for patients who were not 
using a DMD at the time of survey administration (n=54) in comparison with patients using 
a DMD (n=131): attributes concerning effectiveness were more important in the decision 
for patients currently using a DMD, while patients who were not using a DMD valued 
attributes related to unwanted effects significantly higher. Although ranked only 16th, the 
administration method was more important for patients taking orally administered DMDs 
(mean RIS=2.5; 95% CI 1.6, 3.4) in comparison with patients taking parenteral 
(intramuscular, subcutaneous or intravenous) DMDs (mean RIS=1.0; 95% CI 0.6, 1.5), which 
was a significant difference (U=1416, z=-3.28, p=.001). The safety of the DMD was 
significantly more important for patients with a diagnosis of MS longer than 4.6 years 
compared to patients with shorter disease durations (U=3174, z=-3.03, p=.001). Male 
patients were significantly more concerned about the influence of DMD use on lifestyle and 
with the effect on life expectancy in comparison with female patients (U=1366, z=-2.55, 
p=.011; U=1468, z=-2.14, p=.032). No significant differences  were found in the importance 
scores of attributes of higher and lower educated patients. Results of all subgroup analyses 
are provided in S5 Figures. 
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Table 2. Group average relative importance scores of attributes in decision making as 








Effect on disease progression 9.64 9.48 9.81 
Effect on quality of life 9.21 9.00 9.42 
Effect on relapse rate 7.76 7.39 8.13 
Severity of side effects 7.63 7.33 7.94 
Effect on the severity of relapses 7.39 7.06 7.73 
Effect on current MS symptoms 7.32 7.03 7.60 
Effect on plaque development in the brain 7.31 6.94 7.67 
Safety 6.04 5.62 6.47 
Influence on lifestyle 5.31 4.88 5.73 
Type of side effects 5.00 4.60 5.39 
Effect on life expectancy 4.81 4.36 5.27 
Uncertainty about long-term consequences  4.58 4.18 4.98 
Duration of side effects 3.74 3.45 4.02 
Pace of effect 3.18 2.87 3.50 
Insurance coverage 2.71 2.29 3.12 
Interaction with other medication 1.72 1.46 1.99 
Method of administration 1.58 1.19 1.97 
Mode of action of DMD  0.99 0.81 1.17 
Further development of DMD 0.87 0.73 1.00 
Total DMD costs 0.86 0.68 1.04 
Frequency of administration 0.68 0.48 0.88 
Required monitoring 0.55 0.38 0.72 
Use of DMD among other MS patients 0.34 0.26 0.42 
Ease of travelling 0.29 0.17 0.42 
Duration of administration 0.20 0.17 0.24 
Composition of DMD 0.18 0.13 0.23 
Contact person at pharmaceutical company 0.10 0.06 0.14 
CI, confidence interval; DMD, disease-modifying drug; RIS, relative importance score. 
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Discussion 
The current study aimed to identify the full spectrum of DMD attributes and to quantify 
their relative importance in decision making about DMD treatment according to RRMS and 
CIS patients. Patients reported a total of 34 different attributes that might influence their 
decision. Quantification of the relative importance showed that, as a group, patients place 
the most emphasis on benefits – especially disease progression and quality of life – and on 
unwanted effects when having to make a decision in DMD treatment, rather than usability 
issues. The ranking of the attributes showed that the most important attributes are 
comparable to the attributes used in other stated preference research [12-18]. Preventing 
disease progression was found in previous preference research to be an important attribute 
of DMDs [12-18] but quality of life has not yet been reported in these studies. The effect on 
quality of life – the increase or decrease in the overall well-being of a patient as a result of 
the DMD – could be interpreted as a summarizing attribute, incorporating the DMD’s 
beneficial effects and burdens into one attribute. This could explain its importance for 
patients. However, data from high quality randomized controlled trials on the effects of 
DMDs on quality of life are lacking for DMDs that have been available for the treatment of 
MS for some time now. It is encouraging that new RCTs and many observational studies are 
including quality of life as an outcome measure, since the effect of the DMD on quality of 
life is regarded as important information by the patients.  
Regarding unwanted effects, the severity of non-life threatening physical and psychological 
side effects – essentially, the extent to which these side effects outweigh the desire to treat 
MS – was found to be the most influential attribute in decision making. This is in contrast to 
the results from the most comprehensive study about preferences for DMD attributes 
conducted among a large number of RRMS patients, which found life-threatening or 
severely disabling side effects to be the most important attribute and minor side effects to 
be the least important [17]. However, this study included four levels for life-threatening side 
effects denoted as risk of death or becoming severely disabled (0 out of 1,000; 0.5 out of 
1,000; 1 out of 1,000; or 10 out of 1,000), while common side effects were split into three 
levels of types of common side effects (headaches and muscle or joint aches; increased risks 
of infection; and mood changes). Our study did not include levels, and therefore these could 
not influence how patients valued the attributes, perhaps explaining the differences 
between the two studies’ findings. 
Noteworthy are the relatively low ranking and importance scores of administration method 
and administration frequency, ranked 17th and 21st respectively, as derived from the best-
worst scaling, while in the literature these attributes were found to be of substantial 
importance in decision making among MS patients [17, 28, 29]. Attributes that were valued 
more highly than mode and frequency of administration by patients in our study, such as 
insurance coverage, total costs, continuous development of the DMD and interaction with 
other medication, were not included in other studies. Moreover, influence on lifestyle was 
valued relatively highly in our study. Although it was described to patients as “the extent to 
which a patient’s habits or lifestyle have to be adjusted for proper use of the medication, 
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such as the flexibility in time of administration, restrictions on consuming alcohol, driving, 
sports, work, etc.”, patients may have also included administration method and frequency 
in this attribute, resulting in a higher ranking in comparison with administration method 
and frequency.  
Subgroup analyses showed heterogeneity in preferences of patients according to different 
characteristics. For example, attributes related to unwanted effects were stated to be more 
influential in decision making by patients with no prior DMD experience in comparison with 
patients who had experience with DMD use. These findings reinforce the individuality of 
preferences and the need to incorporate the individual’s perspective into the clinical 
decision making process. It underlines the need for shared decision making, as this approach 
is focused on supporting patients in developing informed preferences based on objective 
information [30].  
By investigating patients’ preferences about DMD attributes, our study may help to identify 
which information patients need about DMDs in order to make an informed decision, 
therefore enabling clinicians to adjust their information provision accordingly to facilitate 
the process of shared decision making and to support the development of informed 
preferences in patients. However, clinicians should also take into account that the study 
results provide guidance for the average patient. As heterogeneity in the results show, 
different patients could find different attributes of DMDs important for decision making. 
Therefore, clinicians should inform each patient who wants to be involved in the decision 
making about the pros and cons per option based on the patient’s personal preferences. As 
a result, clinicians should support the patient to elicit what is important to him or her and 
adjust the consultation accordingly, i.e. incorporate the patient’s preference in the decision 
or delay decision making and empower the patient with a patient decision aid. A patient 
decision aid contains concise summaries of the evidence on important attributes of the 
treatment options and includes a preference clarification method to assess what attributes 
of the treatment options are of importance for the individual patient. A decision aid could 
therefore support the shared decision making process in clinical practice [31]. The results 
of the current study will inform the development of such a decision aid for MS patients who 
need to make a decision about DMD treatment.  
A strength of our study is the thorough methodology of a nominal group technique followed 
by a best-worst scaling used for identification and prioritization of attributes. Using focus 
groups with a nominal group technique ensured the direct elicitation of patients’ 
perspectives on all important DMD attributes for decision making, whereas prior preference 
studies focused only on a selection of attributes and/or relied on literature review and 
consultations with clinical experts for identification of attributes. Comparing attribute 
rankings from the nominal group technique and the best-worst scaling, there were 
considerable differences. Although data saturation was achieved in the identification of 
DMD attributes in the nominal group technique, we did not aim for data saturation in the 
ranking of the attributes. Due to variation in the attributes reported per nominal group 
technique, not all 34 attributes were included in the rankings of each focus group, resulting 
in lower validity of the overall ranking in the nominal group technique. In addition, the 
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ranking in the nominal group technique was established after an interactive process of 
participants discussing the attributes and possibly influencing each other’s opinion in 
comparison to the best-worst scaling in which respondents filled out the survey by 
themselves. The differences in rankings emphasize the importance of using a quantitative 
method such as a best-worst scaling for prioritization of the attributes, in addition to 
qualitative work on identifying attributes.  
Some limitations should be taken into account with the interpretation of the results. We 
used patient-centred methodologies for identifying the attributes. However, we cannot 
exclude that attributes important for some patients were not included in the study. In the 
best-worst scaling, one patient reported an additional attribute to be important: the effect 
of the DMD during pregnancy on the unborn child. Although it is generally recommended 
to discontinue DMD treatment before trying to conceive, treatment with certain DMDs can 
be continued in case of highly active MS [32-36]. Moreover, during DMD treatment patients 
may become pregnant inadvertently. A possible reason for omission of this attribute in the 
best-worst scaling may be that the 19 patients questioned in the focus groups and the six 
healthcare professionals questioned by interview regarded these risks inherent to safety or 
side effects. Another reason for omission by the patients in the focus groups may be that 
they already had children or stopped thinking about having children as the average age of 
patients in the focus groups was 46.8 years (SD 8.8), meaning that 68% of patients were 
between 38.0 and 55.6 years old and ranging from 30 to 68 years old. Actually, only 2 out 
of 15 women in the focus groups were between 30 and 35 years of age, the other being 
older. Thus, the number of women in child-bearing age was relatively low, which could 
explain the omission of the attribute regarding pregnancy risks. Furthermore, to be able to 
include a large number of attributes, the best-worst scaling did not include attribute levels. 
The importance scores therefore present the patients’ preferences for attributes of DMDs 
in general; preferences for a specific DMD with a certain attribute level may deviate from 
the scores obtained in this study. Additionally, although the recruitment method enabled 
the inclusion of RRMS and CIS patients from all regions of the Netherlands, the samples for 
the focus groups and the best-worst scaling contained a relatively high proportion of 
women, older participants and more highly educated participants in comparison with the 
average MS patient population in the Netherlands [37] and may contain patients who are 
more involved in their disease management due to our recruitment method via websites 
and mailing lists of patient organizations. Patients may therefore have a better 
understanding of what the benefits and risks entail and this could influence the 
generalizability of the results. Differences were found between men and women in 
importance of attributes, but subgroup analyses revealed no major difference according to 
age and level of education of the patient. Moreover, our recruitment method did not enable 
us to collect data from medical records, and therefore diagnosis, disease duration, relapses 
experienced and DMD history were self-reported by patients. This may have resulted in 
incorrect reporting of medical and sociodemographic characteristics. In addition, the 
transferability of our findings to other settings could be uncertain since the health care 
system and practice could potentially impact the importance of some attributes, For 
141878 Ingrid Kremer BNW.indd   40 19-02-20   09:49
I M P O R T A N T  A T T R I B U T E S  O F  D I S E A S E - M O D I F Y I N G  D R U G S  I N  D E C I S I O N  M A K I N G  
41 
example, we could expect that the total DMD costs would be more important in countries 
where patients have out-of-pocket contributions. Lastly, the subgroup analyses had an 
exploratory purpose. We did not aim to recruit a minimum number of patients for each 
subgroup. Therefore, the difference in importance of attributes according to the subgroups 
should be interpreted with caution. 
In conclusion, this study shows that patients with RRMS and CIS find beneficial and 
unwanted effects to be the most important DMD attributes in making decisions about DMD 
treatment, more important than usability issues with taking the DMD. The effect on disease 
progression and quality of life were the most important attributes. However, this study also 
recognizes the heterogeneity in preferences of patients. When having to make a decision 
about DMD treatment, clinicians should be aware of what the average patient finds 
important and incorporate information on these attributes in the education for the shared 
decision making process. However, person-centred clinical decision making requires 
eliciting the individual patient’s preferences for DMD treatment at the point of the decision.  
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Supplementary information  
S1. Exploratory phase: literature review 
Methods 
A literature search was conducted to identify any articles reporting on attributes of DMDs 
that are of importance for decision making in DMD treatment from a patient’s or healthcare 
provider’s perspective. Any articles (quantitative and qualitative research, expert opinions) 
or abstracts were included in this review that reported on DMD attributes for decision 
making from a RRMS or CIS patient’s or healthcare provider’s perspective. Three search 
strings were entered in PubMed, EMBASE and PsycINFO, and were searched from 
November 2004 until November 2014. The search was restricted to articles reported in 
English, Dutch, German and French. Figure 1 provides the search strings for PubMed. 
Additionally, abstracts from conferences on MS (CMSC ACTRIMS Annual Meetings, Joint 
ACTRIMS-ECTRIMS meeting) and shared decision making (Society for Medical Decision 
Making, International Shared Decision Making Conference) were searched up to 1 year 
(November 2013 until November 2014). Selection of articles was conducted by 
consecutively assessing the relevance according to title, abstract and full text. Reference 
lists of identified articles were searched for any additional articles that match the inclusion 
criteria. DMD attributes that were reported as being of importance for patients, 
neurologists and/or MS nurses in the decision making process about DMD treatment for MS 
were combined into a list with a description of the attribute, if provided. The list was 
completed with attributes included in DMD decision aids for MS known to the authors and 
studies on reasons for DMD non-adherence in MS patients.  
Results 
The electronic search and reference check resulted in 1,213 unique articles. Selection of 
relevant articles on preferences for DMD attributes based on title and/or abstract resulted 
in the exclusion of 1,143 articles. Of the 70 remaining articles, 55 articles were excluded 
because they did not focus on patients’ or healthcare providers’ preferences for DMD 
attributes for treatment of RRMS or CIS or because of the study design. Fifteen references 
were considered relevant for this review. Full articles (n=10) as well as abstracts (n=5) 
reporting important DMD attributes for decision making were included. The results of the 
selection procedure are presented in figure 2. Of the 15 studies, 2 were qualitative [1, 2] 
and were 2 expert opinions [3, 4]. Out of the quantitative studies, 6 were conjoint analysis 
[5-10] and 5 were surveys [11-15]. Most articles reported attributes from the patients’ 
perspective. Only 3 articles were found about the healthcare providers’ perspective [3, 4, 
13]. 
In total, 19 attributes were found. Three main categories of attributes could be identified, 
each consisting of multiple attributes: attributes related to benefits of DMDs, attributes 
related to unwanted effects of DMDs, and attributes related to ease of use of DMDs. A 
2
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fourth category “others” consisted of treatment adherence, composition of DMDs and cost. 
The attributes derived from the 15 articles were compared with attributes from existing MS 
decision aids [16-18] and a selection of studies focusing on patients’ reasons for non-
adherence [19-21] to evaluate whether major attributes were missing. One attribute, 
“impact on daily life”, was added. Table 1 presents all 20 attributes and a summary of any 
provided descriptions in the literature. 
 
Search string 1.  
multiple sclerosis [MeSH] OR multiple sclerosis, relapsing-remitting [MeSH] OR multiple  
sclerosis[tiab] OR ms[tiab] OR clinically isolated syndrome[tiab] OR cis[tiab] 
AND 
patient preference[MeSH] OR preference[tiab] OR preferences[tiab] OR 
perspective[tiab]OR perspectives[tiab] OR desire[tiab]OR desires[tiab]OR view[tiab]OR 
views[tiab]viewpoint[tiab]OR attitude[tiab] OR attitudes[tiab] OR decision[tiab]OR 
decisions[tiab]patient value[tiab] OR patient value[tiab] OR patients values[tiab] OR 
patients values[tiab]OR physician value[tiab] OR physician values[tiab]OR physicians 
value[tiab] OR physicians values[tiab]OR nurse value[tiab] OR nurse values[tiab]OR nurses 
value[tiab] OR nurses values[tiab] 
AND 
Immunosuppressive agents[MeSH] OR immunotherapy[MeSH] OR disease modif*[tw] OR 
immunosuppress*[tw] OR immunomodulat*[tw] OR immunotherap*[tw]  
 
Search string 2.  
multiple sclerosis [Mesh] OR multiple sclerosis, relapsing-remitting [Mesh] OR multiple  
sclerosis[tiab] OR ms[tiab] OR relapsing remitting multiple sclerosis[tiab] OR remitting-
relapsing multiple sclerosis[tiab] OR Clinically isolated syndrome[tiab] OR cis[tiab] 
AND 
Immunosuppressive agents[MeSH] OR immunotherapy[MeSH] OR disease modif*[tw] OR 
immunosuppress*[tw] OR immunomodulat*[tw] OR immunotherap*[tw] 
AND  
decision support techniques [MeSH] OR decision making, computer-assisted [MeSH] OR 
decision support*[tiab] OR decision aid*[tiab] OR decision tool*[tiab] OR decision 
instrument*[tiab] OR decision technolog*[tiab] OR decision technique*[tiab] OR decision 
system*[tiab] OR decision program*[tiab] OR decision algorithm*[tiab] OR decision 
method*[tiab] OR decision intervention*[tiab] OR decision material [tiab] 
 
Search string 3. 
multiple sclerosis [Mesh] OR multiple sclerosis, relapsing-remitting [Mesh] OR multiple  
sclerosis[tiab] OR ms[tiab] OR relapsing remitting multiple sclerosis[tiab] OR remitting-
relapsing multiple sclerosis[tiab] OR Clinically isolated syndrome[tiab] OR cis[tiab] 
AND 
Immunosuppressive agents[MeSH] OR immunotherapy[MeSH] OR disease modif*[tw]OR 
immunosuppress*[tw] OR immunomodulat*[tw] OR immunotherap*[tw] 
AND 
interview*[tiab] OR interviews[MeSH:noexp] OR experience*[Tw] OR qualitative[tiab] 
Figure 1. Search strategy in PubMed 
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2 through reference 
check
1213 unique articles
screened on title/    
abstract
70 articles screened on 
full text (if available)
15 articles included
Excluded through title/ abstract screening
220 not fulfilling population
922 not fulfilling DMD attribute preferences
1 not fulfilling study design (protocol)
Excluded through full text screening
  1 not fulfilling population
47 not fulfilling DMD attribute preferences
  7 not fulfilling study design (protocol)
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Table 1. Attributes and their descriptions derived from literature review 
Attribute Description Articles 
Attributes related to benefits 
Effect 
(in general) 
Efficacy, clinical benefits, success rate, 
burden of disease or treatment failure 
Bhanegaonkar 2011; 
Gasperini 2011; Goodin 2007; 
Hanson 2013; Hanson 2014; 
Sommers 2009; Visser 2011 
Effect on relapse 
frequency 
 
Goodin 2007; Hanson 2014; 
Johnson 2009; Sommers 2009; 
Wilson 2014a; Wilson 2014b 
Effect on worsening of 
lesions in the brain 
Prevention of formations of new or 
enhancing T2 lesions in the brain 
Goodin 2007; Hanson 2014; 
Wilson 2014a; Wilson 2014b 
Effect on disability 
progression 
Worsening of disability or MS 
symptoms (EDSS score) without 
relapses 
Goodin 2007; Hanson 2014; 
Johnson 2009; Wilson 2014b 
Effect on MS symptoms Feeling better due to improvements in 
existing MS symptoms 
Wilson 2014a; Wilson 2014b 
Pace of effect 
 
Visser 2011 
Action of DMD Uncertainty as to the action of the 
DMD 
Visser 2011 
Attributes related to unwanted effects 
Side effects Articles reporting on side effects or 
adverse events differed greatly in how 
side effects were classified, according 
to the type and/or severity of side 
effects. These side effects are 
considered to be minor but 
uncomfortable or common side 
effects. 
E.g. local or systemic, tolerability, 
mild-significant-severe risk and 
vigilance, injection site reactions, flu-
like symptoms, gastro-intestinal 
symptoms, lipoatrophy, depression, 
vision changes, headaches, muscle 
joint ache, infections 
Bergmann 2014; Bhanegaonkar 
2011; Coan 2011; Gasperini 
2011; Goodin 2007; Gustavsson 
2011; Hanson 2013; Hanson 
2014; Miller 2006; Utz 2014; 
Visser 2011; Wilson 2014a; 
Wilson 2104b 
(long-term) Safety Risk on life-threatening or severely 
disabling side effects, such as liver 
failure, PML, or leukaemia, also after 
Gasperini 2011; Goodin 2007; 
Hanson 2013;  
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the patient has stopped using the 
DMD 
Hanson 2014; Johnson 2009; 
Miller 2006; Visser 2011 
Time on market Time duration a DMD has been used Wilson 2014b 
Attributes related to ease of use of DMD 
Convenience  
(in general) 
Convenience in administration of the 
DMD 
Bhaengoankar 2011; Gasperini 
2011; Hanson 2013; Hanson 
2014 
Mode of administration Pill, intramuscular injection, 
subcutaneous injection or intravenous 
infusion.  
Bergmann 2014; Gustavsson 
2011; Hanson 2013; Miller 2006; 
Sommers 2009; Utz 2014; Visser 




Frequency of administration per day, 
week or month 
Bergmann 2014; Gustavsson 
2011; Utz 2014; Visser 2011; 







Bergmann 2014; Gasperini 2011; 
Gustavsson 2011 
Impact of DMD on daily 
life 
Consisting of the frequency of 
administrating the DMD; the method 
of storing the DMD and its 
consequences for traveling; required 
preparation before administration; 
and whether the DMD contains 
animal or human products.  
University College London NHS 
Trust 2004 
Others 





Bhanegaonkar 2011; Gasperini 
2011; Goodin 2007 
Cost/ cost-effectiveness Healthcare coverage or out-of-pocket 
expenses 
Bhanegaonkar 2011; Gasperini 
2011; Hanson 2013; Miller 2006; 
Sommers 2009 
DMD, disease-modifying drug. 
2
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S2. Exploratory phase: interviews with healthcare professionals 
Methods 
Interviews with MS-related healthcare professionals were conducted to obtain their 
perspectives on important DMD attributes in the decision making about DMD treatment. A 
convenience sample of 7 neurologists and 7 MS-specialized nurses employed in hospital in 
the Netherlands were contacted by e-mail (P.J.) to invite them to participate in a 20-minute 
telephone interview. All contacted healthcare professionals consulted RRMS or CIS patients 
about DMD treatment on a regular basis. Healthcare professionals that were willing to 
participate were asked to contact I.K. to schedule the interview. Telephone interviews were 
fitting for the structured form and not sensitive content of the interview. At the beginning 
of the interview, demographic characteristics and work experience with MS patients were 
recorded. Each healthcare provider was asked which DMD attributes they considered to be 
of importance in the decision making about DMD treatments for patients. After the 
healthcare provider’s attributes were elicited, his/her perspective on any additional 
attributes derived from literature was asked. Audio recordings of interviews were used to 
enable transcription of the attribute descriptions and were deleted afterwards. Each 
interview resulted in a list of attributes that are of importance according to the healthcare 
provider. One overall attribute list was created by comparing all attributes from the 
interviews with the attributes derived from literature. 
Results 
Six healthcare professionals (3 neurologists, 3 MS-specialized nurses) were willing and able 
to participate in the interview. The neurologists all treated 200 or more MS patients yearly 
and had work experience ranging between 8 and 24 years. Participating nurses had 10 to 
14 years of work experiences as an MS-specialized nurse. Further details on characteristics 
of the health professionals are presented in table 1. Four attributes were reported by the 
healthcare professionals that were not found in the literature: 1) effect on quality of life for 
the patient; 2) effect on brain atrophy, 3) ease of use for the neurologist, meaning the 
degree of complexity for the neurologist regarding authorization from health insurance or 
procedures regarding delivery of DMD; 4) total costs of DMDs, meaning that the total costs 
need to be considered as part of the Dutch Healthcare budget if a patient doubts whether 
to use a DMD. Therefore, costs had a broader definition than costs as elicited from the 
literature, which represented insurance coverage or out-of-pocket expenses.  
 
Table 1. Characteristics of healthcare professionals  
Neurologists (N=3) MS nurses (N=3) 
Male n (%) 3 (100) 0 (0) 
Female n (%) 0 (0) 3 (100) 
Age (years) Mean ± SD 50.7 ± 8.1 52.3 ± 3.1 
Work experience (years) Mean ± SD 18 ± 8.7 12.0 ± 2.0 
MS, multiple sclerosis; SD, standard deviation. 
 
141878 Ingrid Kremer BNW.indd   50 19-02-20   09:50
I M P O R T A N T  A T T R I B U T E S  O F  D I S E A S E - M O D I F Y I N G  D R U G S  I N  D E C I S I O N  M A K I N G  
51 
S3. Focus groups with nominal group technique 
Results 
Table 1 presents all DMD attributes that influence the decision making about DMD 
treatment as identified by patients in the focus groups. In table 2, the ranking of all reported 
DMD attributes is presented with the frequency with which they were included in the top 
10 and top 5 and their mean importance scores. Compared to the results of the literature 
review and interviews with healthcare providers, 12 additional attributes were reported. 
Furthermore, participants described 4 attributes differently from literature and healthcare 
providers. Side effects were split up into type, duration and severity of non-life threatening 
side effects. Influence on life style was described by patients as the required changes in 
habits and activities one has to make in contrast to the literature which incorporates 
administration frequency, ease of traveling and having a premixed syringe available. 
Traveling was reported as a separate attribute by the patients and having a premixed 
syringe was considered to be a part of the method of administration or making traveling 
easier. Time on the market had a comparable description as uncertainty about long-term 
consequences and was therefore deleted. Composition of the DMD was of importance for 
possible allergic reactions instead of the natural or chemical components. Two attributes 
were found not to be of importance for patients: effect on brain atrophy and ease of use 
for neurologists.  
 
2
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Table 1. Attributes and their descriptions as derived from the focus groups 
DMD attribute Description 
Effect on disease 
progression/ becoming 
disabled 
Proven inhibitory effect of the DMD on developing physical and 
cognitive disabilities on the long-term. 
Effect on current MS 
symptoms 
Proven effect of the DMD on reducing MS symptoms, especially 
fatigue, that someone is experiencing at the moment.  
Effect on the number of 
relapses 
Proven inhibitory effect of the DMD on the number of relapses 
experienced by a person.  
Effect on the severity of 
relapses 
Proven effect of the DMD on reducing the severity of relapses. 
Effect on development of 
plaques in the brain 
Proven inhibitory effects of the DMD on the development and 
presence of plaques (scarring) in the brain which can be 
identified on an MRI. 
Effect on quality of life Proven effect on improving the overall (physical, mental and 
social) well-being of a patient as a result of the DMD [22]. 
Effect on life expectancy Proven effect of the DMD on prolonging life duration. 
Pace of effect Speed at which the beneficial effects occur after administrating 
the DMD 
Action of DMD The way the DMD works in the body and therefore has beneficial 
effects, e.g. reducing inflammations that cause nerve damage.  
Safety Risks of serious side effects that can be life-threatening or result 
in severe disabilities.  
Type of side effects Risk of physical or psychological side effects that are not life-
threatening or leading to severe disabilities. Examples of these 
side effects are injection site reactions, panic attacks, 
gastrointestinal symptoms, flu-like symptoms, hair loss, and 
flushing. 
Duration to which side 
effects persist 
The extent to which effects are temporary (e.g. muscle pain) or 
permanent (e.g. subcutaneous lumps) 
Severity of side effects The extent to which the severity of the side effects outweigh the 
desire to treat MS. 
Uncertainty about long-term 
consequences 
The lack of knowledge and experience regarding serious side 
effects on the long-term, especially for medication that have 
been only shortly available on the market. 
Method of administration The form in which the DMD is to be taken (tablet, injection or 
infusion), and whether this can be self-administered or whether 
help is needed.  
Frequency of administration How often the DMD should be taken per day, week or month. 
Duration of administration Length of time that the administration of one dose takes up. 
Traveling The ease with which the DMD can be brought on holidays or 
outings. The extent to which cooling of the DMD is needed and 
regulations regarding possession of the medication when 
traveling abroad is considered.  
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Required monitoring Medical checks that are required during the use of the DMD, 
such as blood tests and MRIs.  
Use of DMD among other MS 
patients 
The proportion of MS patients in the country that is currently 
using the specific DMD. 
Insurance coverage The extent to which the medication is reimbursed by the health 
insurance.  
Total costs Total costs of the DMD for the health insurance, independent of 
the out-of-pocket expenses for the patient  
Interaction with other 
medication 
Interaction of the DMD in combination with other medication, 
including contraception, which may change the effectiveness of 
either one of the medications or which may result in additional 
side effects. 
Composition of DMD The substances processed in the DMD that may cause allergic 
reactions.  
Contact person at 
pharmaceutical company 
The extent to which help from the pharmaceutical company is 
available, such as a nurse, which the patient can contact about 
questions regarding side effects and administration. 
Development of DMD The extent to which the DMD will remain in constant 
development after has become available on the market, in order 
to fine-tune the DMD in effectiveness and side-effects 
Influence on lifestyle The extent to which a patient’s habits or lifestyle have to be 
adjusted for proper use of the medication, such as the extent of 
flexibility in time of administration, being able and allowed to 
drive, work, do sports, drink alcohol, etc.  
Adherence rates The known rates for a specific DMD of patients persisting to use 
the DMD over a long period of time, following the prescribed 
dose.  
Availability of DMD in the 
Netherlands 
Whether the DMD is available in the Netherlands or whether it 
must be obtained abroad.  
Brand recognition The extent to which the DMD is known to patients because it is 
appointed by neurologists, nurses, websites and other 
information sources 
Legal liability Whether a statement of legal liability needs to be signed before 
being able to start the DMD 
Issuance of DMD The method of acquiring the DMD, e.g. method of delivery, place 
it can be picked up.  
Wash out requirement Minimum required wash out period and method in case of 
stopping or switching treatments. 
Shelf life Duration the DMD can be kept before using it. 
DMD, disease-modifying drug; MS, multiple sclerosis. 
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1 Type of side effects 12 11 2.11 
2 Effect on disease progression/ becoming disabled 11 9 1.82 
3 Method of administration 16 9 1.58 
4 Effectiveness in reducing relapse rate 13 8 1.45 
5 Safety 15 9 1.16 
6 Insurance coverage 13 8 0.95 
7 Duration to which side effects persist 5 4 0.74 
8 Influence on lifestyle 12 7 0.63 
9 Required monitoring 8 5 0.58 
10 Frequency of administration 8 3 0.58 
11 Effect on current MS symptoms 7 3 0.55 
12 Severity of side effects 6 3 0.47 
13 Traveling  7 4 0.32 
14 Effect on quality of life 4 3 0.32 
15 Uncertainty about long-term consequences 8 2 0.32 
16 Effect on life expectancy 3 2 0.32 
17 Interaction with other medication 7 2 0.26 
18 Action of DMD 3 1 0.26 
19 Pace of effect 4 1 0.21 
20 Effect on development of plaques in the brain 4 2 0.13 
21 Contact person at pharmaceutical company 2 1 0.11 
22 Development of DMD 6 1 0.05 
23 Use of DMD among other MS patients 3 1 0.05 
24 Total costs 1 1 0.05 
25 Duration of administration 2 0 0 
 Composition of DMD 2 0 0 
Effect on the severity of relapses 2 0 0 
28 Adherence rates 0 0 0 
Availability of DMD in the Netherlands 0 0 0 
Brand recognition 0 0 0 
Issuance of DMD 0 0 0 
Wash out requirement 0 0 0 
Shelf life 0 0 0 
Legal liability 0 0 0 
DMD, disease-modifying drug; MS, multiple sclerosis. 
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S4. Subgroup analyses in best-worst scaling 




















81.44 9.68  
(9.49-9.86) 
94.40 1821  
(-1,17)2 
.244 




97.56 9.22  
(9.01-9.43) 
91.63 1983  
(-0,53)2 
.596 
Effect on relapse rate 5.76  
(4.54-6.98) 
58.30 8.13  
(7.76-8.49) 
98.38 1196  
(-3,61)2 
<.001 




139.04 7.33  
(7.01-7.66) 
84.50 863  
(-4,92)2 
<.001 




62.59 7.67  
(7.34-8.01) 
97.64 1312  
(-3,16) 2 
.001 




81.11 7.40  
(7.10-7.71) 
94.46 1812  
(-1,20) 2 
.230 
Effect on plaque 




72.70 7.47  
(7.08-7.87) 
95.90 1585  
(-2,09) 2 
.038 
Safety 6.31  
(5.05-7.57) 
NA 6.00  
(5.54-6.46) 
NA .511 .611 
Influence on life style 5.30  
(4.02-6.58) 
92.41 5.31  
(4.86-5.77) 
92.52 2117  
(-0,01) 2 
.992 
Type of side effects 6.97  
(6.06-7.89) 
NA 4.63  
(4.63-4.22) 
NA 4.361 <.001 




71.37 5.04  
(4.54-5.53) 








105.67 4.42  
(4.00-4.84) 
90.24 1764  
(-1,39) 2 
.168 




135.96 3.45  
(3.15-3.74) 
85.03 946  
(-4,59) 2 
<.001 
Pace of effect 2.55  
(1.78-3.31) 
76.89 3.27  
(2.92-3.62) 
95.18 1698  
(-1,65) 2 
.101 
Insurance coverage 2.43  
(1.39-3.47) 
89.89 2.72  
(2.27-3.18) 







84.33 1.78  
(1.48-2.08) 







106.89 1.54  
(1.11-1.96) 
90.03 1731  
(-1,52) 2 
.131 




87.33 1.00  
(0.81-1.19) 







99.04 0.84  
(0.70-0.97) 
91.38 1943  
(-0,69) 2 
.492 
Total DMD costs 0.84  
(0.35-1.32) 
87.41 0.86  
(0.66-1.06) 







111.70 0.68  
(0.45-0.91) 
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Required monitoring 0.97  
(0.34-1.61) 
99.81 0.49  
(0.31-0.66) 
91.2 1922  
(-0,77) 2 
.441 
Use of DMD among 
other MS patients 
0.41  
(0.22-0.60) 
107.74 0.33  
(0.24-0.42) 
89.88 1708  
(-1,61) 2 
.109 
Ease of travelling 0.47  
(0.07-0.87) 
104.67 0.26  
(0.13-0.40) 







110.04 0.19  
(0.15-0.23) 
89.48 1646  
(-1,85) 2 
.066 
Composition of DMD 0.20  
(0.11-0.30) 
99.63 0.18  
(0.12-0.24) 
91.27 1927  
(-0,75) 2 
.460 





98.02 0.11  
(0.06-0.15) 
91.55 1970,5  
(-0,58)2 
.566 
CI, confidence interval; DMD, disease-modifying drug; MS, multiple sclerosis; NA, not applicable; RIS, relative 
importance score. 
1 t-statistic (df=182) 
2 Mann-Whitney U (z-score) 
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Comparison of preferences of healthcare 
professionals and patients with multiple 
sclerosis for attributes of disease-modifying 
drugs: a best-worst scaling study
Published as: 
Kremer IEH, Evers S, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare 
professionals and MS patients for attributes of disease-modifying drugs: A best-worst 
scaling. Health Expect. 2018;21(1):171-80.
141878 Ingrid Kremer BNW.indd   61 19-02-20   09:50




Background. The choice between disease-modifying drugs (DMDs) for the treatment of 
multiple sclerosis (MS) becomes more often a shared decision between the patient and the 
neurologist and MS nurse. This study aimed to assess which DMD attributes are most 
important for the healthcare professionals in selecting a DMD for a patient. Subsequently, 
within this perspective, the neurologists’ and nurses’ perspectives were compared. Lastly, 
the healthcare professionals’ perspective was compared with the patients' perspective to 
detect any differences that may need attention in the communication about DMDs. 
Design. A best-worst scaling (BWS) was conducted among 27 neurologists and 33 MS nurses 
treating MS patients to determine the importance of 27 DMD attributes. These attributes 
were identified through three focus groups with MS patients in a previous study (N=19). 
Relative importance scores (RISs) were estimated for each attribute. Multivariable linear 
regression analyses were used to compare the different perspectives.  
Results. According to the neurologists and nurses, safety of the DMD was the most 
important DMD attribute in the treatment decision, closely followed by effect on disability 
progression, quality of life and relapse rate. MS patients agreed with the importance of the 
last three attributes, but valued safety significantly lower (b=-2.59, p<.001).  
Conclusions. This study suggests that, overall, neurologists and nurses regard the same 
DMD attributes as important as MS patients with the notable exception of safety. This study 
provides valuable information for the development of interventions to support shared 
decision making, and highlights which attributes of DMDs may need additional attention. 
Key points 
 Understanding the healthcare professionals’ perspective about the importance of 
attributes of disease-modifying drugs for multiple sclerosis, and comparing this 
perspective with the patients’ perspective, would be important to develop a 
patient decision aid that is accepted by, and usable for, both patients and 
healthcare professionals in the shared decision making process 
 The healthcare professionals and patients overall agree about the importance of 
the effects of DMDs on disability progression, quality of life and relapse rate, but 
safety was valued significantly lower by patients.  
 The study results provide guidance for the selection of information to be included 
in a patient decision aid for disease-modifying drugs in multiple sclerosis to 
effectively support the patient and healthcare professional in making a shared 
decision. 
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Multiple sclerosis (MS) is a degenerative disease of the central nervous system causing 
physical and cognitive disabilities [1]. The relapsing-remitting form of MS (RRMS) can be 
treated with disease-modifying drugs (DMDs) to reduce progression or even induce 
improvements. DMD treatment requires long-term administration with a minimum of 
missed doses. DMDs are classified as first, second or third line treatments. First line DMDs 
are used in patients with mild disease activity. In case of high disease activity or intolerance 
to the side effects, second or third line DMDs may be chosen. These DMDs have more 
favourable effectiveness rates but less favourable safety profiles [2, 3]. Overall, thirteen 
DMDs are currently approved by the European Medicine Agency and the Food and Drug 
Administration [4, 5]. This variety in DMDs often provides MS patients with more than one 
acceptable option for treatment. 
Therefore, a choice between DMDs needs to be made, which is often difficult. Besides 
differences in effectiveness rates and safety profiles, the DMDs can differ in other 
characteristics, or attributes, such as mode of administration and side effects. To make an 
optimal choice, the patient’s preferences for such attributes should be incorporated in the 
decision. In shared decision making, the patient makes the decision about the treatment 
together with the healthcare professional [6]. The healthcare professional ensures the 
patient is informed about the best available treatment options, and supports the patient in 
clarifying the advantages and disadvantages of each of the options. The patient 
communicates his/her values and preferences for these advantages and disadvantages, and 
deliberates with the healthcare professional, in this case a neurologist and/or an MS nurse, 
about the treatment options to reach a decision. Decision aids, which are specifically 
designed to support shared decision making, have been shown to improve the patient’s 
involvement in the decision and the quality of the decision [7]. 
Understanding the preferences of patients and healthcare professionals for treatment 
options could inform the development of a decision aid. Although the treatment decision 
should be individualized to every patient and should include the patient’s preferences and 
healthcare professional’s opinion tailored to the patient’s needs, the evaluation of the 
average perspectives about the importance of the treatment attributes in the decision could 
be useful for developing a patient decision aid that meets most patients’ and healthcare 
professionals’ informational needs. An assessment of the average preferences could be 
valuable for selecting the information that needs to be included in the decision aid to ensure 
effectively supporting the shared decision making process without making the use of the 
decision aid too cognitively burdensome for the patient. Preferences of patients for 
attributes of DMDs have been evaluated in several stated preference studies [8-16]. 
Recently, focus groups and a best-worst scaling were conducted to identify and prioritize a 
range of attributes that could be important in clinical decision making from the patients’ 
perspective [8]. This study found that the average MS patient regarded the effects on 
disability progression and quality of life as the most important attributes of DMDs in the 
decision, followed by the effect on the relapse rate, severity of side effects and the effect 
3
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on the severity of relapses [8]. Several studies showed that preferences of healthcare 
professionals for treatment options can differ from the preferences of patients [17-21]. 
These differences in preferences could result in different expectations and information 
needed from the decision aid [19]. In MS, one study has assessed the neurologists’ 
perspective regarding the importance of a limited number of five attributes in the DMD 
choice [22]. To our knowledge, the patients’ perspective on important DMD attributes for 
choosing between DMDs has not yet been directly compared with the healthcare 
professionals’ perspective. 
This study aimed first to use a rigorous method, a best-worst scaling, to identify which DMD 
attributes the healthcare professionals (neurologists and MS nurses) find important to take 
into consideration in the decision regarding DMD treatment. As the relationship with the 
patient may differ between neurologists and MS nurses because of the more frequent and 
informal contact between MS nurses and patients, the second aim of this study was to 
evaluate whether the perspectives on the importance of DMD attributes differ between 
neurologists and MS nurses. Third, the overall MS healthcare professionals’ (neurologists 
and MS nurses) perspective was compared with the MS patients’ perspective on the 
importance of DMD attributes in the treatment decision.  
Methods 
A best-worst scaling case 1 as described by Flynn and Marley [23] was conducted to obtain 
the neurologists’ and MS nurses’ perspective on the importance of attributes of DMDs. In 
contrast to discrete choice experiments a best-worst scaling allows for obtaining the relative 
importance of attributes for a large number of attributes, regardless of the levels of the 
attributes [24]. The best-worst scaling was embedded in an online questionnaire. Therefore, 
the Checklist for Reporting Results of Internet E-Surveys was followed for reporting the 
design and the results [25]. We used the same best-worst scaling that was performed to 
elicit preferences for patients with MS [8]. The best-worst scaling included 27 attributes, 
which were identified in a two-stage procedure. First, in an exploratory phase, possible 
relevant attributes were identified through a literature review and interviews with three 
neurologists and three nurses. Second, three focus groups (N=19) were conducted to elicit 
the attributes that MS patients regarded important in the decision. At the end of each focus 
group, any additional attributes from the exploratory phase that were not mentioned yet, 
were discussed to evaluate whether these additional attributes were relevant as well. A 
total of 27 important attributes for the decision about DMD treatment were identified. 
Using Sawtooth SSI Web version 8.2.0, four best-worst scaling versions, each consisting of 
17 unique choice tasks with 5 attributes per choice task, were created to obtain the most 
efficient, fractional design. In such a design, it is not needed to include all possible 
combinations of attributes in the choice tasks, which is far too burdensome to administer. 
Instead, specific sets of five attributes from the full attribute lists are created to ensure that 
the relative importance of each attribute can be derived. Each attribute was presented 12 
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or 13 times in the four best-worst scaling version, was combined at least once with every 
other attribute, and appeared two to four times in each position in the choice task. Each 
respondent randomly received one of the best-worst scaling versions. In every choice task, 
the respondent was asked to state which attributes were the most and the least important 
in the decision about DMDs, making a hypothetical trade-off between the attributes [24]. 
The best-worst scaling was pilot tested among researchers (n=3) and MS patients (n=3) to 
ensure comprehensibility of the questionnaire. An example of a choice task for neurologists 
and MS nurses is presented in Figure 1. Further description on the identification, selection 
and definition of attributes and on the development of the choice tasks and the 
questionnaire is described in detail elsewhere [8]. 
 
 
Figure 1. Example of a choice task in the best-worst scaling 
 
In addition to the best-worst scaling choice tasks, questions about demographical and 
professional characteristics were included. The respondents had to answer all questions to 
complete the questionnaire. At the end of the questionnaire, an optional open question 
provided the respondents the opportunity to report any important attributes in the decision 
about DMD treatment they missed in the choice tasks of the best-worst scaling.  
Subjects 
Healthcare professionals were eligible for participation in the study if they were 
neurologists (i.e. MS-specialized neurologists or general neurologists) or MS nurses (i.e. MS-
3
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specialized nurses or nurse practitioners, physician assistants or nurse consultants 
specialized in MS) and involved in the treatment of MS patients in the Netherlands. These 
healthcare professionals generally work in hospitals. The Netherlands counts about 80 
(academic or general) hospitals. The neurological department of a hospital generally 
consists of multiple neurologists of which some neurologists may have one or a few specific 
areas of focus. The exact number of MS neurologists in the Netherlands is unknown, but 
most departments have one, two or three neurologists who focus on the treatment of MS 
patients. About 135 MS nurses were working in the Netherlands at the time of the study.  
Neurologists with a focus on the treatment of MS were identified by searching websites of 
all hospitals in the Netherlands. We compiled a mailing list for 120 neurologists through the 
network of one of the authors (PJ) - including the MS working group of the Dutch 
Neurologists Association and the MSmonitor Working group - or through personal contact 
with the hospital. The neurologists were asked to participate through an e-mail explaining 
the purpose of the study and containing a direct link to the online questionnaire. 
Additionally, an extra reminder e-mail, in which the neurologists were personally 
addressed, was sent to 52 members of the MS Working Group of the Dutch association for 
neurology and the MSmonitor Working Group, of which six neurologists responded to have 
completed the questionnaire earlier and four neurologists responded to have completed 
the questionnaire after the e-mail was sent.  
Nurses were contacted through a call on the communication system of the professional 
association for MS nurses to which about 150 MS nurses and other nurses with an interest 
in MS had access, and, additionally, through an e-mail to 88 nurses to increase response. 
MS nurses for this mailing list were identified via an inventory of MS caregivers and 
healthcare institutions published on a patient information website about MS endorsed by a 
Dutch patient association. Additionally, all nurse practitioners and physician assistants in 
MS (N=15) were also contacted through a mailing list of their professional association. In 
case of no response among the neurologists and nurses, a reminder e-mail was sent after 
one and two weeks after the first e-mail. The neurologists and nurses were informed that 
by completing the questionnaire they gave consent for their responses to be used in the 
study. Cookies were used to prevent the same respondent from filling out the questionnaire 
twice. The study was fully anonymous, and no data, such as IP addresses, were recorded 
that could lead to the identity of the healthcare professional. 
Analyses 
Only completed questionnaires were included in the analyses. Descriptive statistics were 
used to present characteristics of the neurologists and MS nurses. To evaluate the 
preferences of the healthcare professionals for the DMD attributes, Sawtooth SSI Web 
version 8.2.0 was used to perform a hierarchical Bayes model employing a multinomial logit 
procedure [26]. A raw score for the importance of each attribute was calculated in an 
iterative process of estimating each respondent’s utility score conditionally on estimates of 
other respondents’ utility scores. The raw score was rescaled to a relative importance score 
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(RIS) on a ratio scale [27]. The RIS of an attribute represents the importance of the attribute 
in relation to the importance of the other attributes in the decision about the DMD 
treatment of MS according to the professionals. The RISs of all 27 attributes for each 
respondent sum up to 100. Therefore, if there would be no difference in importance of the 
attributes, each attribute would obtain a RIS of 3.7. Deviations from this score would 
suggest that some attributes are more important in the treatment decision than others. To 
ensure only responses of neurologists and MS nurses who answered the questions carefully 
were included in the analyses, respondents with a fit statistic (root likelihood) below .247 
were omitted from the analyses as a fit statistic below this score would suggest random 
answers to the choice tasks [28]. In addition to the RISs, most-minus-least counts were 
calculated to confirm the rankings of the attributes. To adjust for an imbalance in the 
number of times an attributes was shown to each respondent in the best-worst scaling, the 
most-minus-least counts were divided by the frequency of each attribute being included in 
the questionnaire across the four versions [24]. 
Multivariable linear regression analyses with robust standard errors were conducted with 
SPSS for Windows version 24 to assess whether the RISs of the 27 attributes differed 
between neurologists and MS nurses while controlling for sex and three professional 
characteristics. Two characteristics indicated the amount of experience in treating MS 
reated per year. The third characteristic denoted the extent to which the 
healthcare professional was specialized in treating MS patients on a continuous scale, and 
was defined as the number of MS patients treated as proportion of the total number of 
patients treated. 
To assess whether the RISs assigned by the neurologists and nurses to the 27 attributes 
differed from the RISs assigned by the MS patients, hierarchical Bayes analyses was 
conducted including responses of the neurologists and nurses, and responses of patients 
obtained in a previous study [8]. A second linear regression model was built to control for 
age, sex and level of education in the function between the respondent type (i.e. healthcare 
professional or patient) and the RISs of the 27 attributes. Level of education was 
dichotomized into respondents who had completed primary and/or secondary school only 
and respondents who had completed any additional type of tertiary education. The 
patients’ perspective was obtained from a previous study among 185 patients with 
relapsing remitting MS or clinically isolated syndrome, and with a range in experience with 
DMDs (from having never used a DMD to having used more than 3 different DMDs) and 
duration of diagnosis. Further detailed description of the patient recruitment and the 
patients characteristics can be found elsewhere [8].  
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Of the 120 neurologists and an estimated 140 nurses contacted, 79 healthcare professionals 
accessed the questionnaire between 20 November 2015 and 8 February 2016. In total, 62 
healthcare professionals completed the questionnaire (estimated overall completion rate 
of 24%), of which two healthcare professionals did not meet the inclusion criteria because 
they were working in Belgium (n=1) or did not treat MS patients on a regular basis (n=1). 
The sample of 60 healthcare professionals that met the inclusion criteria consisted of 27 
(45%) neurologists and 33 (55%) nurses. Table 1 presents their characteristics. Twenty-four 
(89%) neurologists reported to be specialized in MS. Of the MS nurses, 23 (70%) MS-
specialized nurses, 1 (3%) nurse consultant MS, 7 (21%) nurse practitioners MS and 2 (6%) 
physician assistants MS completed the questionnaire. The median proportion of MS 
patients expressed as a percentage of the total number of patients treated was 20% among 
neurologists and 50% among nurses, of which 8 nurses reported to only treat MS patients.  
 
As all fit statistics of the questionnaires were above .247 (mean .557; range .341, .769), 
indicating that none of the healthcare professionals answered the choice tasks completely 
at random, all completed questionnaires were included in the analyses. The ranking of the 
DMD attributes according to the mean RISs showed that healthcare professionals regarded 
safety, i.e. risks of life threatening or severely disabling adverse events, as most important 
(mean RIS (SD): 9.29 (0.92)), but was followed closely by effect on disability progression, 
effect on quality of life and effect on relapse rate with only small differences between the 
RISs (mean RIS (SD): 9.27 (1.58), 9.19 (0.83) and 8.89 (0.88), respectively). Other highly 
ranked attributes were effect on development of plaques in the brain (i.e. MS activity on 
MRI), severity of side effects and the effect on severity of relapses. Ten DMD attributes were 
of little or no importance in the decision for the healthcare professionals with mean RIS 
below 1.0, including the required monitoring and administration frequency. The results of 
the adjusted most-minus-least counts (Supporting information Table Most-minus-least 
counts) did not substantially affect the rankings obtained based on the hierarchical Bayes 
analyses, and therefore confirmed the results. Of the 60 neurologists and nurses, 2 (3%) 
neurologists reported additional DMD attributes that were not included in the best-worst 
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Sex, N (%) Male  21 (35.0) 20 (74.1) 1 (3.0) 
 Female 39(65.0) 7 (25.9) 32 (97.0) 
Age (in years) mean (SD) 47.6 (8.7) 49.7 (9.2) 45.9 (8.1) 
 Range 30-64 35-64 30-59 
Work function, N (%) MS Specialized 
neurologist 
24 (40) 24 (88.9) - 
 General 
neurologist 
3 (5.0) 3 (11.1) - 
 MS nurse 23 (38.3) - 23 (69.7) 
 Nurse 
practitioner MS 
7 (11.7) - 7 (21.2) 
 Physician 
assistant 
2 (3.3) - 2 (6.1) 
 Nurse consultant 1 (1.7) - 1 (3.0) 
Work experience (in 
years) mean (SD) 
 45 (75.0) 16 (59.3) 29 (87.9) 
 15 (25.0) 11(40.7) 4 (12.1) 
Number of MS patients 
treated yearly, mean 
(SD) 
 24 (40.0) 11 (40.7) 13 (39.4) 
 36 (60.0) 16 (59.3) 20 (60.6) 
Proportion MS patients 
from total number of 
patients treated (in %) 
Median (IQR) 40 (20-67.5) 20 (10-40) 50 (40-95) 
IQR, interquartile range; MS, multiple sclerosis; SD, standard deviation 
Comparison of neurologists with MS nurses 
Only few differences were found between neurologists and nurses (Table 2). When 
comparing neurologists to nurses, relatively large differences in mean RISs (absolute 
difference in RISs of 1 or more) were found in effect on current MS symptoms, effect on life 
expectancy, total costs of the DMD, which were higher for the neurologists, and interaction 
with other medication, which was higher for nurses. However, when controlling for sex, the 
years of work experience, the number of MS patients treated each year and the degree of 
focus on MS treatment, only a significant difference was found between neurologists and 
nurses in the low ranked attributes total cost of the DMD (b=-1.27, p=.015) and interaction 
with other medication (b=2.09, p=.007). These differences resulted in quite substantial 
shifts in ranking: total cost of the DMD was ranked 17th by neurologists (RIS=1.22) and 25th 
by nurses (RIS=0.16), and interaction with other medication was ranked 18th by neurologists 
(RIS=1.10) and 13th by nurses (RIS=2.97). Based on their RISs though, these attributes did 
not influence the treatment decision severely.  
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Comparison of healthcare professionals (neurologists and MS nurses) with patients 
When controlling for age, sex and level of education, there were significant differences 
found between the RISs of the healthcare professionals and the MS patients for six 
attributes at an alpha of .05: effect on relapse rate and safety were more important for 
neurologists and nurses, while effect on current MS symptoms, pace of effect, insurance 
coverage and further development of the DMD were more important for the patients in the 
decision about DMDs. Furthermore, while the difference in RIS of 1.01 between the 
healthcare professionals and patients for influence on lifestyle was quite substantial, this 
difference was not significant when controlling for age, sex and level of education (p=.063). 
For safety, the difference was the most notable: the RIS for patients was substantially lower 
than for neurologists and nurses (b=-2.59, p<.001), making safety the fourth most important 
attribute for neurologists and nurses, and only the eighth most important attribute for 
patients. Table 3 presents the results of the multivariable regression analyses for all 27 
attributes. Fig. 2 presents the relative importance score of each attribute according to MS 
patients and neurologists and MS nurses.  
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The healthcare professionals and the patients both valued effect on disease progression, 
quality of life and relapse rate highly, which is not unexpected because these are the 
primary aims of DMD treatment. The most notable difference between the two 
perspectives was found in the importance of safety. The healthcare professionals gave 
significantly more value to this attribute compared with patients. More specifically, safety 
was ranked as fourth most important by healthcare professionals, while ranked only eighth 
by patients, who gave more value to other attributes focused on effectiveness and the 
severity of more common side effects. In the process of shared decision making, this could 
be an issue. Healthcare professionals may, for example, be less inclined than patients to 
choose a DMD for which experience and research has shown risks for life-threatening or 
severely disabling side effects, such as progressive multifocal leukoencephalopathy. 
Motivations of patients, neurologists and nurses for the importance of the attributes were 
not elicited in the questionnaire, therefore we can only speculate about the reasons for the 
difference found in the importance of the attributes, in particularly safety. A first 
explanation for the difference in the importance of safety might be that healthcare 
professionals have a different understanding of the seriousness of the risks and 
consequences than patients. Second, patients might be willing to take more risk, as a 
previous study showed that patients were willing to accept larger risks than the risks 
associated with the DMDs available at that time, in exchange for effectiveness in reducing 
relapse rate and disability progression [9]. Healthcare professionals may be less inclined to 
take these risks, for example, because of forensic and legal liability in case of incidents of 
serious adverse events.  
This study shows which attributes are most important in the decision, and that the rankings 
of the attributes are overall quite similar for neurologists, MS nurses and MS patients, with 
the exception of a few attributes – especially safety. It should be noted that the rankings 
reflect the average preferences. Therefore, the discrepancies do not necessarily play a role 
in every consultation. However, incorporating the patient’s preferences in the decision is 
an essential part of reaching a shared decision, which may be complicated if the healthcare 
professional and patient do not agree on the importance of some attributes in the decision. 
Patient decision aids can, besides provide information, also support the patient and the 
healthcare professional in eliciting and discussing the patient’s preferences [30]. The results 
of this study contribute to the development of an MS decision aid by indicating the 
attributes – those attributes that both patients and healthcare professionals find most 
important and those attributes that are substantially more important for either patients or 
healthcare professionals – about which information and preference elicitation questions 
should be included in the decision aid to enable effective support for reaching a shared 
decision. Moreover, this study shows that a best-worst scaling could be a useful tool in the 
future development of other interventions for supporting shared decision making, such as 
patient decision aids. Especially when there is a risk of developing overly cognitive 
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burdensome tools, a best-worst scaling may be useful in selecting the most essential 
attributes. 
Some limitations of this study need to be considered. Only an estimated 24% of the 
contacted healthcare professionals completed the questionnaire. Possibly, more healthcare 
professionals with a more positive attitude towards research responded because of our 
recruitment methods. Therefore the sample might not perfectly represent all MS 
neurologists and MS nurses in the Netherlands because they may have been better 
informed about the latest DMD developments, and they might have had different 
preferences for DMD attributes accordingly. Another limitation could be the small sample 
size, but the number of eligible healthcare professionals for this study is also limited. The 
Netherlands counts about 80 hospitals of which most hospitals have one, two or three 
neurologist with a focus on MS and one or two MS nurses, and we made efforts to invite all 
of them to participate. The sample size limited the ability to conduct a latent class analysis. 
In future research, evaluation of heterogeneity in preferences using latent class analysis 
could potentially provide more insight into groups of healthcare professionals with similar 
preferences. Furthermore, in order to compare the perspectives of the neurologists and the 
MS nurses with those of the patients, the best-worst scaling for both parties included the 
same attributes. These attributes were, however, identified through focus groups among 
patients only, and may not be the same attributes that the neurologists and MS nurses 
would have reported if focus groups among them would have been performed. 
Nevertheless, only 2 neurologists reported other attributes that were not included in the 
best-worst scaling – teratogenic properties and uncertainty whether effects would be 
achieved” – to be of importance as well. Another limitation is that it was necessary to ask 
different questions in the best-worst scaling for healthcare professionals compared with the 
patients. Both groups were asked to choose the most and least important attribute for 
decision making, but patients were expected to answer this question according to their 
individual situation, while healthcare professionals were asked to answer the question for 
MS patients in general. This difference in framing of the question may have led to 
differences in what is regarded as important in the decision. Additionally, because of small 
deviations from normality of the residuals and homoscedasticity found in the regression 
analyses, generalization of the found differences in total costs of the DMD and interaction 
with other medication between neurologists and nurses and the differences in effect on 
relapse rate, insurance coverage, and further development of the DMD between the 
healthcare professionals and the patients beyond our sample should be done with caution. 
Lastly, it is uncertain whether our results may be transferred to other settings as the 
healthcare systems in other settings may differ. Therefore, some attributes, such as DMD 
costs, may be more important for the decision in other settings. Other limitations that apply 
to the best-worst scaling method and the results of the patients’ perspective have been 
reported elsewhere [8]. 
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This study showed that safety, effect on disability progression and effect on quality of life 
were the most influential attributes of DMDs for healthcare professionals in the treatment 
decision. The importance of these and other highly ranked attributes did not differ between 
neurologists and nurses when making a decision for MS patients in general. Additionally, 
the average healthcare professionals’ perspective and the average patients’ perspective 
agree that the ability of DMDs to reduce disability progression and maintain or improve 
quality of life are the most important attributes of a DMD. The perspectives differ however 
considerably about the importance of safety. These results provide valuable information for 
the development of interventions to support shared decision making. This study also 
demonstrates the feasibility of combining focus groups and a best-worst scaling to identify 
important attributes that could later be included in a patient decision aid. A best-worst 
scaling could be an interesting method when having to restrict the number of attributes for 
inclusion in a patient decision aid. 
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Background. The treatment decision with regard to start disease-modifying drugs (DMDs) 
for multiple sclerosis (MS) is preference sensitive. Shared decision making is important. 
Patient decision aids support patients and healthcare professionals in making a shared 
decision. To date, there is no patient decision aid available for MS patients in the 
Netherlands.  
Aim. To describe the systematic development of a patient decision aid based on the 
principles of multi-criteria decision analysis (MCDA) of DMDs for MS.  
Methods. Recommendations of the International Patient Decision Aid Standards were 
followed. The user-centred developmental process consisted of six stages: 1) determining 
the scope; 2) organizing focus groups and conducting best-worst scaling surveys of the 
intended users (patients, neurologists and nurses) to determine which characteristics of 
DMDs should be included in the MCDA-based patient decision aid; 3) determining the 
format and delivery; 4) conducting a literature review on the characteristics of the DMD; 5) 
developing a prototype; and 6) alpha testing of the patient decision aid on 
comprehensibility and usability with patients and healthcare professionals. 
Results. The online MCDA-based patient decision aid is designed and intended to support 
patients with relapsing-remitting MS or a clinically isolated syndrome (CIS) with regard to 
DMDs labelled for MS. Alpha testing of the prototype identified several problems regarding 
content and framing, methods for weighting the importance of criteria, and the end screen 
providing an overview of the treatment options ranked according to the patient’s 
preferences. Adaptations were made accordingly. However, further development is needed 
to verify rankings and validate the patient decision aid. Moreover, the feasibility of 
implementation and the value of the patient decision aid for supporting shared decision-
making should be studied. 
Discussion. The patient decision aid was well-received overall with patients and 
professionals, but further development is needed. Furthermore, beta pilot testing with 
patients and healthcare professionals at the point of clinical decision making will assess 
the feasibility of implementation in clinical practice.   
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Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system that 
manifests most often during young adulthood. People diagnosed with the relapsing-
remitting disease course of multiple sclerosis (RRMS) experience exacerbations of MS signs 
and symptoms which can recover over time, though signs and symptoms may remain [1]. If 
patients have multiple relapses, disability can accumulate, resulting in substantial loss of 
quality of life [2-4].  
RRMS patients and patients diagnosed with clinically isolated syndrome (CIS) - defined by a 
single event resembling an MS relapse, but in the absence of the MS diagnosis yet [1] face 
the decision of starting treatment with disease-modifying drugs (DMDs). DMDs can delay 
or prevent the accumulation of disabilities by reducing the number of relapses and reducing 
the number new (gadolinium enhancing on T1 or new T2) or enlarging lesions on MRI scans 
of the brain. Currently, twelve DMDs are formally authorized for the treatment of RRMS in 
the Netherlands; three of these have been authorized for CIS [5]. New DMDs are in the 
pipeline.  
The decision for starting DMD treatment is preference-sensitive: it requires a trade-off 
between treatment benefits and treatment burden in which the patient’s preferences and 
values should play a key role [6]. Healthcare professionals should invite the patient to 
participate in the decision making process, inform patients about their treatment options 
and elicit the patient’s preferences for the treatment options in order to include these 
preferences while making a shared decision regarding treatment [7]. Shared decision 
making could potentially result in better drug use compliance [8]. However, MS patients 
may have difficulty in understanding treatment options: health literacy in itself is an issue 
for a substantial proportion of the Dutch population [9], and for MS patients the decision 
to start with a DMD can be even more difficult, due to the large number of treatment 
options and the cognitive and mental symptoms many patients experience [10, 11].  
Patient decision aids support and enable patients to participate in shared decision making 
by explaining the treatment options, their potential benefits and burdens, and help patients 
to form and communicate their preferences for the treatment options [12]. Patient decision 
aids have been shown to support patients in feeling more informed, feeling more certain 
about the decision, and for the decision to be more congruent with the patient’s 
preferences [12]. Patient decision aids can thus affect the patient’s decision substantially. 
Accordingly, the adequate development and quality of patient decision aids are important 
[13, 14]. 
Only a few patient decision aids are available or are being developed for decisions about 
DMDs for MS [15, 16], and no patient decision aids are currently available in the 
Netherlands. The objective of this paper was to describe our developmental process of a 
patient decision aid for decisions for all DMDs available for patients with RRMS and CIS in 
the Netherlands, provide transparency regarding the developmental process and the 
content of the patient decision aid, and discuss the challenges we encountered in 
developing such a tool. Transparency in the development and content of the patient 
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decision aid enables the appraisal of whether the developmental process and quality of the 
patient decision aid are adequate. 
Methods 
Recommendations by the International Patient Decision Aid Standards (IPDAS) [13] guided 
the development of the patient decision aid, which consisted of six stages; these are 
described below. We applied the principles of a user-centred design, involving the end-
users in different stages of the developmental process [17].  
Stage 1. Scope of the patient decision aid 
The scope of the patient decision aid was determined within a steering group consisting of 
three health services researchers and an MS neurologist, verified through consultation of 
an advisory group consisting of three representatives of patient organisations for MS, three 
MS neurologists, two MS nurses and an expert in patient decision aid development. The 
steering group determined a priori that the patient decision aid would be based on the 
principles of multi-criteria decision analysis (MCDA) [18]. 
Stage 2. Assessment of decisional needs 
Focus groups and surveys of the prospective users (MS patients and healthcare 
professionals) were conducted to assess the patients’ decisional needs, i.e. the 
information about treatment options that should be provided. Methods have been 
reported in detail elsewhere [19, 20]. In short, three focus groups were conducted with 
RRMS patients with prior experience in making a decision about DMDs or using DMDs. 
Subjects were asked to list and define the DMD characteristics they considered important 
to consider while making the treatment decision, and to individually select the 10 most 
important characteristics. All characteristics selected at least once for the top 10 by any of 
the subjects were then included in a best-worst scaling survey to prioritize the 
characteristics according to importance in a larger sample of patients and among 
neurologists and MS nurses. The best-worst scaling survey presented 17 choice tasks. Each 
choice task consisted of a unique combination of five characteristics derived from the 
compiled list in the focus groups. In each choice task, respondents had to select the most 
and least important characteristic of DMDs for decision making. The best-worst scaling 
resulted in a ranking of DMD characteristics according to their importance in the 
treatment decision. This ranking guided the inclusion of information in the patient 
decision aid. The final selection of characteristics and their definitions were verified within 
the advisory group, and discussed with two experts in the development of MCDA-based 
patient decision aids. 
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Stage 3. Format 
The steering group chose to use MCDA to construct the patient decision aid because of the 
large number of DMD options and characteristics of DMDs important in the decision. 
Trading-off multiple characteristics of a number of alternatives could be difficult, especially 
if patients have cognitive and mental symptoms. The MCDA approach makes the trade-off, 
which is usually an implicit cognitive process, explicit. By combining the importance of 
characteristics with how well DMDs perform on these characteristics, MCDA provides a 
summary of how well the treatment options fit the preferences, i.e. the implicit cognitive 
process is performed by the MCDA tool. Therefore, we hypothesized that the MCDA tool 
may relieve overall cognitive burden for patients, which could be helpful for patients who 
might experience cognitive and mental problems. MCDA supports decision makers when 
having to trade-off many, often conflicting, characteristics of two or more alternative 
options. Without any formal support, such trade-offs could be a cognitively burdensome 
exercise, even for people without cognitive or mental issues, resulting in suboptimal and 
non-transparent decisions. By ranking the alternative treatment options according to the 
patient’s preferences, the patient decision aid supports patients and healthcare 
professionals in directing the focus of the deliberation in terms of characteristics and 
alternative options to discuss [18].  
Stage 4. Review and synthesis of evidence 
To determine the performance of each DMD on efficacy characteristics, an inventory of all 
pivotal randomized controlled studies of DMDs for MS was made through a database 
search. Moreover, the database search identified relevant meta-analyses synthesizing the 
results of pivotal studies on the efficacy of DMDs in comparison with a placebo or other 
DMDs. The Cochrane Controlled Register of Trials (CENTRAL) was searched (latest update 
12 June 2017) for reviews using the term “multiple sclerosis”. Due to a lack of evidence of 
the effects of certain DMDs in comparison with a placebo in pivotal studies, network meta-
analyses of DMDs were identified through a database search in Medline (Pubmed) (latest 
update 12 June 2017), a search for health technology assessment reports in databases of 
the National Institute for Health and Care Excellence and of the Centre for Review and 
Dissemination and through experts. Network meta-analyses include direct comparisons of 
DMDs to a placebo and indirect comparisons of DMDs to other DMDs to estimate the DMDs’ 
performance in comparison with a placebo [21]. The network meta-analysis was selected 
based on search date, acceptability of quality and comprehensiveness in terms of relevant 
DMDs, according to the outcome measures of interest (i.e. the effect on relapse rate and 
disease progression). Effect estimates of DMDs in the selected network meta-analysis [22] 
were compared with results from other network meta-analysis for verification. Effect 
estimates for DMDs not included in the meta-analysis were derived from pivotal studies of 
the DMDs included in its Cochrane review.  
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Since the network meta-analysis included only estimates for effects on relapse rate and 
disability progression, patient-reported effects on quality of life (QoL), cognitive capabilities 
and fatigue were derived from randomized controlled studies identified through a review 
of QoL [23], irrespective of the measurement instrument used. Outcomes for cognition and 
fatigue were based on relevant subdomains of the QoL instruments wherever included and 
reported. If the data of subdomains were not reported, corresponding authors – and in case 
of no response, first and/or last authors – were contacted to retrieve additional data.  
The effect on MRI outcomes was defined - in agreement with the advisory group - as “no 
gadolinium-enhancing lesions and no new or enlarging T2-hyperintense lesions on the MRI” 
[1]. Heterogeneity in operationalization, measurement and reporting of MRI outcomes 
hinders the synthesis of data for many DMDs, and was therefore not included in the 
selected network meta-analysis. Other network-meta-analyses identified through the initial 
search were screened for relevancy of MRI outcomes. If DMDs were not included or only 
partial information was available in the network meta-analyses, missing data were obtained 
from the Cochrane reviews or the pivotal studies. If no pooling of data from multiple studies 
was conducted, the project team pooled the data using RevMan version 5. 
Ease of use, safety profiles and common side effects were based on the Summary of Product 
Characteristics of each DMD and on data from the Dutch Healthcare Institute. Information 
for contra-indications because of comorbidity or other use of medication use were 
identified using summary of product characteristics and information provided by the Dutch 
Healthcare Institute (www.farmacotherapeutischkompas.nl). 
Stage 5. Development of prototype 
A prototype of the patient decision aid was then developed. In MCDA decision aids, 
performances of each treatment on the characteristics as derived from literature need to 
be translated into a performance score between 0 and 1 [18]. A performance score of 1 
represents optimal performance on this characteristic, while a score of 0 represents no 
effect or no evidence available. For efficacy on relapses, disease progression, MRI and time 
to MS diagnosis, linear functions based on relative risk and hazard ratio were assumed. For 
example, a change in relative risk on relapses of 0.65 to 0.80 would result in an equal change 
in performance score as would a change in relative risk of 0.25 to 0.40. For efficacy 
characteristics based on patient-reported outcomes, linear functions were defined based 
on effect size (Cohen’s d). If no data were available from network meta-analysis or the 
pivotal studies, or if no significant difference between the DMD and placebo was found, the 
performance scores of efficacy characteristics was set to zero. Performance scores for 
common side effects were estimated by calculating the DMDs’ weighted risk for side effects. 
For DMDs’ performance on safety profiles, a rule was defined according to the 
categorization of first line and second line medication, which was validated by two clinicians 
from the advisory group. The performance scores for ease of use were not pre-determined, 
since an objective assessment of the difficulty of using each DMD could not be made for all 
patients. Therefore, a patient-centred approach was applied for determining these scores. 
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Each patient who uses the patient decision aid rates his/her own performance scores for 
ease of use per DMD by rating the expected burden of using the DMD on a scale of 0 (not 
difficult at all) to 10 (very difficult). Performance scores for all characteristics, with the 
exception of ease of use, were verified by two MS neurologist (EW, WV).  
Stage 6. Alpha pilot testing 
Iterative alpha pilot testing to evaluate the comprehensibility and usability of the patient 
decision aid was conducted with healthcare professionals (n=3 (MB, EW, WV)), patient 
representatives (n=2 (MK, JS)) and an expert in patient decision aid development (TW) from 
the advisory and project group. Additional patients were recruited using convenience 
sampling via advertisements on the social media platform of a patient organization, MS 
Vereniging Limburg. Patients with prior experience with making a decision about DMDs or 
using DMDs (either with RRMS, CIS or secondary progressive MS (SPMS) and interested in 
participating in the study were asked to contact the researcher (I.K.). Patients who were 
thinking of changing their MS treatment were not eligible. Due to low response, snowball 
sampling was used in addition to the advertisements, via a patient representative in the 
advisory group and a member of the patient organization. A patient representative asked 
other eligible patients to participate. Patients were recruited until data saturation was 
reached.  
A researcher (I.K.) visited the patients at home and healthcare professionals in their work 
environment. Patients and healthcare professionals were instructed to go through the 
patient decision aid in the presence of a researcher, and to verbalize any comments, 
thoughts or difficulties they had regarding the wording, functionality and usability of the 
information provided. The researcher took field notes of any comments, and noted answers 
to prompt questions seeking clarifying comments and observations about the functionality 
of the patient decision aid. A topic list was prepared before the interview to ensure that all 
relevant topics were addressed. If topics had not been fully addressed after the respondent 
had gone through the patient decision aid, the researcher asked additional questions. Based 
on the remarks and observations, revisions were made and the adapted prototype was 
tested with other patients until no new substantial comments came up concerning the 
usability or comprehensibility of the patient decision aid. The protocol of the alpha pilot 
testing was reviewed by the Medical Ethics Committee Academic Hospital Maastricht and 
Maastricht University in the Netherlands (nr. 2018-0434), and it was concluded that the 
Dutch Medical Research Involving Human Subjects Act (WMO) does not apply. The study 
was performed in agreement with the ethical standards laid down in the 1964 Declaration 
of Helsinki and its later amendments. All patients gave their written informed consent. 
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Stage 1. Scope of the patient decision aid 
Patients diagnosed with RRMS or CIS were the target users of the patient decision aid. The 
patient decision aid includes all brand name and generic DMDs available for patients with 
RRMS and CIS in the Netherlands, i.e. interferon beta-1b, interferon beta-1a IM, interferon 
beta-1a SC, peginterferon beta-1a, glatiramer acetate, teriflunomide, dimethyl fumarate, 
natalizumab, alemtuzumab, fingolimod, cladribine and ocrelizumab. The patient decision 
aid also includes the option of no drug treatment, which is the reference treatment in the 
patient decision aid. In the absence of an up-to-date national clinical guideline for MS in the 
Netherlands, the selection of options was informed by the Dutch Healthcare Institute [5] 
and expert opinions from members of the advisory group.  
Stage 2. Assessment of decisional needs 
Nineteen patients with RRMS (79% female) with a mean (standard deviation, SD) age of 
46.8 (8.8) years and a disease duration of 9.5 (8.4) years contributed through focus groups 
to the identification of important characteristics of DMDs with regard to decision making 
on treatment. In total, 34 attributes were identified and defined, and 27 attributes were 
ultimately included in the best-worst scaling survey. The survey was administered to 185 
patients (87% female, with a mean (SD) age of 42 (9.6) years and mean (SD) disease 
duration of 6.4 (5.9) years, and to 27 neurologists and 33 MS nurses. According to these 
patients and healthcare professionals, the effect on disease progression, QoL and relapse 
rate were the most important characteristics for consideration in the treatment decision, 
followed by safety – according to healthcare professionals – or the severity of side effects 
– according to patients. The importance scores of all characteristics are presented 
elsewhere [19, 20]. Comparison of the average rankings of the ten most important 
characteristics according to patients and according to healthcare professionals did not 
reveal substantial differences. After assessment of the importance of the characteristics, 
the characteristics were categorized by the project group to match criteria for MCDA, i.e. 
avoidance of overlapping with other criteria and preference dependence (the importance 
of one criterion is not dependent on the performance of an alternative on another 
criterion) [18, 24]. To avoid preferential dependence, characteristics related to common 
side effects and administration of the DMD were combined into one category each. 
Because of overlap with “influence on daily life”, the administration-related characteristics 
were combined in a new characteristic “ease of use”, which included administration 
method, frequency, duration, the possibility of drinking alcohol and the ability to drive a 
car. Relapse rate and severity of relapses were combined into “effect on relapses”. To 
minimize the overlapping of “effect on MS symptoms” with “effect on disability 
progression”, the former was split into the most common and burdensome symptoms, 
specifically “effect on fatigue” and “effect on cognition” as assessed from the patients’ 
perspective. The effect on disability progression was defined as the change in EDSS score, 
assessed by a healthcare professional. “Effect on QoL” was included separately, as the 
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domains included in QoL measures vary substantially, meaning that not all measures 
include fatigue and cognition specifically. The characteristics included and omitted from 
the patient decision aid are presented in Table 1. Ultimately, nine characteristics of DMDs 
for RRMS patients were included. For CIS patients, a tenth characteristic was included 
after consultation with the advisory group, i.e. “time to definite MS diagnosis”. The 
advisory group agreed with the selection of the characteristics. 
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Stage 3. Format 
The underlying algorithms needed in MCDA to estimate the weightings of characteristics 
and produce rankings of alternatives require a computer-based delivery to enable the 
embedding of MCDA in a patient decision aid. The patient decision aid was, therefore, built 
in a survey software combined with an MCDA-software, which allowed for the immediate 
alignment of the patient’s preferences with the ranking of treatment options. 
Stage 4. Review and synthesis of evidence 
The search in Medline (Pubmed) identified 28 records, of which 7 network meta-analyses 
were assessed as potentially relevant for the outcome “effect on relapses” and “effect on 
disease progression”. Three additional health technology assessment reports including 
network meta-analyses [25-27] were identified through experts. The supporting 
information includes a table (S1 Table) presenting the identified studies according to the 
search date, the DMDs included in the network meta-analysis and the outcomes included. 
The most comprehensive and recent network meta-analysis was selected [22]. Studies have 
shown that generic glatiramer acetate is as effective as brand glatiramer acetate and has 
similar side effects [28]. Therefore, outcomes for the generic DMD were equated to the 
effects and adverse effects of the brand.  
The review for the effects of DMDs on QoL identified 14 RCTs reporting on any QoL 
measurement instrument for measuring the effects of the DMDs of interest. In these RCTs, 
nine different QoL-instruments were used. Reporting on the patient-reported outcomes 
QoL and its subdomains fatigue and cognition was often incomplete and inconsistent. QoL-
instruments were used in 35 instances, of which in only 11 instances differences in change 
scores from baseline to the follow-up point between the DMD and the comparator were 
(partly) reported on subdomains of the QoL-measures. Contacting authors did not result in 
the inclusion of any additional data of interest in the patient decision aid, mainly due to low 
response rates. Since the meta-analysis and QoL-review did not include data for cladribine, 
parameter values for effect measures for cladribine were based on data aggregated by 
Giovannoni et al. [29] or from the pivotal study [29, 30]. 
For MRI outcomes, the network meta-analysis published by the Canadian Agency for Drugs 
Technology and Health was assessed as most relevant, based on the operationalization of 
the outcomes in terms of the proportion of patients with gadolinium-enhancing lesions and 
with new or enlarging T2-hyperintense lesions; this meta-analysis included data for 
natalizumab, dimethylfumarate, fingolimod, teriflunomide and interferon beta-1a SC. 
Through the additional database search specifically for MRI outcomes, a review reporting 
additional data on MRI outcomes was identified [31]. For five DMDs (aletmzumab, 
dimethylfumarate, fingolimod, ocrelizumab and teriflunomide), the data of multiple studies 
were pooled. For three DMDs (glatirameer acetate 40mg, interferon beta-1a SC and 
interferon beta-1b), no data or data for only one of the dimensions of MRI outcomes were 
found. 
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Stage 5. Development of prototype
The patient decision aid was embedded in the software Elicia/Annalisa (Maldaba). Fig 1 
shows several screen shots, translated from Dutch for the purpose of this publication,
illustrating the format and content of the first prototype of the patient decision aid. The 
patient decision aid consisted of four parts. 
Fig 1. Screen shots of the patient decision aid for MS*  
*The screenshots have been recreated from the Elicia/Annalisa® software for translation of the the Dutch content 
to English. Therefore, the layout may deviate slightly from the layout in the Elicia/Annalisa software.
First, general information is provided about MS, description of the different MS disease 
courses and the treatment options for RRMS. General information about the treatment 
options includes a listing of all available options, an explanation of the trade-off in 
treatment characteristics that patients and their healthcare professionals need to make, 
and a description of the treatment characteristics. 
Second, the patient needs to answer a number of questions about their personal
demographic characteristics and medical history relevant to the selection of suitable 
treatment options based on recommendations for clinical practice [5]. These characteristics 
are gender, type of MS, whether first-line and/or second-line treatment options are 
considered, comorbidity, current medication use, if the patient is pregnant or breastfeeding 
or wishes to have children within a year. 
Third, the patient decision aid contains a value elicitation exercise to determine what 
treatment characteristics are important for the patient to consider in his/her treatment 
decision and to attach weights to each characteristic. The value elicitation exercise consists 
of two parts. Initially, the patient selects three to seven characteristics he/she wants to 
include in his/her decision (Fig 1A). Next, the patient rates the importance of each 
characteristic for the decision on a scale from 0 to 10, with 10 being very important, using 
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sliders (Fig 1B/C). A direct rating method was selected by considering the cognitive burden 
for patients and the precision required [24].  
Fourth, a ranking of treatment options is presented according to their suitability to the 
patient’s preferences. The ranking is presented as separate bars for each DMD. Each bar is 
compiled by combining the performance scores based on evidence and literature and the 
weights of the characteristics according to the individual patient using an additive model 
[24]. The overall value per DMD is calculated in two steps. First, the performance score and 
weight of each characteristic are multiplied. Second, all characteristic scores are added. The 
bar representing the overall score for each DMD is broken down in fragments illustrating 
the contribution each characteristic makes to the overall score of the DMD. The ranking is 
purposed to stimulate a discussion between the patient and the healthcare professional 
about the treatment options by showing the patient’s preferences for treatment 
characteristics, the performance of the treatment options on each treatment characteristic 
and how these two relate to each other visually in bars (Fig 1D). Using pop-ups, the 
performance of treatment options is explained in text.  
For each DMD a performance score per characteristic was calculated. To calculate a 
weighted risk of the common side effects for each DMD, first, an inventory of all the 
common side effects associated with any of the DMDs and the associated risks was made. 
Over 300 different side effects were identified. Two members of the project group (IK and 
PJ) clustered related or similar side effects into broader categories to reduce the extensive 
number of side effects to 36 categories. The risk of experiencing a common side effect 
during the use of a DMD was assigned a score between 0 (=high risk) and 1(=low risk): 
sing the DMD; 0.2= 1-10%; 0.4= 0.1-1%; 0.6= <0.1%; 0.8= 
incidental report; 1=never reported. Users of the patient decision aid were able to indicate 
which side effects, with a maximum of five, they would prefer to avoid. Next, patients rated 
how burdensome these side effects would be for them. The performance scores of DMDs 
were calculated accordingly: the risk score per side effect was multiplied by the rating for 
burden and the scores across all side effects were added per DMD and divided by the 
maximum possible score (i.e. score of 36 in case of no side effects at all).  
One of the neurologists indicated during the verification process that the relative 
performance on MRI outcomes of the first-line DMDs were too high or too low in his 
experience. This could result from the heterogeneity in operationalization, measurement 
and reporting the MRI outcomes in pivotal studies, resulting in missing or only partial 
available MRI outcome estimates. Of the first-line DMDs, only for teriflunomide was 
sufficient data available for both aspects considered in the MRI outcome. Therefore, in 
absence of more precise data, no distinction in performance on MRI outcomes was made 
for these DMDs, and the performance scores for first-line DMDs were equated to 
teriflunomide.  
For DMDs’ performance on safety profiles, first line, first generation DMDs scored 0.9 
(relatively safe); first line, second generation DMDs scored 0.8 (due to less extensive 
experience with the DMD); and second line DMDs scored 0.6. Following suggestions of two 
neurologists, an exception was made for natalizumab, with regard to the JC-virus status of 
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patients. If patients were negative, the performance of natalizumab was set at 0.8, as the 
associated risk of serious adverse events is substantially lower. 
Stage 6. Alpha pilot testing 
Alpha testing was conducted in three rounds. First, a neurologist, an MS nurse and three 
patients were asked for feedback. Accordingly, revisions were made to the patient decision 
aid. Next, 10 additional patients were interviewed and observed. The characteristics of 
patients included in rounds 1 and 2 are presented in Table 2. No new major comments came 
up in the last three interviews, indicating that data saturation was reached. Last, the 
neurologist from the first round, two additional neurologists and an expert in patient 
decision aid development provided feedback. The healthcare professionals had a lot of 
experience in the treatment of MS patients with DMDs, were from different hospitals in the 
Netherlands and were currently working in MS care, except for one neurologist, who was 
working as neurologist-researcher in MS. Respondents indicated that the patient decision 
aid has the potential to be a valuable addition to the decision making process. However, 
interviews and observations of respondents also identified issues and areas for 
improvement of the patient decision aid; these were clustered in three overall themes: 
content and framing, weighting methods for the importance of characteristics according to 
the patient, and the presentation of the result of the patient decision aid (Table 3). These 
three themes are discussed below.  
 
Table 2. Characteristics of patients (n=13) involved in the alpha testing 
  N (%)*  
Gender Female 10 (77)  
 Male 3 (23  
Age (years) Mean ±SD  53.9 ±9.0  
 Range 35-64  
Highest educational level Pre-vocational education 3 (23)  
 Vocational education 3 (23)  
 Higher education 7 (54)  
MS type RRMS 11 (85)  
 SPMS 2 (15)  
Time since MS diagnosis Mean ±SD 17.0 ±11.6  
(years) Range 1-38  
Experience with DMDs Yes 13 (100)  
 No 0 (0)  
* unless otherwise specified 
MS: multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SD: standard deviation; SPMS: secondary 
progressive multiple sclerosis 
Content and framing 
Three major issues were identified by healthcare professionals and/or patients regarding 
the content and framing. First, while the patient decision aid initially included only general 
information on RRMS and CIS, a healthcare professional in round 1 of the pilot test indicated 
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that general information about the progressive disease courses would be useful in painting 
a complete picture for the patient. This information was added to the patient decision aid, 
including figures sketching the extent to which disabilities could increase over time in the 
different disease courses. In round 2, most patients agreed that the information about all 
disease courses was useful. Some patients commented that the figures would be more 
logical if they would illustrate how physical abilities could decrease instead of how physical 
disabilities could increase. No majority for one of the two possibilities was identified during 
the interviews with the patients, nor with the professionals in round 3. Therefore, figures 
presenting increase in physical disability were used, as this was regularly used in the clinical 
practice of the healthcare professionals involved.  
A second comment on the patient decision aid made by a nurse in round 1 and reinforced 
by a number of patients in round 2 concerned the query about selecting the side effects 
which the patient would like to avoid. The list of 36 side effects was too overwhelming for 
patients and off-putting. When confronted with the list, a number of patients stated: “I 
don’t want to get any of them”, wanting to select all side effects. Because many patients 
had this reaction to the question, the list of 36 side effects was reduced to ten side effects 
that occur very often or often when using any of the DMDs. The question about side effects 
was adapted to: “Which side effect would you definitely want to avoid?” The algorithm for 
calculating the performance score of DMDs on the side effects was adapted. Any DMD with 
a risk of occurring in 1% or more of patients using the DMD would score zero on the side 
effects. In round 3, no new comments on the cognitive burden for patients of answering 
this question were raised by the professionals.  
As a third issue, in all rounds, the neurologists, MS nurses and the patients indicated that 
questions regarding the type of MS, comorbidity, other substance or medication use and 
whether patients are eligible for first-line and/or second-line medication could be difficult 
to answer, despite adaptations to the formulation of these questions in between rounds, 
with the goal of easing the understandability of the questions. Two solutions were 
considered appropriate and were discussed in rounds 2 and 3 with patients and healthcare 
professionals: 1) the patient receives a note summarizing their medical history, which the 
patient can copy into the patient decision aid; or 2) the healthcare professional (treating 
neurologist or MS nurse) fills out the specific questions on medical history before the 
patient uses the patient decision aid. Beta pilot testing would need to show which method 
is most feasible for implementation. 
In addition, during all rounds a number of textual remarks were processed to clarify 
information or to match explanations currently given by healthcare professionals in clinical 
practice. Examples are to illustrate cognitive disabilities with examples and to elaborate on 
the role of monitoring in securing safety during second line drug use.  
Weighting methods for the importance of characteristics according to the patient 
During the first round of the alpha testing, a neurologist questioned whether the direct 
rating method would be the best approach as a weighting method as “all patients would 
rate the characteristics as very important.” In round 2, observations and interviews with 
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patients did not identify any problems for patients to weight characteristics using the direct 
rating methods, but showed indeed that the direct rating method resulted in relatively flat 
distributions in importance scores. The majority of the patients rated the selected 
characteristics with the same or almost the same score, most often a 9 or 10, representing 
“very important”. In round 3, several other methods were considered and discussed with 
the professionals. Other methods, such as Simple Multi-Attribute Rating Technique and 
Point Allocation [24], were discussed with the professionals as alternatives to direct rating, 
since these methods specifically incite patients to compare the characteristics according to 
their relative importance. However, the neurologists, expert in patient decision aid 
development and the project group regarded these methods as too difficult and cognitively 
burdensome for patients. The risk of flatter distributions of importance scores for the 
characteristics in the direct rating method was therefore accepted, as characteristics could 
in theory be equally important for the patient in the decision. 
In round 2, it became apparent that the initial format for patients to weight characteristics 
using sliders was problematic in several ways: the interval of 1 decimal was distracting; 
scoring 0 was difficult because respondents had to move the slider from zero and back; and 
in terms of coordination the sliders were difficult to use, especially using the mouse pad of 
a laptop. Patients indicated that they would prefer simply selecting the weight between 
zero and ten using check boxes. Adaptations were made accordingly. 
Presentation of the result of the patient decision aid 
Three major challenges were identified regarding the presentation of the result of the 
patient decision aid: ensuring that the patient understands the ranking of the DMDs 
according to the preferences, ensuring that healthcare professionals understand how DMDs 
have been filtered out based on the patient’s eligibility, and ensuring that patients have 
both sufficient and structured information about the most suitable DMDs. From round 1, it 
became apparent that the result screen presenting the ranking of DMDs, the weightings of 
the characteristics and the performance levels of the DMDs according to the characteristics 
could be overwhelming for patients. Therefore, the result screen and its explanation 
underwent a number of adaptations throughout the pilot testing between the different 
rounds and, within round 2, between smaller groups of patients. After round 1, the choice 
was made to present only the ranking of the DMDs to the patient and to collapse the 
information about the weighting of the characteristics and the performance scores of the 
DMDs. The patient would be able to fold out the additional information in the same screen. 
Instructions explaining the functionalities of the result screen were given one page earlier. 
This format was tested in subsequent rounds with patients. The most prominent challenge 
was to instruct patients adequately about the functionalities while considering the 
information processing capacities of MS patients: elaborating on the explanation was too 
tiresome, yet shorter explanations resulted in misunderstandings. In the different 
iterations, the instructions were constantly adapted in response to the patients’ comments 
by adding figures, changing the layout to ease reading and adapting formulations of the 
instructions. Even so, most patients needed additional instructions from the interviewer to 
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fully understand the results. Once the results were fully understood, the patients were 
enthusiastic about the richness of the patient decision aid: “It helps to deepen my 
knowledge and prepare me for the consultation.” In round 3, the project team made the 
choice to present a simplified version of the result screen to the patient first, only presenting 
the rankings of the DMDs, without the ability to fold out extra information (Fig 2A). This 
limited the amount of instructions – presented just above the ranking – that the patient 
needs to understand all of the functions of the result screen. Next in the patient decision 
aid, the patient is asked whether he/she want to learn more about how the ranking was 
compiled. A subsequent screen includes the patient’s weights for characteristics and the 
DMDs’ performances on the characteristics in bars, with pop-ups explaining the bars (Fig 
2B). This way, the patient decision aid was adapted to fit patient preferences and cognitive 
abilities in processing the amount of information about the DMDs better. After these 
adjustments, the patient decision aid expert and the neurologists still questioned whether 
the patient decision aid would be suitable for use by patients with low or middle levels of 
education. Beta pilot testing should show whether supervision by a trained MS nurse is 
needed when going through the patient decision aid and whether this delivery format is 
feasible in clinical practice.  
In round 1, the neurologist commented that an understanding is needed of how questions 
concerning the patient’s eligibility for the DMDs (e.g. type of MS, comorbidity) affect the 
selection of the DMDs in the patient decision aid for each individual patient. Therefore, a 
summary page was included at the end of the patient decision aid stating all criteria that 
affected the selection of DMDs suitable for the patient, the patient’s answers and which 
DMDs were omitted as a result from the patient decision aid. If a patient answered “don’t 
know”, this was also presented. The summary page was further evaluated in the following 
rounds, and no additional comments were made by the respondents.  
The result screen (the ranking and optionally the weighting of characteristics and the 
performance scores of the DMDs), the schematic overview of the DMDs’ characteristics and 
the summary of the assessment of the patient’s eligibility for the DMDs can be printed 
and/or sent to the healthcare professional. 
In round 2, a couple of patients commented that they would prefer additional information 
on the result screen, summarizing the most suitable DMD options. One patient commented: 
“I would not be able to choose based on this [the ranking].” Therefore, in deliberation with 
the patients, a function was added through which the patient could select the three DMDs 
he/she wants to read more about, based on the initial ranking of the DMDs. This 
information, which is identical to the information in the pop-ups for the performance bars, 
is provided in a tabular form presenting the characteristics of the three DMDs side by side.  
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Fig 2. End screens: Parts I and II
Other minor remarks
A number of minor remarks regarding the format, scope and functionality of the patient 
decision aid were made in all rounds of the pilot testing, and adaptations were made 
accordingly where possible (S2 Table). However, technical functionalities of the software 
limited certain desired adjustments, such as spacing between text, enlarging check options, 
accentuating the cursor on the screen, using progress bars instead of page numbers, 
including menu tabs to switch between chapters, using pop-ups for more information and 
additional reading. Before beta-testing of the patient decision aid, a switch to different 
software will be made so that additional functionalities and layout requirements can be 
incorporated. 
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Table 3. Major comments and adaptations in the alpha test 
Round Major comment Adaptations made 
Weighting method for importance of DMD characteristics by patient 
1 Direct rating does not force patient to 
differentiate in importance of 
characteristics 
Observations of rating by patients in 
round 2. 
2 Several patients rated all characteristics as 
very important. 
Alternative weighting methods (i.e. Simple 
Multiattribute Rating Scale, (SMART) and 
Point Allocation) were incorporated in the 
patient decision aid as a try-out.  
3 Other weighting methods were found to 
be too complex.  
Direct rating was applied.  
Usability of sliders 
 
2 Intervals of 1 decimal are too small. Check boxes replaced the sliders.  
2 Sliders are difficult for scoring zero. 
2 Sliders are difficult if patient’s 
coordination is reduced. 
Patient’s ability to answer questions 
1 Patients cannot decide on their eligibility 
for second-line treatment. 
Framing of questions adapted: "Are you 
willing to accept higher risks of severe 
adverse events, for more efficacy?"  
Patients might not be able to answer 
questions regarding other medication use. 
Explanation of medications was added. 
2 Too difficult to answer which type of 
medication to include. 
Question whether to include all DMDs was 
deleted.   
Questions about comorbidity, other 
substances, MS type are too difficult for 
patients. 
Since a 'don't know' option was available, 
no adjustments were made. 
3 Patients need instructions on how to 
answer questions about MS type and type 
of DMDs. 
Patients may receive a note summarizing 
their medical history or the healthcare 
professional fills out the question for the 
patient.  
Rating side effects 
1 Do not include all 36 side effects. It could 
scare people.  
 
2 The list of side effects puts off: "I don't 
want to get any of them." 
List was reduced to the 10 most common 
side effects. 
3 No comments were made. 
 
Disease courses 
1 Include the progressive types of MS and 
add illustrations to clarify the differences 
in disease courses. 
Information and figures were added. 
2 Figures should illustrate the decline in 
abilities, instead of the increase in 
disabilities. 
Contradictory reactions. Figures were kept 
as they were to connect to the verbal 
explanation of the disease course. 
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3 Consider whether to illustrate the decline 
in abilities, instead of the increase in 
disabilities. 
Summary page 
1 The healthcare professional needs to 
know how the patient’s answers affected 
the selection of DMDs. 
Summary page was added, including 
information about DMD selection based 
on the patient’s eligibility. 
2 no additional comments 
 
3 no additional comments 
 
End screen 
1 The amount of information on the end 
screen is overwhelming. 
Information on weighting and 
performance scores of the DMDs was 
made optional. Instructions were added to 
explain the additional functions to 
patients. 
2 The instructions are too elaborate and 
difficult to understand. 
The instructions were adjusted a number 
of times and tested with new patients. 
Visual instructions were added in figures 
which showed how to access additional 
information. Still, instructions were too 
difficult for all patients to understand the 
whole end screen. The end screen was 
divided in two parts. The first part 
presents only the rankings of the DMDs 
and explanations focus only on explaining 
these rankings. Access to the second part, 
which explains in depth how the rankings 
were compiled, is optional. 
3 The patient decision aid may not be 
suitable for patients to go through 
individually, except for highly-educated 
patients. Consider whether an MS nurse 
should guide the patient in the use of the 
patient decision aid. 
Beta test should show whether the 
guidance of an MS nurse is feasible and 
desirable for patients.  
Additional reading 
2 Preference for the possibility of reading 
more information on DMDs of choice. 
An option to select three DMDs to read 
more about was included. The patient 
decision aid provides a schematic 
overview of the selected DMDs, according 
to the characteristics. 
3 No additional comments were made.  
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A systematic approach was used to develop an online patient decision aid about DMDs for 
the treatment of MS. The approach consisted of defining the scope, assessing users’ 
decisional needs, establishing a format, reviewing the evidence, developing a prototype and 
iteratively alpha testing the prototype. The alpha test showed the prototype had some 
issues regarding the content and framing, the methodologies used for weighting the options 
and the end screen.  Adaptations were made accordingly, but room for improvement 
remains and some issues should be further studied, since only alpha testing has been 
conducted thus far.  
Strengths and weaknesses of the patient decision aid 
The developed patient decision aid differs from most other patient decision aids in the 
approach used. The MCDA-based approach was applied as we hypothesized that this 
approach averts putting a high cognitive burden on the MS patient to study and understand 
all available DMDs for the treatment of MS by performing an explicit trade-off of 
(conflicting) characteristics according to the patient’s preferences. Using the approach in 
our patient decision aid, the patient is able to make a selection of treatment options he/she 
wants to read more about. The deliberation and consultation with the healthcare 
professional can then be focused on the selected DMDs, as these best fit the patient’s 
preferences. The application of the MCDA approach did, however, also introduce new 
difficulties for patients in terms of understanding the ranking of the treatment options and 
how ranking was compiled. Changes in the delivery of the patient decision aid could support 
patients in this. Whether the MCDA-approach actually reduces overall cognitive burden 
should be further studied, preferably by comparing decision-making with the MCDA-based 
patient decision aid to decision-making without the decision aid or with the decision aids 
without decision analysis.   
The application of the MCDA approach does mean that the patient decision aid may not 
fulfil all criteria for patient decision aids as established by the IPDAS [32]. For example, in 
the patient decision aid it is optional for patients to read information about all treatment 
options, including the probabilities on outcomes, risks and procedures involved; this 
information is provided per DMD is after the preference elicitation. Because the patient 
decision aid explicitly includes the patient’s preferences in the ranking, it is only optional for 
the patient to read the information. This approach increases the personalization of the 
patient decision aid to the patient’s informational needs, but could decrease the patient’s 
knowledge gain about all treatment options in comparison with other patient decision aids. 
The MCDA approach resulted in other challenges as well, specifically concerning the 
translation of the outcome estimates into performance scores between zero and one. 
Comparability of the DMDs for a specific characteristic is difficult when some clinical data is 
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lacking or has not been completely reported, such as the data for MRI outcomes. 
Performance scores were in that case set to zero, the same score if no significant difference 
between the treatment option and placebo was found. We, however, acknowledge that 
lack of evidence is not the same as no efficacy, and lower levels of evidence, such as results 
from observational studies and expert opinions. Validation of the performance scores with 
a larger group of clinical experts is needed to increase the objectivity of the scores. 
Moreover, inclusion of additional data from Phase IV studies, including observational ones, 
could enhance the overall picture of all treatment options.  
The alpha testing was primarily aimed at establishing the content, usability and 
comprehensibility of the patient decision aid. Further development of the patient decision 
aid is still needed, such as improvements in layout and functionalities (which were limited 
by the software), and the appropriate delivery of the patient decision aid needs to be tested 
with regard to maximizing understanding of the results (i.e. whether the aid should be used 
by the individual patient or used under the supervision of a trained nurse).  
This patient decision aid contains components specifically for MS patient in the 
Netherlands. The patient decision aid could, however, be transferred to other countries. 
Adaptations to the content of the patient decision aid should be made for it to fit country-
specific contexts, for instance regarding eligibility criteria for DMDs and, possibly, regarding 
aspects that should be included (e.g. out-of-pocket expenses might be important in 
countries where DMDs are not fully covered by health insurance). 
Recommendations and implications for implementation and further research 
The patient decision aid is designed and intended to support discussion about treatment 
options and patient’s preferences between the patient and healthcare professional to 
ultimately make a shared decision about starting DMDs. Therefore, the patient decision aid 
must not replace the consultation with the healthcare professional, nor should the result of 
the patient decision aid dictate what the “best” DMD would be. 
In absence of a clinical guideline from the Dutch Society for Neurology, the patient decision 
aid has been developed based on the best available evidence in the literature and following 
recommendations from the Dutch Healthcare Institute. The guideline is currently in 
development. To facilitate implementation, it is recommended that patient decision aids 
relate closely to clinical guidelines [33]. Therefore, the patient decision aid should be 
reviewed and updated, if needed, as soon as the clinical guideline has been completed, and 
formal relations with these clinical guidelines should be established. Moreover, the field for 
MS treatments is developing quickly, making the decision for treatment only more complex 
as new treatments come to market. Keeping the patient decision aid, and for that matter 
the clinical guidelines, up to date is challenging, but of great importance. The online format 
of the patient decision aid ensures that changes to its content, i.e. new treatment options, 
changes in eligibility criteria or new evidence about outcomes and burden, will reach users 
immediately. However, monitoring these developments will be challenging. Structures 
should be set up to ensure immediate updates when new evidence becomes available.  
4
141878 Ingrid Kremer BNW.indd   105 19-02-20   09:50
C H A P T E R  4  
106 
 
Translating evidence into performance scores was more challenging for some 
characteristics than others, such as safety and MRI outcomes. Safety does not translate 
easily to a score between 0 and 1 because the data is textual and, although based on among 
others the summary of product characteristics, the translation introduces subjectivity. 
Moreover, the reporting of outcome measures on DMDs was inconsistent and there is a gap 
in high level evidence about the comparative effectiveness of DMDs on a number of 
characteristics, such as quality of life, MRI outcomes, and cognition. Lower level evidence, 
such as observational studies or expert opinions could fill these gaps until higher level 
evidence becomes available. Delphi studies could be useful to reach consensus among 
experts regarding the performance scores. 
The patient decision aid has been user tested only with patients who had previously made 
a decision about DMDs, and were not considering switching treatment at the time of 
testing. Overall, the participants in the alpha test were positive about the potential use of 
the patient decision aid, but since implementation of the patient decision aid was not yet 
pilot tested, participants could only speculate and the actual added value for shared 
decision-making should be further studied. Further development of the patient decision aid 
is needed regarding the verification of the rankings made by the decision aid, including the 
influence of uncertainty about effect estimates, and improving understandability of the 
patient decision aid through evaluation of the required health literacy, and adaptation of 
the delivery of the patient decision aid and validation of the patient decision aid. 
Afterwards, a beta pilot test needs to be conducted to test the feasibility of implementing 
the patient decision aid in clinical practice with patients actually making the treatment 
decision, and to evaluate the potential benefits of the patient decision aid on the quality of 
the decision as other patient decision aids have been shown to demonstrate [12]. It has also 
been argued that patient decision aids positively affect treatment persistence and 
treatment adherence [34], and therefore increase health outcomes and decrease the use 
of healthcare resources [35], although evidence supporting this is still limited [12, 35]. A 
randomized controlled trial comparing the patient decision aid to usual care should be 
conducted to assess these effects and should evaluate what the influence is on the patient’s 
cognitive burden in making the decision.  
Conclusion 
We systematically developed and alpha tested an MCDA-based online patient decision aid 
about DMDs for MS. MCDA-based decision support tools could be perceived as a black box 
if the developmental process and content of the tool have not been made transparent. This 
paper aimed to provide more insight into the developmental process and challenges faced 
during this process. Issues identified in the prototype were resolved as much as possible, 
though some issues remain. Whether adaptations in the delivery of the patient decision aid 
overcomes these issues, should be further studied. Further development is needed, 
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including beta pilot testing to evaluate the feasibility of implementation in clinical practice, 
followed by a randomized controlled trial to assess clinical and economic effects.  
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Table 1. Network meta-analyses identified for efficacy outcomes 
 Reference Search date DMDs Outcome 
CADTH 2014 [1] Oct 2013 ATZ (ARR only), DMF, FIN, 
GA20, IFN (excl. PEGINF), 
TF 
ARR, patients with 
sustained disability 
progression (either 
confirmed after 3 or 6m) 
Couto et al. 2016 
[2] 
09 Nov 2015 ATZ,DMF, FIN, GA20, GA40 
(ARR only), IFNB, PEGIFN, 
NTZ, TF 
ARR, patients with 
disability progression  
Del Santo et al. 
2012 [3] 
NR IFN, GA, NTZ, FIN vs. 
placebo 
relapse-free rate 
Fillippini et al. 
2013 [4] 
Feb 2012 IFN, GA, NTZ, MTX, 
Methotrexate, CYC, AZA, 
IMM, Corticosteroids 
Recurrence of relapses, 
patients with disability 
progression 
Fogarty et al. 
2016 [5] 
Mar 2016 ATZ, NTZ, FIN, DMF, 
PEGIFN, GA,20, GA0, IFNB, 
TF 




al. 2013 [6] 
12 Nov 2012 IFNB, TF, GA, NTZ, FIN, 
MTX, but not vs. placebo 
patients free of relapses, 




Huisman et al. 
2013 [7] 
14 Nov 2014 FIN vs. DMF in highly 
active RRMS; FIN vs. NTZ in 
rapidly evolving severe MS 
ARR, difference in EDSS 
change, patients with 
confirmed disability 
progression 
ICER 2017 [8] 15 Sep 2016 ATZ, DMF, FIN, GA20, 
GA40, IFNB, NTZ, PEGIFN, 
TF, OCR, DAC, RTX 
ARR, patients with 
disability progression 
confirmed  
Tramacere et al. 
2015 [9] 
30 Sep 2014 IFN, GA, NTZ, MTX, FIN, TF, 
DMF, ATZ, PEGIFN, DAC, 
OCR, LAQ, AZA, IMM 
patients with new 
relapses, patients with 
disability worsening 
Zintzaras et al. 
2012 [10] 
Jan 2011 FIN, NTZ, RTX, CLAD, IFNB-
1a, TF, FINVs. IFNB-1b 
250ug/ placebo 
Patients free of relapse, 
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Table 2. Minor comments and adaptations made in accordance with comments in 
response to the alpha test 
 Round Minor comments Adjustments 
Content and framing   
1 Illustrate cognitive disabilities with examples Adjusted accordingly. 
  Consistent use of terminology for "relapses" Adjusted accordingly. 
  Provide nuances in discussing disease progression. Adjusted accordingly. 
  Differentiate in the occurrence of different side 
effects.  
Adjusted accordingly. 
  Provide the generic drug names first, followed by the 
brand name in brackets for reasons of independence. 
Brands are better known 
to patients. Brand name 
is followed by generic 
name. 
  Elaborate on the role of monitoring programs to 
improve safety and reduce risks. 
Adjusted accordingly. 
  Information about whether the patient is planning to 
travel in the short term and needs vaccinations would 
support the consultation. 
Adjusted accordingly. 
  Explain second-line medication Adjusted accordingly. 
  Patients need more information about the process of 
injecting medication. 
Adjusted accordingly. 
  Information about monitoring during use of second-
line medication to feel at ease about safety 
Adjusted accordingly. 
  Link to useful/reliable patient information Adjusted accordingly. 
2 Wish to have children should include option “don’t 
know” 
Adjusted accordingly. 
  Travel plans should include option “don’t know”. Adjusted accordingly. 
  Choosing characteristics is difficult. “They are all 
important.” 
- 
  Pictures presenting the degree of disability 
progression for explaining natural course of different 
MS types is confronting. 
- 
  Figures explaining MS types should be “wavy”. - 
3 Difficulty distinguishing between characteristics, also 
after reading additional information.  
- 
End screen   
1 Would be informative to see ranking of medication 
based on a single characteristic 
The performance scores 
per DMD provide this 
information. 
  In result screen, add the possibility to change weights 
to see their effect immediately.  
 - 
  In result screen, rank medication from most to least 
fitting to patient’s preferences. 
Software limits the ability 
to make adjustments 
accordingly. 
  In result screen, distinguish between first-line and 
second-line medication. 
Software limits the ability 
to make adjustments 
accordingly. 
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  Explain the direction of the side effects in the result 
screen as this could be counterintuitive 
Adjustments made 
accordingly. 
 2 Repeat characteristics above the performance bars in 
result screen 
Software limits the ability 
to make adjustments 
accordingly. 
  Remove numbers in performance bars or put them in 
the bars, not underneath them 
Software limits the ability 
to make adjustments 
accordingly 
 3 Selection of DMD to read more about should be 
presented under the result screen. The link between 
the ranking and the selection should also be clearer.  
Software limits the ability 
to make adjustments 
accordingly. 
  Should be able to select DMD in Result screen for 
further information. 
Software limits the ability 
to make adjustments 
accordingly. 
  End screen seems like a black box. - 
Other   
 1 Provide clinicians with an instructional card about the 
patient decision aid for use in clinical practice.  
Beta-testing 
  A separate patient decision aid for CIS might be 
obsolete because of the earlier diagnosis of RRMS 
according to the new McDonald diagnostic criteria.  
- 
  Consider adding treatment options for PPMS and 
SPMS. 
- 
  It’s difficult for colour-blind people to distinguish red 
and green. 
Software limits the ability 
to make adjustments 
accordingly. 
  Online is difficult because I would like to highlight text 
and go back to it if I need a break. 
Option added to print 
text. Patient decision aid 
already included option 
for saving progress.  
  Consider whether text can be read out to people. Beta-testing 
 2 Include the option to send results to the specialist. Beta-testing 
  Include the option to print all results or send it to e-
mail. 
Beta-testing 
  Notice of missing answers is unclear. Software limits the ability 
to make adjustments 
accordingly. 
  Difficult to select answer options: check boxes are too 
small 
Software limits the ability 
to make adjustments 
accordingly. 
  It’s difficult to see the cursor on a white screen. Software limits the ability 
to make adjustments 
accordingly. 
  Difficulty with returning to patient decision aid after 
accessing an external link for further reading.  
Include information as 
pop-up in same screen. 
Software limits the ability 
to make adjustments 
accordingly. 
  Reactions to questions should appear immediately 
under the question after answering instead of on the 
next page.  
Adjusted accordingly. 
4
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  Space for summaries or notes would be useful. Adjusted accordingly. 
  Effect on QoL should be excluded because QoL will 
never be the same again.  
- 
  Page numbering at the top of the page is off-putting: 
“29 pages!” 
Software limits the ability 
to make adjustments 
accordingly. 
  PPMS doesn’t have to be explained. - 
 3 Formulate sentences addressing the reader directly. Adjusted accordingly. 
  Simplify language. Too much jargon.  Adjusted accordingly. 
Before beta-testing the 
reading level of the 
patient decision aid will 
be reviewed.  
  Include menu tab that shows new chapters and ability 
to go back to a previous chapter.  
Software limits the ability 
to make adjustments 
accordingly. 
  Use a progression bar instead of page numbers. Software limits the ability 
to make adjustments 
accordingly 
  Switch order of safety and side effects in the 
presentation of DMD characteristics 
Adjusted accordingly. 
  Too much emphasis on ease of use due to additional 
questions for rating the performance. 
Questions concerning 
rating burden of use 
positioned after 
questions concerning 
weighting of criteria.  
  Delete question about alcohol. Puts too much 
emphasis on it. Include a statement that all DMDs 
could be used with normal alcohol use.  
Adjusted accordingly. 
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Background. For patients with relapsing-remitting multiple sclerosis (RRMS), non-
adherence and discontinuation of disease-modifying drug (DMD) treatment is problematic. 
Shared decision making can decrease non-adherence and discontinuation rates by ensuring 
that patients’ treatment choices are congruent with their informed values. However, shared 
decision making may come at an additional cost, resulting, for example, from the 
implementation of patient decision aids or from increased consultation time with the 
physician or care team. This study aims to explore the potential cost-effectiveness of shared 
decision making for RRMS in comparison with usual care, from a limited societal perspective 
over a lifetime.  
Methods. We adapted a previously developed state transition model that evaluates the 
cost-effectiveness of a range of DMDs for RRMS in comparison with the best supportive 
care. Three potential effects of shared decision making were explored: 1) a change in the 
initial DMD chosen; 2) a decrease in the patient’s persistence in using the DMD; and 3) an 
increase in adherence to the DMD. One-way and probabilistic sensitivity analyses of a 
scenario that combined the three effects were conducted to evaluate the robustness of the 
results. A threshold analysis was further conducted to estimate at which costs SDM per 
patient may be cost-effective. 
Results. Each effect separately and all three effects combined resulted in higher quality-
adjusted life years (QALYs) and costs due to the increased utilization of DMD, the primary 
cost driver. A decrease in discontinuation of DMDs influenced the incremental cost-
effectiveness ratio (ICER) most. The combined scenario resulted in 1.12 QALYs gained and a 
€20,009 increase in costs, leading to an ICER of €17,875 per QALY gained. The probability of 
shared decision making being cost-effective for a threshold of €50,000 per QALY was 98.5%. 
The ICER was sensitive to drug prices, the risk of disease progression, the discount rate and 
to the perspective taken. Shared decision making could maximally cost €23,639 to be cost-
effective at a threshold of €50,000 per QALY.  
Conclusion. Shared decision making could potentially be cost-effective for supporting 
patients’ choices between DMDs, especially if shared decision making would help to 
decrease treatment discontinuation. Shared decision making was found to be cost-effective 
even if upfront intervention costs are high. With new initiatives being explored to increase 
the uptake of shared decision making, this study informs clinicians and policy decision 
makers about the potential economic value of such investments, and which assumptions 
and parameters should be explored in future trial-based studies.  
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Currently, a large number of disease-modifying drugs (DMDs) are available to reduce the 
number and severity of relapses in patients with relapsing-remitting multiple sclerosis 
(RRMS) [1, 2]. Relapses are exacerbations of physical and cognitive symptoms that resolve 
partially or completely (remissions) after weeks or months [3]. By reducing the number of 
relapses, DMDs also delay the accumulation of disabilities. Patients with RRMS most often 
have several options in the treatment with DMDs, including the choice to refrain from DMD 
use. The use of DMDs can be burdensome for patients due to side effects and administration 
regimens; these characteristics differ between DMDs.  
Decision making about treatment for RRMS is therefore difficult and the patient should be 
involved [4] for several reason. First, More efficacious DMDs are associated with a higher 
risk of severe or life-threatening adverse events, resulting in these DMDs typically being 
indicated for patients with high disease activity [5]. Moreover, patients experience the 
burden of administration and common side effects differently, which puts a different value 
on DMDs with certain attributes [6]. Second, healthcare providers making a treatment 
decision without consulting the patient often make inaccurate assessments of the patient’s 
preferences for treatment options, instead basing assessment on personal preferences and 
experience [7]. Third, persistence with and adherence to treatment regimens are 
suboptimal among many patients [8-11]. Treatment persistence refers to patients 
continuing treatment over the long-term [12], and treatment adherence is defined as “the 
extent to which a patient acts in accordance with the prescribed interval, and dose of a 
dosing regimen” [12]. Real-world studies in MS show that discontinuation rates in the first 
year after DMD treatment initiation range between 10 and 31% [9-11]. Of the people who 
do persist, only 60% of patients taking injectable and orally administered DMDs were 
reported to have optimal adherence [8].  
Shared decision making is an approach that can help explicitly to integrate informed 
patient’s preferences for treatment options into clinical decisions [13]. Healthcare 
professionals enable the patient to develop informed preferences for treatment options by 
sharing information. In turn, the patient shares his/her preferences with the healthcare 
provider. Consecutively, the patient and healthcare professional discuss the best matching 
treatment options, considering the patient’s preferences and the best available evidence, 
to make a treatment decision together [13]. Shared decision making is often supported by 
patient decision aids which inform patients about their options and help them to 
understand and express their preferences [14]. Patient decision aids have been shown to 
facilitate shared decision making [14] and could improve treatment adherence [15].  
The implementation of shared decision making with or without a patient decision aid can 
also have implications for resources. Trenaman et al. [16] distinguish three categories for 
how resources could be affected through the use of a patient decision aid, potentially 
increasing or decreasing costs: 1) delivery of the patient decision aid and its effect on 
consultation time; 2) short-term costs because patients may opt more often for more or 
less expensive options; or 3) long-term costs because of a postponed intervention or 
5
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changes in persistence and adherence. For example, implementation of shared decision 
making with or without patient decision aids could increase consultation time and thus 
increase costs [14, 17]. Furthermore, cost reductions in the short term have been reported 
for one-off interventions because patients chose less invasive and less costly interventions 
[18, 19]. In addition, patient education and value elicitation could support patients in 
developing a more persistent and adherent attitude towards taking a particular medication. 
As a result, health outcomes would improve and utilization of health care, and consequently 
costs, would decrease [20]. The consequences for costs may depend, however, on the 
treatment decision and the context [16]. While there is less evidence on the consequences 
of shared decision making and patient decision aids regarding persistence, adherence, 
health outcomes and costs for chronic diseases requiring long-term treatment [16], various 
efforts are underway to create training and tools for MS. 
An investment in shared decision making has an opportunity cost, diverting funds used for 
other aspects of the healthcare system, including the budgets used to pay for drugs. It is 
therefore important to understand the cost-effectiveness of interventions that support 
shared decision making, similar to how decision makers assess the cost-effectiveness of 
drugs for reimbursement decisions. [21]. Accordingly, this study aimed to evaluate the 
potential lifetime cost-effectiveness of shared decision making with regard to DMDs for 
RRMS in comparison with usual care from a societal perspective. The study has an 
exploratory nature to determine the headroom for implementation of shared decision 
making for DMDs for RRMS. Therefore, we also estimate the maximum costs at which 
shared decision making remains cost-effective. The results will inform decision makers and 
clinicians about the potential value of implementing shared decision making in clinical 
practice. By explicitly modeling the different consequences of shared decision making (i.e. 
the costs of delivery of shared decision making, treatment choice, persistence and 
adherence) on relapses, quality-adjusted life years (QALYs), and costs, this study also aimed 
to reveal which effects drive the cost-effectiveness. Results could underline the need to 
develop effective interventions for implementing shared decision making (e.g. patient 
decision aids), and to help in designing future trial-based and model-based economic 
evaluations of shared decision making and other interventions focused on improving 
persistence and adherence during long-term treatment.  
Methods 
We adapted a state transition model developed by the Institute for Clinical and Economic 
Review in the United States, which evaluated the cost-effectiveness of a range of DMDs for 
MS [22]. The model structure and inputs, based on various other models [23-29], has 
previously been validated through rounds of public comments, cross-validation with other 
models, and sensitivity analyses [22]. We modified the model to assess the cost-
effectiveness of implementing shared decision making regarding DMDs choice, and 
estimated the potential societal costs, QALYs and incremental cost-effectiveness using a 
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Dutch perspective and following clinical practice and guidelines for economic evaluations in 
health care [30]. For reporting, we followed the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) [31].  
Population 
The modeled population were adults with RRMS without prior experience with DMDs in the 
Netherlands. These patients had a mean age of MS onset of 37 years [32, 33]. Within this 
population, 29% were male [32, 33]. 
Intervention and comparator 
Implementation of shared decision making in the intervention group was compared with 
usual care in the control group. In the intervention group, the healthcare professional 
applies the principles of shared decision making with the patient during the decision making 
process about DMDs. Patient decision aids are commonly used during or between two 
consultations to educate patients about their treatment options and to help clarify personal 
values regarding the treatment options [14]. During a (follow-up) consultation, the patient 
and healthcare professional discuss the treatment options and the patient’s preferences to 
make an informed and shared decision on treatment [13]. In the control group, we assume 
that usual care decisions are mostly made in accordance with the healthcare professional’s 
judgment of what fits best with the patient’s needs, with little attempt to determine or 
acknowledge what the patient’s preferences might be with regard to the decision. In both 
groups, patients would be prescribed a treatment with a DMD or no active treatment (best 
supportive care).  
Model structure 
To model the disease course of RRMS and the risk for progression to secondary progressive 
MS (SPMS), twenty health states defined by the Expanded Disability Status Scale (EDSS) 
were included according to the model described by Zimmermann et al. [34]. Patients with 
RRMS could enter the model in health states with an EDSS score between 0 and 9. During a 
cycle of 12 months, patients could improve or worsen in RRMS health states, remain stable, 
or progress to SPMS. The transition probabilities were estimated based on natural history 
[27]. The effectiveness of each DMD is modeled through applying a relative risk for each 
DMD to the transition probabilities [34]. In the SPMS health states, patients could progress 
to a higher EDSS state or remain in the same health state, i.e. patients could not improve. 
Patients could experience a relapse or die in each health state. If patients discontinued their 
first DMD, they could switch to another DMD, or to best supportive care. After 
discontinuation of the second DMD, patients were assumed to be switching to best 
supportive care. The model takes a lifetime horizon: the effects of shared decision making 
on costs and QALYs are simulated until a patient dies or reaches the age of 100. A limited 
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societal perspective was taken, in which healthcare costs and costs outside the healthcare 
sector (i.e. productivity losses related to MS, informal care and community services) were 
included. A discount rate of 1.5% for effects and of 4.0% for costs was applied in accordance 
with the Dutch guideline for economic evaluations in health care [30]. Table 1 presents key 
assumptions made in the model. 
 
Table 1. Key assumptions of the model by Institute for Clinical and Economic Review and the adapted 
model comparing for shared decision making with usual care  
Assumptions of the model by Institute for Clinical and Economic Review [34, 35] 
 Mortality risk within each health state was the same for RRMS and SPMS. 
 Patients progressing to SPMS continued treatment with DMD. 
  
 The treatment effects of a DMD were equal for the first choice and the second choice. 
 After discontinuation of second DMD, patients switch to best supportive care. 
 No vial sharing was included. 
Additional assumptions of adapted model comparing shared decision making with usual care 
 Distribution of EDSS state of Dutch patients entering the model was equal to the 
original model. 
 In usual care, decisions are mostly made in accordance with the healthcare 
professional’s judgement with little involvement of the patient’s preferences in the 
decision. 
 Shared decision making affects initial treatment choice, DMD discontinuation and DMD 
adherence. 
 Effects of shared decision making on adherence and discontinuation remain stable over 
time. 
 Non-adherent patients experience limited effects of the DMD. 
 Discontinuation rates of the second DMD were equal to the discontinuation rate of the 
first DMD. 
 Patients choosing best supportive care as initial treatment choice remained on best 
supportive care. 
DMDs, disease-modifying drugs; EDSS, Expanded Disability Status Scale; QALYs, quality-adjusted life years; RRMS, 
relapsing-remitting MS; SPMS, secondary progressive MS 
Intervention effects 
Three effects of shared decision making were assumed and modeled (Figure 1 and further 
specified in the supplementary material): 1) shared decision making changes the DMD mix 
chosen; 2) shared decision making increases the proportion of optimally adherent patients, 
and 3) shared decision making increases persistence with the chosen treatment. Key 
assumptions for modeling shared decision making in comparison with usual care are 
presented in Table 1. Effect 1 was based on the fact that patients’ preferences are elicited 
and included in the treatment choice during a shared decision making process and these 
preferences might differ from physicians’ preferences [7]. The proportions of patients 
initiating a specific DMD treatment or opting for best supportive care were therefore 
assumed to differ between the groups, also following studies for other health decisions [18, 
19, 36, 37]. The treatment initiation and treatment sequencing, i.e. the categorization of 
DMDs in first-line treatments for mild to moderate RRMS and in second-line treatments for 
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highly active RRMS or RRMS not responding to first-line treatment, was informed by current 
clinical practice in the Netherlands, based on expert opinions and recommendations 
provided by the Dutch Healthcare Institute [5], in the absence of formal up-to-date clinical 
guidelines. Effects 2 and 3 were based on the theory by Stalmeier [20] that patients develop 
a more pronounced attitude towards taking the medication continuously and accurately. 
Patients are expected to be better informed and consequently have more accurate 
expectations about the effects and treatment burden of the chosen treatment option [20]. 
Consequently, a better match is made between the patient’s preferences and the treatment 
attributes. Patients on DMD treatment can be either optimally adherent or non-adherent 
over time. Non-adherent patients were assumed to not experience the full benefits of the 
DMDs, and have a 42% higher risk of relapses overall [8] and a 7.5% higher risk of severe 
relapses specifically [38]. A weighted average of the outcomes was calculated. 
Figure 1. Model structure. Patients diagnosed with relapsing-remitting multiple sclerosis 
(RRMS) receive either shared decision making or usual care to make a decision regarding 
treatment with disease-modifying drug. Three effects of shared decision making are 
modeled: 1) a change in initial treatment choice; 2) a decrease in discontinuation rate 
(persistence); 3) an increase in the proportion of adherent patients. If patients choose a 
drug treatment, they are either adherent or non-adherent. Non-adherent patients were 
assumed to have higher risks of experiencing (severe) relapses. Patients enter the model 
in any of ten RRMS-related health states based on the Expanded Disability Status Scale 
(EDSS). During each 12-month cycle, the patients’ disability status could worsen, improve 
or remain stable. Moreover, patients could progress to secondary progressive MS (SPMS). 
5
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Patients could experience a relapse or die in any health state. If patients discontinue their 
initial treatment, they are assumed to switch to another active treatment or to best 
supportive care according to a pre-determined probability. If patients discontinue their 
second treatment, they are assumed to be switching to best supportive care.  
DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale, RRMS, relapsing-remitting MS; SPMS, 
secondary progressive MS 
Usual care profile 
A profile for the usual care group was defined, and these parameters were kept constant 
for usual care in all further analyses. The usual care profile is presented in Table 2.  
Treatment choice. Due to a lack of published data about the proportion of newly 
diagnosed patients choosing to start DMD treatment or best supportive care, rates were 
based on expert opinion, informed by data describing current use of each DMD by patients 
from the Drug Information System of the National Health Care Institute in the Netherlands 
[39].  
Discontinuation. Discontinuation rates of drug therapies reported in controlled phase II or 
III trials are most likely the optimal persistence rates among patients using the DMD, but do 
not reflect real-world persistence as these are often lower [9-11, 40]. Therefore, 
discontinuation rates were based on real-world data [9-11]. No data were available for 
ocrelizumab and alemtuzumab. Discontinuation rates were therefore determined based on 
the rate of natalizumab, proportionately according to differences found in trial 
discontinuation rates between ocrelizumab, alemtuzumab and natalizumab. After 
discontinuation of the first DMD, patients could switch to another treatment or to best 
supportive care. Experts concluded that about 95% of patients who discontinued their first 
treatment would switch to another DMD treatment. From pivotal studies, it was estimated 
that 79% [41-51] of patients discontinue due to side effects and 21% [42-47, 50] of patients 
discontinue due to a perceived lack of efficacy. Patients stopping first-line treatment due to 
side effects were assumed to switch to another first-line DMD. Patients stopping first-line 
treatment due to a perceived lack of efficacy were assumed to switch to a more effective 
(second-line) DMD, i.e. natalizumab, fingolimod, alemtuzumab or ocrelizumab. If second-
line DMD-users discontinued treatment, they were assumed to switch to another second-
line DMD (Supplementary material).  
Adherence. The proportion of adherent patients was set to 58.9% for self-injectable and 
oral DMDs in the usual care group [8]. Since administration of alemtuzumab, ocrelizumab 
and natalizumab takes place in hospital, is less frequent and is prescribed to patients with 
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Table 2. Profiles of usual care and shared decision making based on assumed effects  




rate Proportion adherent 
 CAU SDM# CAU SDM# CAU SDM# 
Best supportive care 25.0% 20.0% NA NA 100.0% 100.0% 
Alemtuzumab 0.2% 0.3% 10.4% 5.2% 100.0% 100.0% 
Dimethyl fumarate  33.6% 41.3% 21.4% 10.7% 58.9% 63.9% 
Fingolimod  0.0% 0.0% 10.6% 5.3% 58.9% 63.9% 
Glatiramer acetate 20mg 
(generic) 
0.2% 0.1% 26.7% 13.4% 58.9% 63.9% 
Glatiramer acetate 20mg 
(brand) 
10.6% 3.5% 26.7% 13.4% 58.9% 63.9% 
Glatiramer acetate 40mg 
(brand) 
0.2% 0.1% 21.5% 10.8% 58.9% 63.9% 
Interferon beta-1a  1.0% 0.3% 26.8% 13.4% 58.9% 63.9% 
Interferon beta-1a 22mcg 0.5% 0.2% 27.1% 13.6% 58.9% 63.9% 
Interferon beta-1a 44mcg 0.5% 0.2% 30.1% 15.1% 58.9% 63.9% 
Interferon beta-1b 1.0% 0.3% 25.9% 13.0% 58.9% 63.9% 
Natalizumab  4.0% 6.0% 13.0% 6.5% 100.0% 100.0% 
Ocrelizumab 0.8% 1.2% 13.1% 6.6% 100.0% 100.0% 
Peginterferon beta-1a 1.0% 0.3% 26.4% 13.2% 58.9% 63.9% 
Teriflunomide 14mg 21.4% 26.3% 20.8% 10.4% 58.9% 63.9% 
# Profile in the combined scenario. Parameter values were varied in one-way sensitivity analyses.  
CAU, care as usual; NA, not applicable; SDM, shared decision making.  
Shared decision making profile 
The profile for shared decision making according to the three assumed effects was 
determined relative to the profile of usual care. The profile is specified in Table 2. 
Effect 1: Treatment choice. Including the patient’s preferences in treatment decisions may 
change the choice [18, 19, 36, 37]. No evidence is yet available about how shared decision 
making could influence the treatment choice for MS. Based on stated preference studies, 
we constructed a possible profile regarding the initial treatment choice for the patients 
making a shared decision with their healthcare professional. Stated preference studies 
report that patients value the effects of the DMD most, more than safety, ease of use and 
side effects [6, 52]. Moreover, oral medications have been reported to be preferred in 
comparison with injectable medications [53-56]. Because first-line medications have similar 
effects and safety profiles, the profile specified that fewer patients start self-injectable first-
line DMDs. Stated preference research further suggests that MS patients are less risk averse 
than neurologists [57], and are willing to accept even higher risks than are currently 
associated with DMDs [57, 58]. Therefore, this profile specified that a slightly larger 
proportion of patients with relatively high disease activity at first treatment initiation would 
initiate a second-line treatment if the decision were shared between the patient and the 
healthcare professional. The proportion of patients starting each treatment option is 
specified in Table 2. A variation on the scenario was conducted as well in sensitivity 
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analyses, i.e. assuming the change in treatment would be 50% smaller, resulting in a more 
conservative profile.  
Effect 2: Discontinuation. Patients in the intervention group were assumed to be more 
persistent in using the chosen DMD because they are better informed about its efficacy and 
side effects, have been involved in the treatment decision, and there is a better match 
between the patient’s preferences and the chosen treatment [20]. A relative decrease in 
the discontinuation rate of 50% was applied for the group receiving shared decision making 
compared with the group receiving usual care. This resulted in an averaged absolute 
decrease in discontinuation rate of 11.1% over the different DMDs, which was in line with 
a previous economic evaluation regarding a decision aid for shared decision making in 
osteoporosis assuming a 10% decrease in the discontinuation after shared decision making 
[36]. The relative decrease in the discontinuation rate was varied to 25% and 75% in 
sensitivity analyses. 
Effect 3: Adherence. In previous studies on patient decision aids for other shared 
healthcare decisions, improvement rates in the proportion of adherent patients varied 
between 0 and 50% [36, 37]. Because no data are available for MS, a conservative 
assumption was made regarding improvement for the proportion of adherent patients, i.e. 
a 5% improvement in comparison with usual care. This rate was increased in one-way 
sensitivity analyses to 10% and up to 100% of patients being adherent.  
Model inputs 
Effect estimates. Estimates of effectiveness of DMDs in reducing relapses, slowing down 
disease progression and transition probabilities between health states were in accordance 
with the model published by Zimmermann et al. [34] (supplementary material). Age and 
gender-specific background mortality rates were derived from Statistics Netherlands [59], 
which were adjusted for MS-specific mortality based on the EDSS-score [60].  
Utilites. Utilities and disutilities associated with health states, relapses and adverse events 
were in accordance with the original model [34, 35].  
Costs. Costs were expressed in Euros (1 Euro = 1.16 US dollars: August 2018). All costs 
were, where necessary, inflated using the Consumer Price Index for August 2018 [61]. 
DMD costs. Costs of DMDs (supplementary material) were determined using the 
Pharmacy Purchase Price included in the database of the National Health Care Institute in 
the Netherlands (www.medicijnkosten.nl). A €14 dispensing fee for pharmacists was added 
for each first prescription and €7 for each subsequent prescription [62]. Administration 
costs for alemtuzumab, natalizumab and ocrelizumab were included since these DMDs are 
administered through intravenous infusion in the hospital. In the Netherlands, 
alemtuzumab requires hospitalization of patients during the treatment period, while 
natalizumab and ocrelizumab only require outpatient day treatment. Self-injectable or 
orally administrated DMDs do not incur additional administration costs. Costs related to 
monitoring recommended in the package inserts were included per DMD. Pre-treatment 
monitoring costs were included in the first year of treatment. Any monitoring required after 
discontinuation, including an extra specialist visit, were added as well [34]. Healthcare 
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utilization unit costs were determined in accordance with the Dutch Manual for economic 
evaluations based on reference prices established by the National Healthcare Institute [63] 
or based on tariffs from the Dutch Healthcare Authority [64] (see the supplementary 
material).  
Adverse events costs. The costs of adverse events are covered by the Dutch “Diagnosis-
related-group” (DRG) system. However, these DRG-rates are not publicly available. The 
costs of adverse events contribute only marginally to the total costs [34]. Therefore, we first 
calculated the adverse events costs as proportion of the healthcare costs in the original 
model [34], and applied the same percentage to calculate the adverse events costs as 
proportion of the healthcare costs for the Dutch context in our model.  
Health state costs. Health state costs for each EDSS health state were calculated by 
interpolating the EDSS costs reported by Uitdehaag et al. [65] (supplementary material). 
From a societal perspective, healthcare costs (i.e. inpatient care, day admission, 
consultations, tests and medications other than DMDs), community services, investments, 
informal care and productivity losses were included. For productivity losses, only short-term 
absence costs were included according to the friction cost method required by the Dutch 
economic evaluation guideline [66]. A sensitivity analysis was conducted in which 
productivity losses included the costs of long-term absence, disability and early retirement, 
according to the human capital approach [67]. Relapse costs were also derived from 
Uitdehaag et al. 2017 [65].  
Costs of shared decision making. Applying shared decision making incurs costs through, 
for example, using a patient decision aid (development and administration costs) and 
through extended consultation time. However, there is little data available about the costs 
of shared decision making and no data are available for shared decision making in MS. 
Therefore, we assumed a mean cost per patient of €100. Shared decision making is assumed 
to be applied each time a treatment choice is made, i.e. patients discontinuing their first 
treatment will choose their second treatment again via shared decision making.  
Analyses 
Analyses were conducted in Excel 2016 (Microsoft Corporation, Redmond, WA, USA). Drug 
costs, adverse event costs, other costs within and outside the healthcare sector, total 
societal costs, QALYs, number of relapses and life years were calculated separately for 
shared decision making and for usual care. This enabled the calculation of incremental cost 
effectiveness ratios (ICERs). 
The three effects of shared decision making were first analysed separately in comparison 
with usual care and were then assessed in a combined scenario: a 10% decrease in the 
discontinuation rate in comparison with usual care; a 5% increase in patients with optimal 
adherence in comparison with the usual care group, and initial treatment choices as 
specified in Table 2. A threshold analysis (€20,000/QALY and €50,000/QALY) was performed 
for each effect separately and for the three effects combined to determine the maximum 
costs of shared decision making at which the ICER would exceed the respective thresholds. 
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For the combined profile of the three effects, we conducted further one-way sensitivity 
analyses to evaluate the influence of several parameters on the ICER: drug costs (+20%; -
20%), costs of implementing shared decision making (€0) discount rate (3%; 0% for both 
QALYs and costs) and the perspective taken (healthcare perspective, societal perspective 
using the human capital approach for calculating productivity losses). In addition, a 
probabilistic sensitivity analysis with 10,000 iterations was conducted for the combined 
effects, which was presented in a cost-effectiveness plane. A cost-effectiveness 
acceptability curve was constructed to present the probability that shared decision making 
would be cost-effective in comparison with usual care at a range of willingness-to-pay 
thresholds. Specifications for distributions of the effects of shared decision making are 
included in the supplementary material. Distributions of other parameters were selected in 
line with the model developed earlier [34].  
Internal validity 
Model transparency and internal validity was reviewed by two independent researchers (SP, 
XP). Evaluation of internal validity consisted of internal testing and debugging using null 
input values – as recommended by the ISPOR-SMDM Modeling Good Research Practices 
Task Force [68] - for utilities and disutilities, probabilities of relapses, adverse events costs, 
discount rates, drug costs, all costs, and changed the cohort size. In addition, cell-by-cell 
verification of input calculations and formulas was conducted to identify any errors.  
Results 
Modeling each effect of shared decision making separately showed that shared decision 
making resulted in higher QALYs and costs (Table 3). The associated ICERs ranged from 
€4,384 to €315,555 per QALY gained.  
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Treatment choice. A change in choice of the type of treatment as specified in Table 2 
resulted in an increase in drug cost of €8,288. Health state costs decreased by €3,384, 
resulting in an overall cost increase. Overall QALYs increased (0.21 QALYs gained). A more 
conservative change in treatment choice resulted in similar, but slightly smaller 
consequences. 
Discontinuation. Total costs increased if discontinuation rates dropped 50% due to a larger 
proportion of patients being persistent with their treatment choice, resulting in €15,275 in 
higher drug costs. On the other hand, patients also experienced more beneficial effects, 
resulting in 0.23 more life years, 0.29 less relapses, 0.80 more QALYs and, consequently, 
€11,755 less in health state costs. Varying the relative reduction in discontinuation rate of 
DMDs from a 50% decrease to 25% or 75% decrease affected the ICER slightly, resulting in 
an ICER of €4,384 and €6,828 per QALY gained, respectively, for a 50% and 75% reduction, 
and for shared decision making being the dominant choice if the relative reduction would 
only be 25%.  
Adherence. A change in the proportion of adherent patients of 5% showed minimal 
beneficial effects (0.01 QALY gained, 0.03 less relapses). This resulted in a major increase in 
the ICER to €315,555. Varying the adherence from 10% up to 100% did not affect the ICER 
substantially. 
Combined effects. Combination of all three effects resulted in an ICER of €17,875 per QALY 
gained. The increase in total costs of €20,009 were driven by increased drug costs of 
€36,678. The beneficial effects translated into a QALY gain of 1.12, reduction of relapses of 
0.49, life years gained of 0.31 and a reduction in health state costs of €16,666. More detailed 
results for all effects separately and the combined effects are included in the supplementary 
material. 
Sensitivity analyses 
Sensitivity analyses of the separate effects showed that, if shared decision making was 
assumed to decrease the relative reduction in discontinuation rate by 25%, the total costs 
for the intervention group would be €807 less in comparison with the control group due to 
a decrease in health state costs of €4,994 and an increase of drug costs of €4,189, resulting 
in shared decision making being the dominant choice. In all scenarios, increased drug use 
was the main cost driver, while other costs within and outside the healthcare sector 
decreased (supplementary material).  
Results of one-way sensitivity analyses of the combined effects as defined in Table 2 are 
presented in Table 4 (further detailed in the supplementary material). The ICER was highly 
sensitive to change in the relative risk of each DMD option for EDSS progression. Further, 
the substantial influence of drug costs on the ICER was confirmed: a 20% increase and 
decrease in DMD costs resulted in ICERs of €24,147 and €11,604 per QALY gained, 
respectively. Moreover, the ICER increased to €25,568 and €29,191 if, respectively, a 
discount rate of 3% or a healthcare perspective was applied. The threshold analyses 
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suggests that, in the scenario of combined effects, shared decision making could maximally 
cost €23,639 to be cost-effective at a threshold of €50,000 per QALY (Table 5).   
Figure 2 presents the ICERs for the 10,000 iterations of the probabilistic analysis in a cost-
effectiveness plane for the combined effects. The probability of shared decision making 
being cost-effective in comparison with usual care is 79.2% for a willingness-to-pay 
threshold of €20,000 per additional QALY, increasing to a probability above 98.5% and 
higher for thresholds of €50,000 and higher (Figure 3). 
  
5
141878 Ingrid Kremer BNW.indd   131 19-02-20   09:50




141878 Ingrid Kremer BNW.indd   132 19-02-20   09:50
E X P L O R I N G  T H E  C O S T - E F F E C T I V E N E S S  O F  S H A R E D  D E C I S I O N  M A K I N G
133
Figure 2. Incremental cost-effectiveness plane of shared decision making versus usual care
WTP, Willingness-to-pay threshold; QALYs, quality-adjusted life years
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Using a state transition model, this study suggests that shared decision making for DMDs 
for RRMS has the potential to be cost-effective, from a limited societal Dutch perspective, 
in comparison with usual care. Assuming that shared decision making would reduce 
discontinuation rates by 50%, increase the proportion of adherent patients by 5%, and 
would lead to a slight increase in DMD initiation and the uptake of second-line and orally 
administered first-line DMDs, the ICER fell below accepted cost-effectiveness thresholds of 
€50,000 for diseases categorized as moderately burdensome in the Netherlands [69]. The 
probability that the intervention would be cost-effective in comparison with usual care was 
98.5% for a threshold of €50,000 per QALY. One-way sensitivity analyses showed that the 
ICER was robust for changes in costs of the intervention, but more sensitive to variation in 
relative risk of progression for each DMD, drug costs, discount rates or changes in 
perspectives. Nonetheless, all ICERs in the sensitivity analyses remained well below the 
commonly accepted threshold for cost-effectiveness of €50,000 per QALY gained [69], 
except when the relative risk of progression for each DMD would be considerably higher. 
Threshold analyses showed that shared decision making will be cost-effective up to a 
maximum cost of €23,639 for a threshold of € 50,000 per QALY, assuming the intervention 
would result in changes in initial treatment choice and a decrease in the discontinuation 
rate and the proportion of non-adherent patients.  
Two similar exploratory studies regarding the cost-effectiveness of shared decision making 
have been conducted, for obstructive sleep apnoea and osteoporosis, and concluded that a 
patient decision aid could potentially be cost-effective [36, 37]. In contrast to our study, 
these studies found that the intervention’s cost of delivery had substantial influence on the 
cost-effectiveness of a patient decision aid, in addition to the influence of variations in the 
cost of the treatment [37]. We found that the cost of shared decision making had little 
impact on the ICER. This could be explained by the considerable difference in treatment 
costs for obstructive sleep apnoea and osteoporosis, which were only a fraction of the 
treatment costs for RRMS. 
The actual effects of shared decision making for MS on treatment choice, persistence, 
adherence, and the cost of implementing the intervention are still largely unknown. 
Therefore, our study has an exploratory nature. Further trial- and registry-based evaluations 
would be needed to assess the real-life effects of shared decision making for MS. Modeling 
each potential effect of shared decision making separately allowed for assessment as to 
which of the three expected effects were most influential with regard to its cost-
effectiveness, and therefore informs further research and development of the intervention. 
Improvement in treatment adherence was found to have little effect on total QALYs. Various 
studies on enhancing adherence to medical intervention also failed to find a QALY and/or 
cost improvement with increased adherence rates - larger than the assumed adherence rate 
in our study - in trial-based economic evaluations [70, 71]. In contrast, the other two effects 
did affect the cost-effectiveness: a change in treatment initiation resulted in more 
incremental QALYs gained, and decreased discontinuation rates brought about the largest 
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incremental QALY gain. If shared decision making would reduce the discontinuation by only 
25%, increased drug costs are leveled out by reduced health state costs causing shared 
decision making to be dominant over usual care, while with higher relative reductions in 
discontinuation rate, the drug cost increase exceeds the savings in health state costs. The 
importance of using shared decision making in decreasing discontinuation was also found 
for patient decision aids which support shared decision making in osteoporosis [36]. Our 
results suggest that the development of interventions to support shared decision making 
for RRMS should focus mainly on reducing the discontinuation of DMDs for the 
interventions to be cost-effective, since the type of treatment initiated is dependent on the 
patient’s preferences and needs, and should not be directed by any intervention.  
 
A strength of the current study is that a previously developed and validated model, used by 
regulatory bodies for policy decision making and pricing, was adapted to explore the cost-
effectiveness of shared decision making in comparison with usual care. Moreover, a number 
of sensitivity analyses were conducted to establish the robustness of the results and 
conclusions. Inherent to the study design, however, is the simplification of real-life 
situations in a model. In addition to the limitations described by Zimmerman et al. [34] 
concerning the quality and quantity of data available for the natural history of MS and DMD 
effectiveness, this model has some additional limitations. First, the model is based on the 
assumption that once patients choose best supportive care, as first, second or third 
treatment course, they remain on best supportive care. In clinical practice, however, 
patients might choose to postpone treatment initially, but decide after a while to start a 
DMD. This might underestimate the increase in drug costs as a consequence of shared 
decision making in comparison with usual care and thus, to some extent, the ICER. Further 
research is needed on whether shared decision making affects the probability of patients 
starting DMDs after initially opting for best supportive care. Second, non-adherence might 
increase over time, while in the model non-adherence is assumed to be constant over time. 
This could overestimate the effect of shared decision making. Third, cladribine has currently 
become available for patients with highly active RRMS or for patients who did not respond 
to a first-line DMD [5], but was not included in the model as treatment option. Since 
cladribine received market authorization for highly active RRMS only in 2017 and was not 
included in the basic health insurance package in the Netherlands until March 2018, we 
expect that the share of patients currently choosing cladribine would be small, and would 
therefore have only marginal impact on the results.  
 
This exploratory study was specifically conducted for the Netherlands. Certain aspects of 
our model may limit the applicability of the results to contexts other than the Netherlands. 
For example, drug costs and recommendations for treatment sequencing (including the 
categorization in first-line and second-line therapy) differ between countries. In sensitivity 
analyses, we increased the drug cost with 20%, which showed that this parameter has a 
substantial effect on the ICER. In this scenario, the Dutch drug costs would still be 50% to 
84% lower than the US drug costs [34]. Shared decision making may, therefore, have more 
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substantial impact on drug costs and the ICER in the United States. Moreover, assumed 
treatment sequencing was validated with Dutch clinicians, but clinical practice could differ 
in other countries [72]: e.g. fingolimod is prescribed in the Netherlands only after another 
DMD has been ineffective, but is approved as first-line treatment option in the US.  
 
In conclusion, this study suggests that shared decision making for MS could potentially be a 
cost-effective intervention. Although shared decision making requires short-term 
investments in training staff, setting up structures for shared decision making and 
developing and/or acquiring patient decision aids, long-term savings should be considered 
in policy decisions, since threshold analyses show that shared decision making could even 
be cost-effective even if upfront intervention cost are high. To our knowledge, this is the 
first study assessing the potential cost-effectiveness of shared decision making for RRMS. 
The current study could further inform the design of a trial-based study, which should be 
conducted to verify the assumptions made in the study and its results. This study provides 
insights for policy makers and clinicians regarding the potential value of implementing 
appropriate interventions to support shared decision making in treatment decisions for 
RRMS. Real-world current evidence on the cost-effectiveness of shared decision making is 
still limited [16], and not available for RRMS. Real-world data on long-term treatment 
discontinuation rates after shared decision making should be collected.  
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Figure 1. Detailed model structure
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Table 1. Parameters derived from the model by the Institute for Clinical and Economic 
Review (1, 2) 
Parameter 
Distribution of patients entering the model in each EDSS state 
Probability of moving between EDSS states, RRMS and SPMS 
Probability of conversion from RRMS tot SPMS 
Annual Relapse rate, RRMS, SPMS 
Probability of severe relapse (adherent patients) 
Mortality multipliers of all-cause general population mortality 
Annual disutility from adverse events 
Healthcare resource utilization due to adverse events 
Annual utility scores per health state, RRMS and SPMS 
Disutility mild/moderate and severe relapses 
Relative risk for EDSS progression 
Rate ratio for relapse rate (adherent patients) 
 
 
Table 2. Distribution of patients entering the model (Source: Zimmerman et al. (2)) 
Health state* p Range 
1 0.22 0.17-0.26 
2 0.28 0.23-0.34 
3 0.24 0.19-0.29 
4 0.15 0.12-0.18 
5 0.06 0.05-0.07 
6 0.00 0.00-0.00 
7 0.00 0.00-0.00 
8 0.00 0.00-0.00 
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Table 3. Relative Risk of EDSS Progression per treatment option 





       
Treatment option RR Range RR Range RR Range 
Supportive Care 1.00  1.00  1.00  
Alemtuzumab 0.42 0.25-0.68 0.28 0.22-0.35 0.28 0.05-0.35 
Dimethyl fumarate  0.62 0.46-0.84 0.53 0.43-0.63 0.73 0.63-0.83 
Fingolimod  0.68 0.51-0.90 0.46 0.39-0.55 0.69 0.61-0.77 
Glatiramer acetate 20mg (generic) 0.74 0.58-0.94 0.63 0.55-0.71 0.79 0.71-0.87 
Glatiramer acetate 20mg (brand) 0.74 0.58-0.94 0.63 0.55-0.71 0.79 0.71-0.87 
Glatiramer acetate 40mg (brand) 1.17 0.69-1.92 0.67 0.52-0.86 0.81 0.64-0.98 
Interferon beta-1a IM 0.79 0.63-1.00 0.83 0.74-0.94 0.90 0.80-1.00 
Interferon beta-1a 22mcg SC 0.81 0.52-1.23 0.70 0.55-0.85 0.83 0.68-0.98 
Interferon beta-1a 44mcg SC 0.73 0.52-0.99 0.64 0.54-0.73 0.79 0.70-0.89 
Interferon beta-1b 0.66 0.46-0.89 0.65 0.55-0.77 0.80 0.69-0.91 
Natalizumab  0.56 0.37-0.84 0.31 0.25-0.40 0.31 0.25-0.40 
Ocrelizumab 0.47 0.28-0.76 0.35 0.27-0.44 0.35 0.27-0.44 
Peginterferon beta-1a 0.63 0.37-1.02 0.63 0.47-0.86 0.79 0.59-0.98 
Teriflunomide 0.72 0.52-0.97 0.67 0.56-0.79 0.81 0.69-0.92 
EDSS, Expanded Disability Status Score; RR, relative risk 
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Table 4. Healthcare utilization unit costs, range and standard error 
Parameter Unit cost Standard 
error 
Drug costs (3)   
Teriflunomide 14mg €992.88 /28EA  
Interferon beta-1a IM  €916.68 /4EA  
Interferon beta-1b  €766.92 /14EA  
Glatiramere acetate 20mg (brand) €856.80 /30EA  
Glatiramere acetate 40mg (brand) €794.76 /30EA  
Fingolimod  €1,916.70 /30EA  
Glatiramere acetate 20mg (generic) €771.00 /30EA  
Alemtuzumab  €7,420.00 /1.2ml  
Peginterferon beta-1a €1,126.34 /1ml  
Interferon beta-1a 22mcg SC €868.56 /0.5ml  
Interferon beta-1a 44 mcg SC €1,076.88 /0.5ml  
Dimethyl fumarate  €1,295.40 /60EA  
Natalizumab  €1,670.58 /15ml  
Ocrelizumab  €5,871.20 /300mg vial  
Utilization costs   
Administration Costs (4)   
Inpatient stay €413.08 42.15 
Outpatient day treatment €288.63 29.45 
Laboratory Costs (5)   
Complete blood count €14.57 1.49 
Serum Creatinine €3.52 0.36 
Urine analysis €4.33 0.44 
Thyroid €14.30 1.46 
Liver €21.40 2.18 
MRI €240.54 24.54 
ECG €47.54 4.85 
ALT €3.76 0.38 
Metabolic panel €61.47 6.27 
Visit Costs (4)   
GP visit €34.51 3.52 
Specialist visit €103.53 10.56 
Adverse event costs# (2)   
PML  €26,008.09 2,653.89 
Hospital stay for disorders of the biliary 
without complications 
€4,966.30 506.77 
Inpatient stay for depression €4,308.94 439.69 
Hospital stay for influenza/pneumonia €6,309.02 643.78 
Serious infection €12,398.49 1,265.15 
Cranial nerve disorder €8,685.00 886.22 
Patient decision aid costs (6) €100.00 10.20 
* Normal distribution was applied for costs.  
# Estimation of adverse event costs is explained in the supplementary material. 
GP, general practitioner; PML, Progressive multifocal leukoencephalopathy  
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Table 5. Health state and relapse cost 
Parameter Unit cost Range Standard error 
EDSS state costs: healthcare costs only 
(7) 
   
0 €2,496 1997 -2996 255 
1 €3,539 2831 -4247 361 
2 €4,582 3665 -5498 468 
3 €5,624 4499 -6749 574 
4 €6,667 5333 -8000 680 
5 €7,709 6167 -9251 787 
6 €8,541 6833 -10250 872 
7 €9,303 7443 -11164 949 
8 €10,065 8052 -12079 1,027 
9 €10,828 8662 -12993 1,105 
EDSS state costs: productivity costs 
(FCM), informal care, investments and 
services (7) 
   
0 €105 84 -125 11 
1 €1,118 894 -1342 114 
2 €2,131 1705 -2558 217 
3 €3,145 2516 -3774 321 
4 €4,158 3327 -4990 424 
5 €5,172 4137 -6206 528 
6 €9,398 7518 -11278 959 
7 €14,695 11756 -17634 1,500 
8 €19,993 15994 -23991 2,040 
9 €25,290 20232 -30348 2,581 
EDSS state costs: productivity costs 
(HCA), informal care, investments and 
services (7) 
   
0 €11,322 9058-13586 1,155 
1 €13,373 10698-16047 1,365 
2 €15,423 12339-18508 1,574 
3 €17,474 13979-20969 1,783 
4 €19,525 15620-23430 1,992 
5 €21,576 17261-25891 2,202 
6 €27,122 21698-32546 2,768 
7 €33,833 27067-40600 3,452 
8 €40,545 32436-48654 4,137 
9 €47,256 37805-56707 4,822 
Relapse costs: healthcare costs (8)    
  Mild/moderate €2,042 1634-2451 208 
  Severe €2,042 1634-2451 208 
Relapse costs: productivity costs*, 
informal care, investments and services 
(8) 
   
  Mild/moderate €1,052 842 -1263 107 
  Severe €1,052 842 -1263 107 
Health state costs were calculated using interpolation of data from Uitdehaag et al. (7). A separate formula was 
used to calculate health states costs of Expanded Disability Status Scores (EDSS) 0 to 5 (direct costs=1,002.7EDSSx 
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+ 2,403; indirect costs=1,972.8EDSSx + 10,891.8) and for EDSS 6 to 9 (direct costs=733.1EDSSx + 3,818.3; indirect 
costs=6,456.4EDSSx + 12,646.9) because of the categorization of costs in Uitdehaag et al. (7).  
For probabilistic sensitivity analyses, a normal distribution was applied in according with the previous published 
model (1, 2). 
FCM, Friction Cost Method; HCA, Human Capital Approach 
* Early retirement, invalidity and DMD costs excluded 
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The proportions of patients initiating a specific DMD treatment or opting for best supportive 
care were assumed to differ among the groups, following studies for other health decisions 
(6, 13-15). 
The mix of treatment initiations was informed by current clinical practice in the Netherlands 
based on expert opinions and recommendations provided by the Dutch Healthcare Institute 
(16), in the absence of formal up-to-date clinical guidelines. A patient’s eligibility for certain 
types of DMDs is determined by the degree of disease activity and whether previous DMD 
treatment has been unsuccessful in reducing relapses (16). Interferon beta-1a IM, 
interferon beta-1a 22 mcg and 44 mcg SC, interferon beta-1b SC, peginterferon beta-1a, 
glatiramer acetate (generic 20mg and brand 40 mg and 20 mg), teriflunomide and dimethyl 
fumarate are generally considered first-line treatments in the Netherlands. Natalizumab, 
alemtuzumab, fingolimod, ocrelizumab and cladribine are considered second-line 
treatments for patients with highly active MS because of their higher efficacy, but also less 
favourable safety profiles (16). Patients choosing for DMD treatment were assumed to 
either start first-line DMDs or, in the case of highly active MS at onset, directly start a DMD 
usually defined as a second-line treatment, with the exception of fingolimod. In the 
Netherlands, fingolimod can be prescribed only if treatment with another (first-line) DMD 
has been ineffective. Table 1 presents the proportion of patients initiating each treatment 
for usual care and different profiles of shared decision making. 
 
Table 7. Specification of treatment initiation in the intervention and control group 
 Treatment initiation  
 CAU SDM# SDM$ 
Best supportive care 25.0% 20.0% 22.5% 
Alemtuzumab 0.2% 0.3% 0.3% 
Dimethyl fumarate  33.6% 41.3% 37.4% 
Fingolimod  0.0% 0.0% 0.0% 
Glatiramer acetate 20mg (generic) 0.2% 0.1% 0.1% 
Glatiramer acetate 20mg (brand) 10.6% 3.5% 7.1% 
Glatiramer acetate 40mg (brand) 0.2% 0.1% 0.1% 
Interferon beta-1a  1.0% 0.3% 0.7% 
Interferon beta-1a 22mcg 0.5% 0.2% 0.3% 
Interferon beta-1a 44mcg 0.5% 0.2% 0.3% 
Interferon beta-1b 1.0% 0.3% 0.7% 
Natalizumab  4.0% 6.0% 5.0% 
Ocrelizumab 0.8% 1.2% 1.0% 
Peginterferon beta-1a 1.0% 0.3% 0.7% 
Teriflunomide 14mg 21.4% 26.3% 23.8% 
# Profile in the combined scenario. 
$ Values in the one-way sensitivity analyses 
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Switching between treatments after first discontinuation 
After discontinuation of the first DMD, patients could switch to another treatment or to 
best supportive care. Experts concluded that about 95% of patients who discontinued their 
first treatment would switch to another DMD treatment. From pivotal studies, it was 
estimated that 79% (17-27) of patients discontinue due to side effects and 21% (18-23, 26) 
of patients discontinue due to a perceived lack of efficacy. The 5% of patients switching to 
best supportive care were assumed to be equally distributed between the patients 
discontinuing due to side effects and those discontinuing due to lack of efficacy. Patients 
stopping treatment due to side effects were assumed to switch to another first-line DMD, 
resulting in an 8% chance of switching from a first-line DMD to each of the other first-line 
DMDs (i.e. 79% of those discontinuing due to side effects switch to one of the other nine 
first-line DMDs – and 5%/2 switch to best supportive care). Patients stopping treatment due 
to a perceived lack of efficacy were assumed to switch to a second-line DMD, i.e. 
natalizumab, fingolimod, alemtuzumab or ocrelizumab, resulting in a 5% chance of 
switching from a first-line DMD to each second-line DMD (i.e. 21% of those discontinuing 
due to side effects switch to one of the four second-line DMDs, and 5%/2 switch to best 
supportive care). If second-line DMD-users discontinued treatment, they were assumed to 
switch to another second-line DMD. 
  
5
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Table 8a. Detailed results of scenario analyses and sensitivity analyses 
















Effect of SDM vs. CAU *        
DMD choice # €397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
 & €397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
Discontinuation rate -10% €397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
 -5% €397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
 -20% €397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
Proportion adherent  +5% €397,646 €47,986 €349.650 €10 7.67 15.28 26,59  
+10% €397,646 €47,986 €349.650 €10 7.67 15.28 26,59  
100% €397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
Combined effects$  
 
€397,646 €47,986 €349.650 €10 7.67 15.28 26,59 
Sensitivity analyses:  
combined effects 
 
Drug costs +20% €406,905 €57,245 €349,650 €10 7.67 15.28 26.59 
Drug costs -20%  €388,387 €38,727 €349,650 €10 7.67 15.28 26.59 
Relative risk progression rate 
EDSS states: improvement  
€384,371 €49,886 €334,475 €10 8.58 15.84 26.85 
Relative risk progression rate 
EDSS states: worsening  
€413,913 €44,895 €369,007 €11 6.53 14.62 26.27 
Costs pDA: €0  €397,646 €47,986 €349,650 €10 7.67 15.28 26.59 
Discount rate: 3% €465,321 €50,231 €415,077 €12 6.98 15.28 21.29 
Discount rate: 0% €811,208 €58,601 €752,584 €23 8.45 15.28 34.28 
Healthcare perspective  €203,427 €47,986 €155,436 €5 7.67 15.28 26.59 
Human capital approach  €728,727 €47,986 €680,721 €20 7.67 15.28 26.59 
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Table 8b. Detailed results of scenario analyses and sensitivity analyses 
    shared decision making 

















Effect of SDM vs. CAU *        
DMD choice # €402,551 €56,274 €346.266 11 7.88 15.19  26,64 
 & €400,181 €52,130 €348.040 10 7.78 15.23  26,62 
Discontinuation rate -10% €401,163 €63,261 €337.896 6 8.47 14.99  26,82 
 -5% €396,840 €52,176 €344.656 8 8.00 15.17  26,68 
 -20% €407,635 €78,373 €329.257 4 9.13 14.70  27,03 
Proportion adherent  +5% €400,878 €51,152 €349.715 10 7.68 15.25  26,59  
+10% €403,972 €54,318 €349.643 10 7.69 15.23  26,59  
100% €422,535 €73,314 €349.211 10 7.75 15.06  26,59 
Combined effects$  
 
€417,655 €84,664 €332.984 7 8.79 14.79  26,90 
Sensitivity analyses:  
combined effects 
 
Drug costs +20% €433,934 €100,943 €332,984 7 8.79 14.79 26.90 
Drug costs -20%  €401,376 €68,385 €332,984 7 8.79 14.79 26.90 
Relative risk progression 
rate EDSS states: 
improvement  
€398,972 €91,725 €307,240 6 10.50 15.70 27.42 
Relative risk progression 
rate EDSS states: 
worsening  
€438,023 €74,661 €363,355 7 6.88 13.89 26.34 
Costs pDA: €0  €417,502 €84,664 €332,832 7 8.79 14.79 26.90 
Discount rate: 3% €486,766 €90,935 €395,823 8 7.82 14.79 21.48 
Discount rate: 0% €839,286 €116,807 €722,464 15 9.98 14.79 34.80 
Healthcare perspective  €236,101 €84,664 €151,434 3 8.79 14.79 26.90 
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Table 8c. Detailed results of scenario analyses and sensitivity analyses 
       
 costs QALY ICER 
Effect of SDM vs. CAU *    
DMD choice # €4,904 0.21 €23,509 
 & €2,535 0.10 €24,294 
Discontinuation rate -10% €3,517 0.80 €4,384 
 -5% -€807 0.33 DOMINANT 
 -20% €9,988 1.46 €6,828 
Proportion adherent  +5% €3,231 0.01 €315,555  
+10% €6,325 0.02 €308,843  
100% €24,889 0.08 €303,809 
Combined effects$  
 
€20,009 1.12 €17,875 
Sensitivity analyses:  
combined effects 
 
Drug costs +20% €27,029 1.12 €24,147 
Drug costs -20%  €12,989 1.12 €11,604 
Relative risk progression rate 
EDSS states: improvement  
€14,601 1.91 €7,640 
Relative risk progression rate 
EDSS states: worsening  
€24,110 0.34 €70,084 
Costs pDA: €0  €19,856 1.12 €17,739 
Discount rate: 3% €21,445 0.84 €25,568 
Discount rate: 0% €28,078 1.53 €18,307 
Healthcare perspective  €32,675 1.12 €29,191 
Human capital approach  €15,837 1.12 €14,149 
*In usual care, 25% of people choose best supportive care, 5% choose a DMD indicated for highly active MS 
(natalizumab/alemtuzumab) and 70% choose one of the first-line DMDs (25% for a first-generation first-line DMD, 
45% for a second generation first-line DMD). Discontinuation rates range between 10% and 31%, depending on 
the DMD. The proportion of patients with optimal adherence is 60%, except for natalizumab, alemtuzumab and 
ocrelizumab for which adherence is assumed to be 100%. 
$ The three effects of shared decision making included in the model are initial treatment choice; discontinuation 
rate, and adherence. Shaded rows present the the values of parameters included in the combined effect analysis. 
# Specified in Table 4 
& Specification of change in treatment initiation as specified in Table 4 decreased by 50%. 
AE, adverse events. 
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CHAPTER 6 
Adherence to web-based self-assessments 
in long-term direct-to-patient research: 
two-year study of multiple sclerosis patients
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Background. Direct-to-patient research via Web-based questionnaires is increasingly being 
used. Missed data or delayed reporting of data may negatively affect the quality of study 
results. It is insufficiently known to what degree patients adhere to agreed self-assessment 
schedule over the long term and whether questionnaires are filled out in a timely manner. 
The objective of this study was to investigate patients’ adherence to a self-assessment 
schedule with low-frequency long questionnaires versus that with a high-frequency short 
questionnaire. 
Methods. In this study, the 36-item MS Impact Profile (MSIP) questionnaire measured 
(perceived) disabilities and the 54-item MS Quality of Life-54 (MSQoL-54) questionnaire 
measured health-related quality of life at 6-month intervals. Additionally, the 2-item 
Medication and Adherence (MA) questionnaire documented medication and adherence to 
disease-modifying medication every month. An experienced MS nurse assessed the 
Expanded Disability Status Scale (EDSS) score via phone. For both the self-assessment 
schedules, we calculated the percentage of patients who had completed all the 
questionnaires in the first 2 years (completion adherence), the percentage of patients who 
completed all the questionnaires within set time frames (interval adherence), the 
relationship between adherence and the EDSS score, and the timing of EDSS assessment. 
Results. Of the 331 patients who enrolled themselves, 301 patients completed at least one 
questionnaire. At month six (M6), M12, M18, and M24, the MSIP was completed by 83.4% 
(251/301), 71.8% (216/301), 68.1% (205/301), and 58.5% (176/301) of the patients, 
respectively; the MSQoL-54 by 82.1% (247/301), 71.8% (216/301), 66.8% (201/301), and 
57.1% (172/301), respectively; and the MA questionnaire by 80.1% (241/301), 70.4% 
(212/301), 62.1% (187/301), and 53.5% (161/301), respectively. For the MSIP, 56.8% 
(171/301) of the patients were 2-year completion adherent; 55.5% (167/301) and 53.5% 
(161/301) of the patients were completion adherent for the MSQoL-54 and MA 
questionnaires, respectively. Whereas 85.5% (142/166) of the patients were interval 
adherent for the MSIP and MSQoL-54, 25.5% (41/161) were interval adherent for the MA 
questionnaire. Completion adherence for the monthly short MA questionnaire was higher 
in patients with moderately high disability (EDSS 5.0-5.5) than for those with no or minimal 
disability (EDSS 0-2.5) (OR 5.47, 95% CI 1.08-27.69; P=.040). Completion adherence was also 
higher in patients with EDSS assessment within 6 months after baseline than in those with 
later assessment (OR 1.810, 95% CI 0.999-3.280; P=.050). 
Conclusions. The 2-year completion adherence to Web-based self-assessments did not 
differ between the low-frequency long questionnaires and a high-frequency short 
questionnaire, but the interval adherence was substantially higher for the low-frequency 
long questionnaires. Personal contact with a member of the research team regarding a 
clinically relevant professional-reported outcome early in the study might positively affect 
the long-term completion adherence in direct-to-patient studies.  
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Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease 
of the central nervous system, mainly affecting persons in young adulthood. In about 80% 
of patients the first phase is characterized by a pattern of recurrent episodes of symptoms 
(relapses), typically followed by complete or partial remissions: relapsing remitting MS 
(RRMS) [1]. Although disease-modifying drugs (DMDs) reduce the frequency and severity of 
relapses, after about 20 years most persons with RRMS progress to the secondary 
progressive (SP) phase, experiencing a steady and unstoppable increase in disability [2, 3]. 
In about 10-15% of the patients symptoms start insidiously and develop slowly without 
relapses: primary progressive MS (PPMS) [1]. In both SPMS and PPMS the continuous 
increase in disability results mainly from degenerative processes that cannot be modified 
by the available DMDs. The multifocal localization of the lesions accounts for the wide 
variety of symptoms that may arise in the course of the disease; these symptoms often 
interfere with physical, cognitive, social or occupational activities. Over the long term the 
MS-related disabilities often represent a substantial burden to patients and their 
environment.  
To enable neurologists to better prognosticate the disease course in individual patients, 
they need to be informed in more detail about the degree of and variation in long-term 
disabilities. To obtain this information patient-reported outcomes (PROs) are increasingly 
being used, in addition to physician-based measures like the Expanded Disability Status 
Scale (EDSS). A PRO is any report of the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the patient’s response by a clinician or 
anyone else [4]. A PRO that is increasingly being used in clinical research is health-related 
quality of life (HRQoL), an overall measure of wellbeing from a patient’s perspective that 
provides a comprehensive measure of health status [5].  
The internet empowers patients to directly participate in research projects without the 
involvement of their physician or physician’s setting [6, 7]. The rapid adoption of the 
internet by MS patients, the limited costs of web-based contacts, and the easy access to 
large numbers of potential participants are all in favour of a direct-to-patient study design 
[6, 8]. The data that can thus be obtained include PROs on various symptoms, (perceived) 
disabilities, HRQoL and treatment, and may complement neurologist- or nurse-reported 
data about diagnosis, disease course, and MRI [6]. 
In view of the scarcity of long-term data on (perceived) disabilities and HRQoL in MS patients 
in the Netherlands, we conceived the prospective, direct-to-patient, interactive, Dutch MS 
Study [9]. The study participants enrolled themselves and agreed to complete two long 
questionnaires on (perceived) disabilities (36 items) and HRQoL (54 items) at six-month 
intervals, and a short questionnaire on medication and adherence to DMD treatment (two 
items) at monthly intervals [9]. 
One of the crucial aspects of long-term direct-to-patient research is the participants’ 
adherence to the predetermined assessment schedule. A reduction in the amount of data 
that patients provide may seriously affect the validity and meaningfulness of the study 
results [10, 11]. Conceivably, the same amount of data can be acquired by the infrequent 
6
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use of long questionnaires, or by the frequent use of short questionnaires. In fact, different 
factors might determine the adherence to a self-assessment schedule: a high frequency 
short questionnaire could be bothersome to patients due to the frequent interference with 
their daily life or frequent confrontation with their disabilities and limitations, whereas a 
low frequency long questionnaire might be cumbersome due to requiring more time to 
complete and thus potentially increasing MS-related fatigue. 
In a previous patient-centred web-based study in RRMS patients, who were included by 
their neurologists, we investigated the adherence to monthly online self-assessments after 
the start of DMD treatment [12]. It was found that 75.5% of the patients completed two 
short questionnaires at all monthly time points over the course of one year, although only 
one in five patients adhered to the monthly intervals between consecutive self-assessments 
[12]. In order to become informed about the long-term adherence of MS patients to low 
frequency completions of long questionnaires versus high frequency completions of short 
questionnaires in a direct-to-patient research setting, this study analysed the two-year 
adherence data in the Dutch MS Study [9]. Given the study design, participation in this study 
was not a priori integrated into patient care. As the embedding of research activities in care 
processes may positively affect patient adherence, and as adherence may decrease over 
time, it was hypothesized that, at least regarding the high frequency short questionnaire, 
the two-year completion adherence would be less than 75%. 
Methods 
Dutch Multiple Sclerosis Study 
The Dutch MS Study is a prospective, web-based, direct-to-patient, interactive study of 
long-term disabilities, perception of disabilities and HRQoL in patients with MS in the 
Netherlands. The innovative study design is characterized by online patient-driven 
enrolment, online data acquisition, the use of PROs, and the use of personal study data by 
patients and authorized healthcare professionals for (self-)monitoring, (self-)management 
or multidisciplinary care. The objectives of the study, design, target population, 
recruitment, ethical aspects, data acquisition, technical aspects, outcome measures, 
assessment schedule, organisation and funding have been described in detail elsewhere [9].  
Patients were informed about the study via the websites of three patient organisations and 
of the MS4 Research Institute (www.ms4ri.nl). By regular mail neurologists and MS nurses 
were sent an informative letter with patient brochures, which they were asked to hand out 
to their patients. The brochure was also sent to the patrons of the National MS Foundation 
Netherlands, as an attachment to the foundations’ quarterly journal and related mailings. 
In the journal, study information was presented by the principal investigator (PJ). 
Information about the study was published twice in health specials of large national and 
regional Dutch newspapers. The protocol was submitted to the ethics committee Medisch 
Ethische Toetsing Onderzoek Patiënten en Proefpersonen in Tilburg, the Netherlands (nr 
141878 Ingrid Kremer BNW.indd   162 19-02-20   09:50
A D H E R E N C E  T O  W E B - B A S E D  S E L F - A S S E S S M E N T S  
163 
 
M379). The committee concluded that a review was not indicated, as the study did not 
qualify for being tested according to the Dutch Medical Research Involving Human Subjects 
Act (http://wetten.overheid.nl/BWBR0009408) [13]. The study is being performed in 
agreement with the Declaration of Helsinki (Ethical Principles for Medical Research 
Involving Human Subjects version 2013; 64th World Medical Association General Assembly, 
Fortaleza, Brazil, October 2013) (www.wma.net) and the Dutch Medical Research Involving 
Human Subjects Act (www.wetten.overheid.nl/BWBR0009 408).  
Technically, the study is a modular application on the Curavista e-Health Platform, build on 
an Oracle database with JAVA-scripting, XML-applets and AJAX protocols. Data processing 
is 256-bits encrypted with VPN-tunnelling. The databases are physically and software 
secured in a dedicated data centre in the Netherlands [9]. On the day of the scheduled 
assessment patients receive a notification by email that a questionnaire is available for 
completion. If the questionnaire is not completed on the scheduled date reminders are sent 
after four and seven days.  
Disabilities, perceptions of disabilities and HRQoL are measured every six months via the 
Multiple Sclerosis Impact Profile (MSIP) and the Multiple Sclerosis Quality of Life-54 Item 
(MSQoL-54) questionnaires. The MSIP is made available first and the MSQOL-54 one week 
later. The medication that is being taken and the adherence to DMD treatment are 
secondary outcomes; these are measured every month via the Medication and Adherence 
(MA) questionnaire. Every six months the completion of the MA questionnaire coincides 
with the completion of the MSIP and MSQoL-54. The completion of the combined MSIP and 
MSQoL-54 takes about 30–45 minutes; completion of the MA questionnaire takes less than 
five minutes.  
Questionnaires 
Multiple Sclerosis Impact Profile 
The MSIP is a measure of MS-related disabilities and perception of disabilities with 
established psychometric properties [14, 15]. It is based on the International Classification 
of Functioning, Disability and Health and reflects an objectified view of the prevalence and 
severity of the impact of MS. The MSIP comprises 36 questions assessing disability (Q1a-
Q36a) and perception of disability (Q1b-Q36b) in the domains muscle and movement 
functions, excretion and reproductive functions, activities involving basic movements, 
activities of daily living, participation in life situations, environmental factors, mental 
functions, and the symptoms fatigue, pain, speech and vision [14, 15]. 
Multiple Sclerosis Quality of Life-54 
HRQoL is assessed with the MSQoL-54 questionnaire, a psychometrically validated MS-
specific multi-dimensional inventory of patient-centred health status [16]. The MSQoL-54 
consists of the 36-item Short Form health survey as a generic core measure to enable 
comparisons to other patient populations and to the general population, supplemented 
with 18 additional questions exploring items relevant to MS patients in the areas of health 
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distress (four items), sexual function (four items), satisfaction with sexual function (one 
item), overall quality of life (two items), cognitive function (four items), energy (one item), 
pain (one item) and social function (one item) [16]. 
Medication and Adherence questionnaire  
The MA questionnaire gives an update of medications that are taken, the number of DMD 
doses missed in the past month, and the date and reason of DMD discontinuation (if 
applicable). 
Disability assessment by phone 
The EDSS is a widely used disability measure in MS. The EDSS quantifies disability in eight 
functional systems and allows neurologists and qualified nurses to assign a functional 
system score in each of these [17]. The functional systems are: pyramidal, cerebellar, 
brainstem, sensory, bowel and bladder, visual, cerebral and other. EDSS steps 0.0 to 4.5 
refer to patients with MS who are fully ambulatory, and EDSS steps 5.0 to 9.5 are defined 
by the impairment to ambulation. A version of the EDSS that can be used as a structured 
interview by phone and that has been validated for serial assessments in a research setting, 
is being used in the Dutch MS Study [18, 19]. All patients were sent an email in which they 
were asked if they agreed to a disability assessment via an interview by phone. The emails 
were sent in order of enrollment. If patients agreed, they were asked to provide information 
about the days of the week and the time of the day they were available for the assessment 
by phone. Patients were free when to contact the study team and when to schedule the 
EDSS interview. In addition to answering the questions of the structured interview during 
the phone contact, the patients had the opportunity to ask study-related information or 
discuss study aspects with the assessing researcher, an experienced nurse specialized in MS. 
Study outcomes 
The outcomes of the present analysis are the adherence to the assessment schedules of the 
MSIP, MSQoL-54 and MA questionnaires during the first two years of the study. Regarding 
the MSIP and the MSQoL-54, patients were classified as completion adherent for the 
respective questionnaire if they had performed all five scheduled six-month assessments 
during the first two years; patients were classified as completion adherent for the MA 
questionnaire if they had performed all scheduled monthly assessments during the first two 
years. Patients were classified as overall completion adherent if they had performed all 
scheduled MSIP, MSQoL-54 and MA assessments in this period.  
Patients who were completion adherent for the MSIP or MSQoL-54 were classified as 
interval adherent if they met the following three criteria: a) median inter-assessment 
interval was 180+10 days or less, b) maximum inter-assessment interval was 180+20 days 
or less, and c) month 24 (M24) completion was within 30 days after the scheduled date. 
Patients who were completion adherent for the MA questionnaire were classified as 
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interval adherent if a) the median inter-assessment interval was 30+3 days or less, b) the 
maximum inter-assessment interval was 30+6 days or less, and c) the M24 completion was 
within 30 days after the scheduled date.  
Statistical analysis  
The numbers of patients who completed the respective questionnaires at the various time 
points were calculated, as well as the intervals between two consecutive assessments and 
between the baseline and M24 assessment. The intervals between two consecutive 
assessments (days) are presented as mean, standard deviation (SD), median, minimum, 
maximum and inter-quartile range (IQR). Friedman’s ANOVA and the Wilcoxon signed ranks 
test were used to test whether the intervals for consecutive time points differed between 
the MSQoL-54, MSIP and MA questionnaires. The numbers of patients who were 
completion or interval adherent are expressed as the percentage of patients who actually 
started participating in the study by completing at least one of the questionnaires. To 
compare the completion adherence rates and interval adherence rates of the three 
questionnaires, Cochran’s Q test was performed. In order to test for significant associations 
between sex, age, EDSS score, and the timing of EDSS assessment on the one hand, and 
completion adherence and interval adherence regarding the low frequency long 
questionnaires (MSIP, MSQoL-54) and the high frequency short questionnaire (MA) on the 
other hand, we used logistic regression analysis. All test were performed in SPSS for 
Windows version 24.  
The EDSS score was categorized into no to minimal disability (scores 0-2.5), fully ambulatory 
with moderate disabilities (scores 3.0-3.5), fully ambulatory with little to moderate effect 
on daily activities (scores 4.0-4.5), ability to walk about 100-200 meters without aid and fully 
or severely impaired in performing daily activities (scores 5.0-5.5), ability to walk about 20-
100 meters with aid (scores 6.0-6.5), and severely disabled in walking or fully restricted to 
bed or chair (scores above 7.0). The timing of EDSS assessment by phone was dichotomized 
into assessment within six months after baseline self-assessment and later than 6 months 
after baseline self-assessment. A P value of 0.05 was applied for significance.  
Results 
Patients 
Three-hundred-thirty-one patients had enrolled themselves in the study at least two years 
before the date of analysis (July 2015), from 23 March 2011 to 15 March 2012. Of these, 
301 (90.94%) had actually started participating in the study by completing at least one 
questionnaire at baseline, whereas 30 (9.06%) patients had effectively not started 
participation. Of the 331 patients 246 (74.32%) were female, 67 (20.24%) male, and for 18 
(5.40%) the sex was unknown. The mean (SD) age was 45.59 (11.05) years; the median was 
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45.13, the minimum was 17.18, and the maximum age was 70.57, IQR 37.82-53.92 (N=310). 
Of the 301 patients who had completed at least one questionnaire at baseline, 234 (77.74%) 
were female, and 67 (22.25%) were male. The mean (SD) age was 45.52 (11.08), the median 
was 44.96, the minimum was 17.18, and maximum was 70.57, IQR 37.82-53.92 (N=298). 
Completions  
The numbers and percentages of patients who completed the MSIP at baseline, M6, M12, 
M18 and M24 were 296 (98.3%), 251 (83.4%), 216 (71.8%), 205 (68.1%) and 176 (58.5%), 
respectively, and the numbers and percentages of patients who completed the MSQoL-54 
at baseline, M6, M12, M18 and M24, were 281 (93.4%), 247 (82.1%), 216 (71.8%), 201 
(66.8%) and 172 (57.1%) (Figure 1). The numbers and percentages of patients who 
completed both these questionnaires at baseline, M6, M12, M18 and M24 were 281 
(93.4%), 247 (82.1%), 215 (71.4%) 199 (66.1%) and 171 (56.8%) (Figure 1). 
Figure 2 shows the numbers of patients who had completed the MA questionnaire at the 
various time points, expressed as the percentage of patients (N=301) who had started study 
participation. The numbers of patients who had completed the MA questionnaire at 
baseline, M6, M12, M18 and M24, were 301 (100%), 241 (80.1%), 212 (70.4%), 187 (62.1%) 
and 161 (53.5%).  
Table 1 shows the numbers and percentages of patients who completed the MA 
questionnaire at all 25 time points, at 24 to one time point(s), or at no time point, 
irrespective of it being consecutive assessments. 
The numbers and percentages of patients who completed the respective questionnaires at 
baseline and at M6, M12, M18 and M24 (five time points), at four, three, two or one time 
point(s), or at no time point, irrespective of it being consecutive assessments, are shown in 
Table 2.  
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Table 1. Numbers and percentages of patients who completed the short Medication and 
Adherence questionnaire at all 25 time points, at 24 to one time point(s), or at no time 
point, irrespective of these being consecutive assessments (N=301). 
Number of completions n (%) 
25 (all) 161 (53.5) 
24 166 (55.1) 
23 171 (56.8) 
22 176 (58.5) 
21 179 (59.5) 
20 183 (60.8) 
19 187 (62.1) 
18 193 (64.1) 
17 194 (64.5) 
16 200 (66.4) 
15 203 (67.4) 
14 208 (69.1) 
13 212 (70.4) 
12 221 (73.4) 
11 223 (74.1) 
10 227 (75.4) 
9 230 (76.4) 
8 233 (77.4) 
7 242 (80.4) 
6 249 (82.7) 
5 256 (85.0) 
4 262 (87.0) 
3 274 (91.0) 
2 279 (92.7) 
1 301 (100) 
0 30  
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Table 2. Numbers and percentages of patients who completed the Multiple Sclerosis Impact 
Profile, Multiple Sclerosis Quality of Life-54, and Medication and Adherence questionnaires 
at baseline and at 6, 12, 18, and 24 months (five time points) at four, three, two, or one 
time point(s), or at no time point, irrespective of it being consecutive assessments (N=301). 











5 (all) 171 (56.8) 167 (55.5) 161 (53.5) 
4 203 (67.4) 202 (67.1) 187 (62.1) 
3 222 (73.8) 219 (72.8) 212 (70.4) 
2 252 (83.7) 246 (81.7) 241 (80.1) 
1 296 (98.3) 283 (94.0) 301 (100) 
0 35 48 30 
Intervals 
The intervals (days) between two consecutive assessments and between the baseline and 
M24 assessment (mean, SD, median, minimum, maximum and IQR values) are given in Table 
3. 
Median values for the intervals between two consecutive six-month assessments ranged 
from 182 to183 days for the MSQoL-54 and the MSIP. The median time between baseline 
and M24 was 730 days for the MSQoL-54 and 731 days for the MSIP. For the MA 
questionnaire the median values for inter-assessment intervals ranged from 30 to 32 days, 
and the M24 assessment was at 749 days (median). The interval between baseline and M6 
significantly differed between the three questionnaires (MSIP vs MSQoL-54 z=-5.37, P 
<.001; MSQoL-54 vs MA z=-8.73, P <.001; MSIP vs MA z=-8.05, P <.001), as did the M6-M12 
interval between the MSIP and MSQoL-54 (z=-2.42, P =.014), and the M12-M18 intervals 
between MSQoL-54 and MA (z=-11.70, P <.001) and between MSIP and MA (z=-11.44, P 
<.001). For the M18-M24 interval no significant differences were found between the three 
questionnaires. Significant differences in time from baseline to M24 were found between 
all three questionnaires (MSIP vs MSQoL-54 z=-4.04, P <.001; MSQoL-54 vs MA z=-6.17 P 
<.001; MSIP vs MA z=-5.59, P <.001). 
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Adherence to low frequency long questionnaires 
Of the 301 patients who started with the study, 166 (55.1%) completed the MSIP and 
MSQoL-54 questionnaires at all five time points, and were therefore completion adherent 
for the low frequency long questionnaires. Of these, 159 (95.8%) completed the M24 
questionnaires within 30 days of the scheduled date; 163 (98.2%) had a median inter-
assessment interval of 180+10 days or less; and 143 (86.1%) had a maximum inter-
assessment interval of 180+20 days or less. In all, 85.5% (N=142) of the patients who were 
completion adherent for the low frequency long questionnaires, were interval adherent for 
these questionnaires. 
Adherence to high frequency short questionnaire   
Of the 301 patients who started participation, 161 (53.5%) completed the MA questionnaire 
at all monthly time points, and were thus completion adherent for the high frequency short 
questionnaire. Of these, 99 (62%) performed the M24 assessment within 30 days of the 
scheduled date; 153 (95.0%) had a median inter-assessment interval of 30+3 days or less; 
and 42 (26%) had a maximum inter-assessment interval of 30+6 days or less. In all, 26% 
(N=41) of the patients who were completion adherent for the high frequency short 
questionnaire, were interval-adherent for this questionnaire.  
Overall adherence 
One-hundred-fifty-two (50.5%) patients were completion adherent for both the low 
frequency long questionnaires and the high frequency short questionnaire, and were 
therefore considered overall completion adherent. In addition, 36 (24%) of the patients who 
were overall completion adherent were interval adherent for both the low frequency long 
questionnaires and the high frequency short questionnaire, and were therefore considered 
overall interval adherent. In all, 12% of the patients who started with the study were overall 
completion and interval adherent.  
Comparative analyses 
The completion rates did not differ between the three questionnaires (Cochran’s Q test: 
x2=5.630; P = .063). From the above it follows that 91.6% (152/166*100) of the patients 
who were completion adherent for the low frequency long questionnaires were also 
completion adherent for the high frequency short questionnaire. Vice versa, 94.4% 
(152/161*100) of the patients who were completion adherent for the high frequency short 
questionnaire were also completion adherent for the low frequency long questionnaires. 
Moreover, 25% (36/142*100) of the patients who were interval adherent for the low 
frequency long self-assessments were also completion adherent for the high frequency 
short self-assessments. Vice versa, 88% (36/41*100) of those who were interval adherent 
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for the high frequency short self-assessments were also completion adherent for the low 
frequency long self-assessments. 
There were no statistically significant differences between men and women regarding the 
completion and interval adherence to the low frequency long questionnaires, the high 
frequency short questionnaire, nor regarding the overall adherence rates. Likewise, no 
association was found between age and adherence.  
As to the EDSS, patients with an EDSS score of 5.0 or 5.5 were found to have higher odds of 
being completion adherent for the high frequency short questionnaire than patients with 
an EDSS score of 0 to 2.5 (OR= 5.47 95% CI= 1.08-27.69, P =.040). Moreover, patients who 
had an EDSS assessment within 6 months after baseline were more likely to be completion 
adherent for the high frequency short questionnaire than those whose EDSS score was 
assessed later (OR=1.810; 95% CI: 0.999-3.280, P =.050).  
Discussion 
In recent years the direct-to-subject approach is being applied increasingly in clinical 
studies, both in trials organized by clinical research organisations and in investigator-driven 
academic research [20, 21]. This development is paralleled by a growing number of studies 
that make use of the internet for the acquisition of patient-reported data. However, it is 
insufficiently known to which degree patients who enrol themselves in web-based studies 
do indeed perform the scheduled assessments and whether they do so on time, especially 
over the longer term. Such knowledge is relevant, as patients who prematurely discontinue 
their participation or who provide data only infrequently or delayed may hamper the 
validity of the study results. 
To obtain insight into patients’ long-term adherence to a self-assessment schedule in a 
setting of web-based direct-to-patient research, we analyzed the numbers of completed 
questionnaires and the inter-assessment intervals in the first two years of the Dutch MS 
Study regarding two low frequency long questionnaires (MSIP, MSQoL-54) and one high 
frequency short questionnaire (MA).  
Principal results 
We found, first, that about 56% of the patients completed the two long questionnaires at 
all five six-month time points (MSIP 56.8%, MSQoL-54 55.5%), and second, that about 54% 
of the patients completed the short questionnaire at all 25 monthly time points. Third, we 
found that over 90% of the patients who completed all questionnaires for one type of 
assessment, also completed all questionnaires for the other type; fourth, that the number 
of patients who completed the questionnaires decreased gradually over time, and, fifth, 
that the patients who completed all of the long questionnaires at six-month intervals in a 
timely fashion by far outnumbered the patients who performed all of the monthly short 
self-assessments in time (85.5% vs. 26%).  
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So, interestingly, over a two-year period no difference was found in completion adherence 
(completion of all scheduled assessments) between less frequent long questionnaires and 
a more frequent short questionnaire. This was so in spite of the evident differences in 
patient burden: the short MA questionnaire had to be completed 5 times more frequently 
than the long MSIP and MSQoL-54, and the completion time of the latter was 6-9 times 
longer than that of the MA questionnaire. This suggests that completion adherence is 
influenced not so much by quantitative aspects like frequency of assessments and 
completion time, but other factors. These factors could be the perceived relevance of the 
questionnaires’ content and the degree to which healthcare providers use the 
questionnaires’ outcomes in their disease management.  
It may well be that patients’ adherence to the completion of online questionnaires is 
influenced by the outcomes’ relevance for the disease management, like decisions on 
treatment initiation, continuation or discontinuation. It is of note that one of the 
characteristics of the Dutch MS Study is that patients may give healthcare professionals 
access to the completed questionnaires and the automatically generated scores. Although 
we suggested the study participants inform their neurologists, MS nurses and other 
healthcare professionals about this option, only 21 patients have authorized one or more 
healthcare professionals. Accordingly, we think that the low utilization of the interactive 
aspect of the study may also explain why at two years about 45% of the patients failed to 
complete all questionnaires.  
Figure 2 suggests that the number of patients who completed the short monthly MA 
questionnaire at a given time point decreased on average by 2.4% per month, an exception 
being the decrease of 7.6% at the first interval. Remarkably, the decrease over time in the 
number of patients who completed the six-month long questionnaires fits in with the 
pattern of decreasing completions of the MA questionnaire. There was another interesting 
observation: the less frequent long and more frequent short questionnaires showed almost 
identical completion percentages at M6, M12, M18 and M24. In combination with the fact 
that more than 90% of the patients who were completion adherent for one type of 
assessment were also completion adherent for the other type, and the quasi-linear 
decrease in the number of completion adherent patients for both types of assessment, this 
observation suggests that non-adherent patients completed virtually all scheduled 
questionnaires up to a certain time point, at which they decided not to complete any more 
questionnaires. From patients’ phone calls to the help desk it became clear, rather 
unexpectedly, that participants were sometimes reluctant to complete the monthly MA 
questionnaire, e.g. because no changes in medication occurred over longer periods or 
because they felt ‘spied on’ by the frequent assessments. It may therefore be hypothesized 
that a reluctance to complete one specific questionnaire may have affected not only the 
completion of that particular questionnaire, but that of the other questionnaires as well. 
Differences between the two types of assessment were found for interval adherence. 
Whereas the majority (85.5%) of patients were interval adherent for the low frequency long 
questionnaires, only a minority (26%) was so for the high frequency short questionnaire. 
The non-adherence in the latter group was mainly due to the fact that approximately three 
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out of four patients (73.9%) exceeded the maximum inter-assessment interval of 30+6 days 
at least once, and less so to four out of ten (38.5%) patients performing the M24 assessment 
later than 30 days after the scheduled date. This difference in interval adherence may relate 
to the difference in assessment frequencies, as less frequent assessments lower the risk of 
one assessment exceeding the maximum inter-assessment interval. The difference may also 
be due to the pre-defined criteria for interval adherence: the allowed time window of six 
days for the monthly completions may have been too narrow for patients who, e.g. due to 
an MS relapse or a concomitant disease, were temporarily unable to complete 
questionnaires. When comparing the intervals for the consecutive time points no consistent 
differences were found between the MSQoL-54, MSIP and MA questionnaires.  
It was found that patients with the ability to walk about 100-200 meters without aid and 
fully/severely impaired in performing daily activities (EDSS 5.0 or 5.5) were five times more 
completion adherent for the more frequent short questionnaire than patients with no or 
minimal disability (EDSS 0 to 2.5). We speculate that this may relate to the former patients 
being more housebound and thus possibly having more time at their disposal, and the latter 
being more involved in familial, professional and societal activities with less time for or 
interest in the regular completion of questionnaires. However, at higher EDSS scores (6.0 
and higher) this association was not found, which could relate to the circumstance that 
cognitive and physical disabilities prevented these patients from performing moderately 
demanding tasks.  
Interestingly, patients who - within six months after completion of the first questionnaire - 
had their disability assessed by an experienced MS nurse via phone, were almost twice as 
likely to be completion adherent for the high frequency short questionnaire than were 
those whose EDSS score was assessed later. This observation suggests that an early personal 
contact between the patient and a member of the research team – with the opportunity to 
ask questions about the study or about individual health status - may positively influence 
adherence to an assessment schedule. 
Comparison to prior work 
Whereas a first experience has been reported with direct-to-patient recruitment for 
enrolment into clinical trials [22], to our knowledge no studies have investigated the 
adherence to online assessments in long-term direct-to-patient research. In general, early 
discontinuation of study participation has been associated with various socio-demographic 
and health-related factors, like male gender [23], being black [24], cognitive impairment 
[25, 26] and difficulties in activities of daily living [25]. We did not find differences in 
completion or interval adherence between males and females. Our finding that patients 
with moderately high disability were more completion adherent for the frequent short 
questionnaire than were patients with no or minimal disability does not contradict a 
previous report on higher drop-out rates in very ill persons. In MS patients disability mostly 
results from impaired mobility and not from deficiencies in general health. 
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In the present study 66.4% of the patients had completed all monthly MA questionnaires 
one year after baseline. In a previous one-year study in MS patients who started daily 
glatiramer acetate treatment, we found that 75.5% of the patients completed all monthly 
short questionnaires on fatigue (five items) and HRQoL (eight items) [12]. This higher 
percentage could relate to the content of the questionnaires: fatigue is a frequent and often 
debilitating symptom in MS that was expected to improve during glatiramer acetate 
treatment, whereas the documentation of medication and missed DMD doses may be less 
appealing to patients. Moreover, in the glatiramer acetate study, patients were included by 
their treating neurologists at the time of treatment initiation, whereas in the present study 
patients enrolled themselves at an arbitrary point in time. Nonetheless, the median monthly 
inter-assessment intervals (30 to 32 days) and the median baseline-M24 interval 
([2x365]+19 days) in the present study compare favourably with the median inter-
assessment intervals (32 to 34 days) and the median baseline-M12 interval (365+52 days) 
in our previous study [12]. 
Limitations 
Our study has several limitations. First, we analyzed data from a study that was not primarily 
designed too (also) investigate the adherence to assessment schedules. Second, by 
comparing the adherence to low frequency long questionnaires with that to a high 
frequency short questionnaire we investigated two variables simultaneously, and we 
therefore cannot identify the relative contribution of a questionnaire’s frequency and 
length to the adherence. Third, we confined ourselves to the analysis of formal aspects of 
the questionnaires and did not consider their content, so it may well be that, irrespective 
of the assessment frequency, patients experienced questions about (perceived) disabilities 
(MSIP) as more disturbing and less motivating than questions about DMD adherence. 
Fourth, although the fairly even distribution of the Dutch MS Study participants throughout 
the Netherlands suggests that the study group is representative of the Dutch MS 
population, this has not been demonstrated; moreover, relatively healthy IT users and 
enthusiasts may be overrepresented in the study group. Fifth, in view of the direct-to-
patient study design we did not verify the MS diagnosis with the patients’ neurologists, nor 
whether the diagnosis was made according to the latest criteria.  
As to the instruments we used, it is important to note that the e-versions of the 
questionnaires have not been validated. There is, however, a vast amount of literature 
showing that e-versions of questionnaires and scales are equivalent to paper-and-pencil 
versions, and that both can be used interchangeably. This has been demonstrated, among 
others, for questionnaires about disability [27], symptoms [28, 29], HRQoL [30, 31], 
psychopathology [28, 32, 33] and psychology [34]. Against this background we thought it 
reasonable to apply e-versions of the MSIP, MSQoL-54 and the Medication and Adherence 
questionnaire. Moreover, should any discrepancies exist between paper and e-version of 
these questionnaires, these will be of minor relevance as we consequently used the e-
versions throughout the study. As to the EDSS assessment, the scoring via interview by 
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phone has been validated for serial assessments in research settings, but it is not 
interchangeable with the physician-derived EDSS, especially for the lower range of disability 
[19].  
Finally, our definitions of completion and interval adherence were based on what we 
considered both realistic from a patient perspective and desirable from the researcher’s 
point of view. To be qualified as completion adherent we required patients to have 
completed all questionnaires. Yet, the completion of five long questionnaires may be easier 
for patients to realize that the completion of 25 short questionnaires over the same time 
period. And, from a research perspective, it may be questioned whether the missing of one 
out five or even one out of 25 assessments substantially hampers the data quality. 
Moreover, the time windows for interval adherence used by us are debatable and, in 
general, criteria for interval adherence will depend on the phenomenon under study and 
the time span covered by a questionnaire. 
Conclusions 
In analysing the two-year adherence to self-assessments in the direct-to-patient Dutch MS 
Study, we found no differences in completion adherence (completion of all scheduled 
questionnaires) between the two low frequency long questionnaires versus the high 
frequency short questionnaire; whereas the interval adherence (completion of 
questionnaires within pre-defined time frames) was considerably higher for the low 
frequency long questionnaires. Moreover, patients with moderately high disability were 
more likely to be completion adherent for the high frequency short questionnaire than were 
patients with no or minimal disability, as were patients who within six months after 
completion of the first questionnaire had their disability assessed by an experienced MS 
nurse via phone in comparison with those who had their assessment later. The latter 
observation may suggest that in web-based direct-to-patient research personal contact 
with a member of the research team or feedback on a clinically relevant professionally-
reported outcome early in the study may positively affect the long-term adherence to self-
assessments. 
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The landscape of disease-modifying drugs (DMDs) for multiple sclerosis (MS) is expanding 
quickly, particularly for relapsing-remitting MS (RRMS). In the last decade, a number of new 
DMDs have entered the market for RRMS; these are either more efficacious or perceived as 
less burdensome in terms of administration regimens (administration method and 
frequency) and side effects. Earlier approved DMDs indicated for RRMS and clinically 
isolated syndrome (CIS) have an advantage over newly introduced drugs, in that many of 
those approved earlier have been in use for over twenty years or more, so there is 
considerable experience with their utilization in clinical practice, and thus extensive 
knowledge is available about their safety. The advances in DMDs for MS provide patients 
with new opportunities to delay disease progression, but also make identifying the right 
DMD for the individual patient more difficult. Knowing the patient’s preferences with regard 
to DMD characteristics and incorporating this knowledge in the decision for a DMD could 
improve the patients’ satisfaction with their treatment and with the quality of care 
provided. Moreover, it could positively affect the patients’ commitment to continuing 
treatment with the chosen DMD over the long term, and to missing no or only a minimal 
number of doses. Patients should thus be actively involved in making decisions for DMDs 
using the shared decision making approach.  
 
The aim of this thesis was two-fold. Part I of this dissertation aimed to develop and pilot 
test a patient decision aid to support patients with MS and their healthcare professionals in 
making a shared decision about treatment with DMDs. To address this aim, three sub-
objectives were formulated: 1) to assess which information about the DMD options is 
important to consider when making a treatment decision, from the patients’ and 
professionals’ perspectives (Chapters 2 and 3); 2) to develop a prototype of the patient 
decision aid that incorporates the informational needs of the patient (Chapter 4); and 3) to 
assess the comprehensibility, usability and acceptability of the patient decision aid for both 
patients and healthcare professionals (Chapter 4).  
Part II of this thesis aimed to inform the design of web-based research in MS and economic 
evaluation of shared decision making for MS. More specifically, Part II aimed 1) to evaluate 
whether shared decision making for DMDs for MS, whether supported with a patient 
decision aid or not, could potentially be cost-effective, and which parameters would most 
affect the cost-effectiveness (Chapter 5); and 2) to evaluate whether a difference in 
frequency and length of questionnaires affects patients’ adherence to online self-
assessment in direct-to-patient research (Chapter 6).  
This final chapter provides a summary of the main findings of this dissertation, discusses the 
methodological challenges and suggests implications for clinical practice, policy and further 
research and development of the patient decision aid.  
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Summary of main findings 
Part I of this dissertation presented several studies conducted to develop a patient decision 
aid according to the recommendations for development of the International Patient 
Decision Aids Standards (IPDAS)[1]. The patient decision aid was intended for patients with 
RRMS and CIS, in the Netherlands, who are considering first time treatment with DMDs or 
switching between DMDs. All DMDs available for MS and CIS were included, as well as the 
option of no treatment. An advisory group consisting of patient representatives, 
neurologists, MS nurses and experts in patient decision aid development was consulted at 
various stages in the developmental process (Chapter 4).  
 
For the first objective of Part I, focus groups with patients and a best-worst scaling survey 
(Chapter 2) were conducted to identify characteristics of DMDs that patients find important 
to consider when deciding about treatment with DMDs, and to prioritize these 
characteristics in the decision according to their importance. As a group, patients found 
primarily benefits - specifically the effects of DMDs on disease progression, quality of life 
and relapse rate – most important, and secondarily, possible treatment burden, such as side 
effects, safety and ease of use. Exploratory analysis identified heterogeneity in preferences 
between patients with different characteristics, such as prior DMD use, disease duration 
and gender. Heterogeneity in preferences shows that there is no “one size fits all” approach 
in decision making for DMDs for RRMS, and that an approach of shared decision making to 
include the individual’s preferences in the decision is warranted. A second best-worst 
scaling survey with neurologists and MS nurses (Chapter 3) enabled assessing what 
healthcare professionals find most important to consider. Overall, neurologists and MS 
nurses agreed that benefits are highly important, just as the patients do, but healthcare 
professionals put more priority on safety aspects, i.e. the risk of severely disabling or life-
threatening adverse events, than did patients. The results of both best-worst scaling surveys 
identified which information should be included in the patient decision aid for DMDs for 
MS, a recommended step by the IPDAS in the development of decision aids for patients [1]: 
to optimally meet decisional patients’ needs, their perspectives and the perspectives of 
healthcare professionals on what should be considered should be elicited. Nine 
characteristics were selected for inclusion in the patient decision aid, and a tenth 
characteristic was included specifically for patients with CIS.  
 
An approach of multi-criteria decision analysis (MCDA) was selected as the underlying 
algorithm for the patient decision aid, as it can relieve the cognitive burden of weighting 
many different (conflicting) characteristics of many different treatment options. This choice 
was also directive in addressing the second objective of developing the prototype of the 
patient decision aid. The patient decision aid is accessible online, which allowed for the 
mathematical computations needed for MCDA. Moreover, the online format enables 
interaction: the patient enters his/her personal and medical information that may influence 
his/her eligibility for DMDs, selects the characteristics he/she finds important in the decision 
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for DMDs and indicates the weight of each characteristic in the decision. Information about 
the different DMDs was obtained through an extensive literature review and was validated 
within the steering group. Based on the information provided by the patient and the 
information retrieved from the literature, the patient decision aid provides the patient with 
a ranking of the DMDs from most to least suitable with regard to his/her preferences. 
Moreover, with the decision aid the patient is able to compare the performance of a DMD 
on a specific characteristic with the performance of other DMDs. 
 
Three rounds of alpha pilot testing with MS patients and healthcare professionals were 
conducted to address the third objective. Both patients and healthcare professionals 
acknowledged the potential added value of the patient decision aid for the decision making 
process, but also points for improvement were reported. Three overarching themes for 
improvement were identified: content and framing, weighting methods for the importance 
of characteristics according to patients, and the presentation of the results of the patient 
decision aid. Adaptations to the patient decision aid were made accordingly, meaning that 
the description of the different MS courses were detailed more fully, unnecessary text and 
questions that were deemed too difficult were adapted or omitted. Moreover, the 
presentation of the results was expanded. Based on a selection of three DMDs made by the 
patient, the adapted version of the patient decision aid provides the patient with a printable 
one-page summary of the DMDs according to their important characteristics. In addition, a 
summary of the patient’s personal and medical history was included and its consequences 
with regard to the patient’s eligibility for each DMD for the interest of the treating 
healthcare professional(s). The ranking of the DMDs, the summary of the three selected 
DMDs, and the summary of the patient’s eligibility for DMD treatment could be shared with 
the healthcare professional(s) and serves as support for the discussion in making a shared 
decision (Chapter 4). 
 
Part II of this dissertation informs the design of web-based health services and research for 
MS, and specifically to assess the potential cost-effectiveness of shared decision making for 
MS. A model-based economic evaluation (Chapter 5) was conducted to address the first 
objective of Part II. The state transition model explored whether shared decision making for 
DMDs for RRMS could potentially be a cost-effective intervention and determined which 
parameters most affect its cost-effectiveness. A change in which DMD treatments are 
initiated, along with increased persistence and increased adherence to DMDs as a result of 
shared decision making were shown to result in increased quality-adjusted life years 
(QALYs) and societal costs, when these effects were modeled separately and combined. In 
the combined scenario the following effects were assumed: 1) more patients initiate DMD 
treatment after diagnosis with RRMS and slightly more patients initiate second generation 
first-line DMDs and second-line DMDs; 2) their discontinuation decreases by 50%, and 3) 
the proportion of patients with optimal adherence increases by 5%. The scenario resulted 
in 1.12 more QALYs and €20,009 more total costs for shared decision making for DMDs for 
RRMS in comparison with usual care. The incremental cost-effectiveness ratio (ICER, i.e. the 
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difference in costs between shared decision making and usual care, divided by the 
difference in QALYs) comes to €17,875 per QALY gained, which is lower than the acceptable 
threshold of €50,000 per QALY gained. Shared decision making for RRMS could thus 
potentially be a cost-effective intervention. Of the three assumed effects of shared decision 
making, a change in relative reduction of discontinuation influenced the ICER most. 
Moreover, a change in drug prices, the risk of disease progression, the discount rate and 
the perspective taken substantially affected the ICER. This study informs clinicians and 
policy makers about the potential economic value of investing in research and 
implementation of interventions to support shared decision making for RRMS. In addition, 
the study provides a rationale for future trial-based studies.  
In a direct-to-patient web-based study with MS patients (Chapter 6), the effect of different 
schedules for self-assessment of perceived disability, health-related quality of life (HRQoL) 
and adherence to medication was assessed to address the second objective of Part II of this 
dissertation. Perceived disability and HRQoL were addressed in 36-item and 54-item 
questionnaires, respectively, every six months, while adherence was questioned using a 2-
item questionnaire every month. Over a 2-year period, no difference was found in the 
proportion of patients completing all scheduled assessments between the two less frequent 
long questionnaires (perceived disabilities and HRQoL) and the more frequent short 
questionnaire (adherence), but patients completed the low-frequency long questionnaires 
more often within a predefined time frame than the high-frequency short questionnaire. 
Moreover, study results suggest that personal contact with a researcher within six months 
after completion of the first questionnaire could beneficially affect long-term adherence to 
completing self-assessments in direct-to-patient research.  
Methodological considerations 
In this section, first the generalizability and transferability of the study results included in 
this dissertation are discussed. Next, the methodological challenges encountered in the 
development of the web-based patient decision aid will be addressed.  
Generalisability 
Generalisability refers to the extent to which inferences based on the results of a study 
concerning a specific sample can be made for the population at large [2]. Patient 
recruitment for the studies included in this dissertation (Chapters 2, 3, 4 and 6) was 
primarily done via the internet, i.e. via social media, advertisements on the websites of 
patient organizations and online mailings from patient organizations. Online recruitment 
made it possible to reach many patients, irrespective of their geographical location, 
treatment centre or latest out-patient consultation. Although the MS patient population 
has been argued to be relatively active on the internet in comparison with other chronically-
ill patient populations [3], the recruitment methods used in the studies have the 
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disadvantage that patients with high levels of health literacy and internet use are possibly 
overrepresented in the study samples in comparison with the study population. Relatively 
large proportions of higher educated participants were included in the focus groups and 
best-worst scaling survey in comparison with the average MS patient population in the 
Netherlands. The alpha pilot testing, which included higher and lower educated patients, 
revealed that individual use of the patient decision aid in clinical practice might be too 
difficult for some patients. Beta pilot testing with patients with a range of different 
demographic and disease characteristics should be conducted to evaluate how patients 
with different levels of education and health literacy can be supported in optimally using 
the patient decision aid.  
Transferability 
Transferability refers to the extent the results of the study could be applied in other 
contexts than the specific context of the study [2]. The focus groups and surveys (Chapters 
2, 3 and 6) in this dissertation have been performed with MS patients and healthcare 
professionals in the Netherlands. Moreover, the patient decision aid (Chapter 4) was 
developed and the economic evaluation of shared decision making (Chapter 5) was 
conducted specifically for the Dutch context. Topics such as the importance of 
characteristics of DMDs in the decision making process could be country-specific, 
determined by characteristics of the healthcare system. For example, Dutch patients do not 
have additional out-of-pocket costs for prescription medication, except for the mandatory 
deductible, which patients may have elsewhere. A characteristic such as out-of-pocket costs 
might, therefore, be important in the decision for DMDs if patients need to pay additional 
fees. Differences in the healthcare systems may thus result in other characteristics being 
included in the patient decision aid. Differences in factors other than reimbursement of 
DMDs, such as country-specific eligibility criteria defined by clinical guidelines or national 
regulatory agencies, ensure that the patient decision aid in the current form and the results 
of the economic evaluation are specifically applicable to the Dutch context. These aspects 
should be considered when transferring the results of the study to other context. The 
structure of the patient decision aid, though, enables relatively easy adaptation for 
application in other contexts if characteristics and eligibility criteria have been identified 
and verified specifically for those contexts.  
Approaches for development and evaluation of the patient decision aid 
The patient decision aid is based on the principles of MCDA [4, 5]. This means that the DMDs 
are described according to certain characteristics and the patient weighs the importance of 
these characteristics. The patient decision aid ranks the available DMDs based on what 
characteristics the patient finds important and how well each DMD performs with regard to 
these characteristics. The ranking of DMDs thus presents which DMDs fit most with the 
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patient’s preferences. A number of methodological challenges were encountered in the 
development of the patient decision aid. 
 
Although an MCDA-based decision support tool is a thorough and systematic approach for 
making decisions by minimizing heuristic decision making, such a tool might seem a black 
box for patients and professionals. First, because solely presenting a ranking of DMDs 
without justification might seem arbitrary if no insight is given into how these rankings have 
been computed. Second, because evidence from clinical trials and other sources needs to 
be translated into a performance score between 0 and 1 for each DMD on each 
characteristics, which comes with its challenges. A first challenge is the variety in the 
amount and quality of evidence between characteristics and per characteristic between 
DMDs. A lack of uniformity in outcome measures between pivotal studies of DMDs and 
incomplete reporting of these outcomes hinder the presentation of equivalent performance 
data for characteristics. A second challenge is that the translation of data into a score 
between 0 and 1 might be vulnerable to manipulation. Whereas such a translation of hazard 
ratios and relative risks is rather straightforward, determining a score for side effects and 
safety based on descriptive data is more challenging and prone to discussion. Consensus 
among experts should be reached. A third challenge is that the quality of the evidence and 
uncertainty surrounding the point estimates of hazard ratios, relative risks, etc. also need 
to be made transparent in (reporting about) the MCDA [4]. Insights into these aspects 
increase the face validity and trustworthiness of the patient decision aid, but 
communicating these uncertainties to patients and healthcare professionals and enabling 
them to include these uncertainties in the decision making is complex. Different measures 
were undertaken to make more transparent for patients, healthcare professionals and/or 
external reviewers, how the patient decision aid arrives at the results, i.e. the ranking of the 
DMDs. The tool provides insight into the performance of each DMD on the characteristics 
in bar charts and in descriptive text, and a paper accompanying the patient decision aid 
describes how the patient decision aid was developed and the type of data that were 
included.  
 
An important step in developing decision instruments based on MCDA is determining the 
criteria that describe the decision – or for this project the characteristics of DMDs - that 
need to be included in the instrument [4, 5]. Omission of relevant criteria or selection of 
irrelevant criteria would substantially affect the validity of the decision instrument [4], 
resulting in ineffective decision support. For the development of the patient decision aid, 
initial qualitative research was followed with a best-worst scaling survey to prioritize the 
criteria (Chapter 2). In best-worst scaling surveys, respondents state their preferences using 
hypothetical choice scenarios [6]. As respondents do not suffer actual consequences of their 
choices in these surveys, it is uncertain whether their answers reflect the choices they would 
make if there were consequences [7], i.e. if they actually had to start using the medication. 
Choice scenarios may be less carefully considered, resulting in inconsistent answers or 
considering only one or a few characteristics, or respondents might provide socially 
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desirable answers [7]. The application of a best-worst scaling in the development of a 
patient decision aid was a relatively novel approach. Conducting a best-worst scaling survey 
enables questioning a larger sample of the total patient population. This approach facilitates 
the development of a patient decision aid that meets the needs of many patients. 
Moreover, priorities can be set with regard to the information needed by patients. A 
limitation of conducting an online survey is, however, that no impression can be obtained 
of how respondents complete these surveys, other than tracking the time for completing 
each question and the whole survey. Accordingly, little can be said about the carefulness 
with which patients completed the choice tasks.  
 
Development of an instrument for a specific target group requires making choices about 
what should be included, but also what should be left out, to ultimately develop an 
instrument that suits patients’ needs as best as possible without the instrument becoming 
too complex or overly burdensome to use. The average stated preferences obtained 
through the best-worst scaling surveys (Chapters 2 and 3) were therefore used to determine 
the selection of criteria included in the MCDA-decision support tool and thus determined 
its content. The heterogeneity of preferences also need to be considered. Exploratory 
analysis showed that respondents with specific characteristics put more emphasis on 
certain characteristics of DMDs in comparison with patients with other characteristics. In 
the best-worst scaling surveys, these preferences were averaged, but individual preferences 
can deviate from the average preference. This shows that clinicians must not automatically 
project results of stated preference research on the patient in front of them. However, 
these averages can be useful for developing interventions for patients. A consideration in 
this is that using average preferences to develop instruments might result in instruments 
being developed for the “average patient”, even though the “average patient” most often 
does not exist. The functionalities of the MCDA-based decision aid to let patients select 
what characteristics they would like to consider in the decision and to put individualized 
weights on these characteristics results in a tool more tailored to the individual patient. 
 
A model-based economic evaluation was conducted to explore whether introducing shared 
decision making, possibly supported by a patient decision aid, in addition to the usual care, 
could potentially be cost-effective. A challenge with such an early-stage health economic 
model is that it focuses on interventions that are still in development or in the early stages 
of empirical studies [8], but information concerning the performance of the intervention is 
needed for the evaluation. Although theories suggest that shared decision making and/or a 
patient decision aids could improve treatment initiation, treatment persistence and 
treatment adherence [9, 10], evidence supporting these theories is not conclusive [10]. 
Point estimates included in the model for the increase in the proportion of patients initiating 
each DMD, for treatment persistence and treatment adherence were, therefore, based on 
assumptions, informed by expert opinions and studies on patients’ preferences for DMD 
characteristics or on the evaluation of patient decision aids for other healthcare decisions. 
There is, therefore, considerable uncertainty about the point estimates and the future 
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outcomes of the intervention. One-way sensitivity analyses and probabilistic analysis were 
conducted to evaluate the robustness of the conclusions regarding the cost-effectiveness 
of shared decision making for DMDs for MS. Still, the study results should be interpreted in 
the context of the assumptions made regarding the three parameters, and can therefore 
give only an indication of the potential cost-effectiveness of shared decision making for 
DMDs for MS. 
Implications for further development and research 
This dissertation covers the development and alpha user-testing on the comprehensibility, 
usability and acceptability of a web-based patient decision aid for DMDs for MS. The alpha 
test included patients who had experience with using DMDs, but were not considering 
switching or starting a DMD at the time of testing. A number of questions and points for 
improvement remain that should be addressed in the further development of the patient 
decision aid. Further development of the patient decision aid is needed regarding the 
verification of the rankings made by the decision aid, including the influence of uncertainty 
about effect estimates, and improving understandability of the patient decision aid through 
evaluation of the required health literacy and adaptation of the delivery of the patient 
decision aid. Next, a beta pilot test should be conducted including patients and healthcare 
professionals who are actually having to make a decision about DMDs [1]. Pilot 
implementation of the patient decision aid in clinical practice would answer questions such 
as 1) what is the most appropriate time point for introducing the patient decision aid to the 
patient?; 2) are all patients able to go through the patient decision aid individually or should 
a trained MS nurse guide the patients in the usage?; 3) what are other barriers and 
facilitators for the implementation in clinical practice? Moreover, the beta pilot would 
provide insights into whether implementation of the patient decision aid results in a trend 
towards resolving decisional conflict compared to baseline and in successful shared decision 
making taking place, as other patient decision aids have been shown to demonstrate 
positive effects on decision quality and on the quality of the decision making process [11]. 
After optimization of the patient decision aid based on the results of the beta pilot test, 
further research should focus on the effectiveness of the patient decision aid in comparison 
with usual care. It has been argued that patient decision aids positively affect patients’ 
persistence and adherence to treatment [9], resulting in improved health outcomes and 
decreased use of healthcare resources [12]. However, evidence supporting these theories 
is limited [11, 12]. A randomized controlled trial would provide the strongest evidence to 
confirm or reject this theory. However, the risk of contamination bias of the control group 
and variations in daily practice, clinical expertise, work culture and patient population 
should be taken into consideration in designing such a trial. Cluster randomization at the 
hospital level would minimize the risk of contamination bias [13]. Variation between 
hospitals is difficult to minimize in the design, as matching of hospitals on such 
characteristics is not feasible, and would thus be limited to controlling for in the analyses. 
7
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An alternative could be an interrupted time series, in which data for the control condition 
is first collected, followed by implementation of shared decision making supported by the 
patient decision aid and collection of data for this intervention [13]. It is necessary to have 
data on the effectiveness of the patient decision aid in comparison with usual care, in order 
to encourage healthcare professionals and policy makers of healthcare organizations to 
invest resources in the implementation of the patient decision aid. Accordingly, this study 
would contribute to providing patients access to the patient decision aid.  
 
The findings in Chapters 5 and 6 provide further guidance for the design of the trial. Since 
MS patients are in general relatively active online [3], online self-assessment during the trial 
would be feasible for the majority of patients, resulting in the efficient collection and 
processing of data. Chapter 6 suggests that personal contact with a member of the research 
team during the trial follow-up could enhance the patients’ adherence to the measurement 
schedule. Chapter 5 identified the extent to which certain outcome measures affect the 
cost-effectiveness of shared decision making. Most importantly, real-world data regarding 
the initiation of DMD treatment (including the type of DMD), patients’ persistence and 
adherence to treatment in the first year, and preferably over the longer term, should be 
collected, in addition to data on MS outcomes, quality-adjusted life years, resource use and 
costs. Using these data, the lifetime effectiveness and cost-effectiveness of shared decision 
making can be estimated more precisely by updating the state transition model described 
in Chapter 5. Moreover, the hypothesis that shared decision making could increase 
persistence and adherence to treatment could be confirmed. If shared decision making 
would indeed result in these beneficial consequences for patients’ commitment to 
treatment, a combination of the patient decision aid with self-managed interventions for 
optimizing treatment persistence and adherence could further be considered.  
 
Currently, dozens of potential new DMDs for RRMS and progressive MS are being studied 
in Phase II and Phase III studies [14] and more are on their way in Phase I studies. The 
number of available treatments is increasing rapidly. This seems promising for the options 
which patients with MS will have in the future. A consequence of the rapid advancements 
in the treatment of MS is that instruments concerning these treatments, such as clinical 
guidelines, patient education material and thus patient decision aids, are perhaps already 
outdated at the moment they become available for the target users. Continuous review of 
new developments and updating of these instruments is called for, which may be time 
consuming and expensive. With limited resources and funding for research, development 
and updating of patient decision aids, this is challenging. Therefore, structures should be 
set up for the immediate collection and processing of data as new DMDs and evidence 
about their efficacy and their cost-effectiveness become available. Periodically updated 
guidelines, such as the yearly-updated Dutch guidelines for epilepsy, may be warranted. 
 
Another direction for research could be exploring possibilities for internationalization of the 
patient decision aid. Currently, patient decision aids and shared decision making are 
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receiving increasing attention. Their importance for increasing quality of care, as well as for 
ethical reasons (“no decision about me without me”), have been recognized internationally 
by the medical profession [15] and by governmental bodies [16]. The patient decision aid 
described in this dissertation contains components specifically for MS patients in the 
Netherlands, such as the availability of DMDs, but the structure and content of the patient 
decision aid could be adapted to fit other settings, making it viable for patients in other 
countries and settings. For DMDs for MS, the development of interventions for patient 
decision support has been initiated in several countries [17-19]. International collaboration 
with patient decision aid developers for DMDs for MS could provide a unique opportunity 
for combining forces, integrating the strengths of the patient decision aids into a patient 
decision aid adaptable to country-specific settings.  
Implications for clinical practice and policy 
This MCDA-based patient decision aid was developed to support patients and healthcare 
professionals in making a shared decision about starting DMDs, but simultaneously to 
minimize the cognitive burden for patients in being involved in such complex healthcare 
decisions. The patient decision aid provides patients with information about the various 
treatment options, asks patients to indicate what is important to them, and based on what 
is important, provides a ranking of the treatment options for the specific patient. In the 
consultation with the healthcare professional, this ranking and the patient information is 
used to start the discussion about the decision for DMDs. The patient decision aid must 
never replace the consultation with the healthcare professional, nor should the ranking 
dictate which DMD the patient should choose. Based on the findings presented in this 
dissertation, it can be concluded that the patients and healthcare professionals were 
positive about the potential use of the patient decision aid for clinical decision making, but 
further development is needed before implementation in clinical practice (Chapter 4). An 
early health economic model (Chapter 5) showed that the implementation of shared 
decision making in clinical practice could potentially be cost-effective, which could be an 
incentive for policy makers in healthcare institutions to consider implementing the patient 
decision aid.  
 
The implementation of a patient decision aid per se is unlikely to automatically result in 
actual shared decision making taking place between patients and healthcare professionals 
[20]. In previous studies, various barriers to the implementation of shared decision making 
according to healthcare professionals have been identified, most importantly lack of time 
to practice shared decision making [21]. Strategies for successful implementation of shared 
decision making include training of healthcare professionals and making patient decision 
aids available, but both require investments. A commitment to prioritize shared decision 
making in all layers of the healthcare organisation – from the healthcare professional 
making decisions with patients to the upper management and board - thus needs to be 
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made in terms of time, funding and efforts [22]. In addition to the healthcare organizations, 
healthcare insurers also need to play a role in facilitating the (financial) accessibility to 
shared decision making [23]. From 2018, the Dutch Health Authority has included a 
registration code for consultations in which shared decision making has been applied [24]. 
The purpose is to make more transparent the degree to which shared decision making takes 
place [24]. Indirectly this could contribute to the financing of shared decision making using 
established finance methods, because the data can be used in negotiations between 
healthcare institutions and health insurers, in the purchase of healthcare services [24]. 
However, healthcare organizations are reluctant to use the code, as it is suitable only for 
specific situations, there is an increase in administrative work and the code provides no 
financial compensation. An even more pronounced hurdle for healthcare institutions are 
the investments required during the start-up phase of implementing shared decision 
making [23]. Both parties, i.e. healthcare insurers and healthcare institutes, agree that they 
share responsibilities in financing this phase [23], which is encouraging for realising the wide 
implementation of shared decision making. However, pioneers are needed to ensure the 
financial and organizational sustainability of implementation of shared decision making in 
clinical practice.  
 
Another important issue for consideration is the public availability of patient decision aids. 
Public availability empowers patients to inform themselves with regard to their healthcare 
and their treatment options even if they have not been made aware by their clinician that 
their preferences matter in the decision. A downside could be, however, that patients are 
presented with treatment options for which they are not eligible because patients cannot 
appropriately answer the eligibility questions themselves. In that case, the patient decision 
aid may be more confusing and obstruct the decision making process rather than supporting 
making a shared decision. Additional studies on the level of support needed by a MS nurse 
or clinician during the use of the patient decision aid in the pilot test should provide more 
insight as to whether public availability of the patient decision aid would be feasible.  
Highlights of this dissertation 
 A patient decision aid to support shared decision making between patient and 
healthcare professionals for DMDs for MS was developed, using certain methodologies 
typically applied in health technology assessment, i.e. best-worst scaling surveys and 
multi-criteria decision analysis.  
 A patient decision aid based on the principles of multi-criteria decision analysis may have 
its advantages in the utilisation if many characteristics of many treatment options need 
to be made, leading to individualised treatment recommendation, but its development 
also has its challenges, such as determining performance scores for treatment options 
for all characteristics.  
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 An early economic evaluation suggests that shared decision making for MS could 
potentially be a cost-effective intervention. Policy makers should consider 
implementation of shared decision making to improve quality of care.  
 Further development of the patient decision aid is recommended to optimise the 
content of the tool and the implementation strategy. Real-world data should be 
collected about the (cost-) effectiveness of the patient decision aid in clinical practice.  
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Patients with multiple sclerosis (MS) can experience various physical, cognitive and mental 
symptoms, which substantially affect quality of life. Advances in disease-modifying drug 
(DMD) treatment for MS provide patients with new opportunities to delay disease 
progression. Twelve different DMDs are currently available for the relapsing-remitting 
course of MS (RRMS) in the Netherlands; four are also available for clinically isolated 
syndrome (CIS), and more DMDs are expected to enter the market in the coming years. The 
increasing number of available drugs makes choosing the right DMD more complex, 
especially since the DMDs have different characteristics in terms of effects and treatment 
burden. Moreover, the choice for a DMD is preference-sensitive: there is no obvious “best” 
choice. Particularly for those with MS, where both the symptoms and the possible DMDs 
are so various, the patient’s preferences for the treatment options should be taken into 
account. This requires the patient’s active participation in the decision making process: a 
shared decision should be made. Shared decision making is a collaborative process between 
the healthcare professional and the patient; the patient is informed by the healthcare 
professional about the disease characteristics, prognosis and the treatment options, so that 
he/she can form preferences for the treatment options, and these preferences can be 
incorporated in the decision. Patient decision aids are designed to support this process. To 
ensure the quality of the developmental process and the patient decision aids, the 
International Patient Decision Aid Standards recommends the following steps for 
development: 1) scoping the patient decision aid; 2) forming a steering group of experts; 3) 
assessing patients’ informational needs according to patients and healthcare professionals; 
4) reviewing and synthesizing clinical evidence for treatment options; 5) developing a 
prototype; 6) testing the comprehensibility and usability of the prototype (alpha pilot test), 
and 7) testing the feasibility of implementing the patient decision aid (beta pilot test).  
 
Part I of this dissertation aimed to develop and pilot test a patient decision aid to support 
patients with RRMS or CIS and their healthcare professionals in making a shared decision 
about treatment with DMDs, following the recommended steps by the the International 
Patient Decision Aid Standards.  
 
Chapter 2 addresses the assessment of patients’ informational needs according to patients. 
Understanding what information about DMDs patients take into consideration when 
choosing a DMD contributes to the selection of information for the patient decision aid. 
Consecutive actions were undertaken to identify characteristics of DMDs that influence 
patients’ decisions for treatment and to prioritize these characteristics according to their 
importance. Three focus groups with RRMS patients (N=19) were performed. A nominal 
group technique was used in these focus groups to obtain a complete list of DMD 
characteristics that could be considered during the decision making process. Afterwards, a 
best-worst scaling survey was developed to prioritize the characteristics. In this survey, 
patients were presented with 17 choice tasks. In each choice task, patients were asked to 
answer which characteristic from a list of five characteristics they found most and least 
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important to consider when having to make the treatment decision. The characteristics’ 
mean relative importance scores (RISs) were calculated.  
Twenty-seven characteristics, which were identified in the focus groups, were included in 
the best-worst scaling survey. RISs were highest for the effect on disease progression (mean 
RIS: 9.64, 95% confidence interval: [9.48-9.81]), quality of life (RIS: 9.21 [9.00-9.42]), relapse 
rate (RIS: 7.76 [7.39-8.13]), severity of side effects (RIS: 7.63 [7.33-7.94]) and relapse 
severity (RIS: 7.39 [7.06-7.73]. Differences in RIS per characteristic were found in patient 
subgroups such as prior experience with DMD use. Explorative subgroup analyses showed 
statistically significant higher RIS for side effect-related characteristics for patients who had 
no experience in using DMDs, in comparison with experienced patients (p < .001). This study 
shows that, on average, patients valued effectiveness and unwanted effects as most 
important to consider when making the decision for a DMD, but there is heterogeneity in 
patient preferences.  
 
In Chapter 3, the perspective of healthcare professionals (neurologists and MS nurses) on 
the information about DMDs needed in the patient decision aid was also assessed as 
healthcare professionals may not adequately predict the patient’s preferences. Therefore, 
this study also compared the healthcare professionals’ perspective with the patients’ 
perspective obtained in Chapter 2. Multivariable linear regression analyses were used to 
compare the RIS per characteristic according to the different perspectives. According to the 
27 neurologists and 33 nurses, safety of the DMD (mean RIS (standard deviation): 9.29 
(±0.92)) was the most important DMD characteristic in the treatment decision, closely 
followed by effect on disability progression (RIS: 9.27 (±1.58)), quality of life (RIS: 9.19 
(±0.83)) and relapse rate (RIS: 8.89 (±0.88)). Little difference was found between the 
perspectives of neurologists and MS nurses, but comparing their perspective with the 
patients’ perspective showed that the RIS for safety was significantly lower in the patient 
group (b=-2.59, p<.001). Accordingly, this study suggests that, overall, neurologists and 
nurses agree about the importance of DMD characteristics, and that in general the MS 
patients’ perspective is similar, with the exception of the relative importance of safety.  
 
The systematic development of the patient decision aid is further described in Chapter 4. 
The online patient decision aid was designed and intended to support patients with RRMS 
or CIS with regard to DMDs labelled for MS in the Netherlands. A steering group consisting 
of neurologists, MS nurses, patient representatives and experts in the development of 
patient decision aids was formed and consulted during the development. A web-based 
format was selected to enable incorporation of the approach of multi-criteria decision 
analysis (MCDA) in the patient decision aid. MCDA can relieve the cognitive burden of 
weighting many different potentially conflicting characteristics of many different treatment 
options. Based on personal and medical information entered in the patient decision aid, a 
selection of DMDs suitable for the individual patient is made. Additionally, the patient 
selects which DMD characteristic he/she wants to consider in the decision and weighs the 
characteristics by rating the importance. The characteristics available for patients to select 
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in the patient decision aid are based on the results of the best-worst scaling surveys 
described in Chapters 2 and 3. Results of an extensive literature review on the effects and 
burdens of the DMDs, validated within the steering group, were incorporated into the 
patient decision aid to describe the different DMD options according to the characteristics. 
The patient decision aid compares the weights of the characteristics to the performance of 
the available DMDs, resulting in a ranking of DMDs from most to least matching the 
patient’s preferences. Moreover, the patient is able to compare the performance of a DMD 
on a specific characteristic to the other DMDs. 
The patient decision aid was then alpha pilot tested with MS patients and healthcare 
professionals in three rounds of interviews (Chapter 4). Both patients and healthcare 
professionals were positive about potential use of the patient decision aid for supporting 
the decision making process, but also reported points for improvement concerning the 
content and framing, the weighting methods for the importance of characteristics, and the 
presentation of the results of the patient decision aid. Adaptations were made accordingly. 
Further development of the patient decision aid is still needed regarding the verification of 
the rankings made by the decision aid, including the influence of uncertainty about effect 
estimates, and improving understandability of the patient decision aid through evaluation 
of health literacy and adaptation of the delivery of the patient decision aid. Moreover, beta 
pilot testing to assess the feasibility of implementation in clinical practice should be 
performed next before implementation of the tool in clinical practice.  
 
Part II of this dissertation aimed to inform the design of web-based health services for MS, 
such as self-monitoring applications and patient decision aids, and research into these 
services. 
 
In Chapter 5, the potential cost-effectiveness of shared decision making for RRMS in 
comparison with usual care from a societal perspective over a lifetime was explored in an 
early-stage economic evaluation. A previously developed state transition model that 
evaluates the cost-effectiveness of a range of DMDs for RRMS in comparison with best 
supportive care was adapted to model three potential effects of shared decision making: 1) 
a change in initial DMD chosen; 2) an increase in the patient’s persistence to the chosen 
DMD; and 3) an increase in adherence to the chosen DMD. One-way and probabilistic 
sensitivity analyses of a scenario that combined the three effects were conducted to 
evaluate the robustness of the results. A threshold analysis was further conducted to 
estimate at which costs SDM per patient may be, for it to be cost-effective. Each effect 
separately and all three effects combined resulted in increased quality-adjusted life years 
(QALYs) and costs for shared decision making in comparison with usual. The increase in 
utilization of DMDs was the primary cost driver. The combined scenario resulted in 1.12 
QALYs gained and €20,009 increased health state costs. The incremental cost-effectiveness 
ratio (ICER) was €17,875 per QALY gained. For a threshold of €50,000 per QALY, shared 
decision making was 98.5% likely to be cost-effective, but the ICER was sensitive to changes 
in drug prices, risk of disease progression, the discount rate and the perspective taken. For 
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shared decision making to be cost-effective, the intervention could maximally cost €23,639 
for a threshold of €50,000 per QALY. We concluded that shared decision making has the 
potential to be cost-effective for supporting patients’ choices between DMDs. Of the three 
assumed effect, the cost-effectiveness is most influenced by a reduction in the 
discontinuation rates. With new initiatives being explored to increase the uptake of shared 
decision making, this study informs clinicians and policy decision makers about the potential 
economic value of such investments. Moreover, this study shows that obtaining real-world 
data on long-term treatment discontinuation after shared decision making is needed.  
 
Chapter 6 focused on optimizing direct-to-patient research via web-based questionnaires. 
Since MS patients are in general relatively active online, online self-assessment during trials 
would be feasible, resulting in the efficient collection and processing of data. Missing data 
or delayed reporting of data by patients may negatively affect the quality of study results. 
Data from the Dutch MS study were analysed to investigate patients’ adherence to a self-
assessment schedule with low-frequency long questionnaires versus a high-frequency short 
questionnaire. The 36-item MS Impact Profile (MSIP) questionnaire and the 54-item MS 
Quality of Life-54 (MSQoL-54) questionnaire measured, respectively, (perceived) disabilities 
and health-related quality of life at 6-month intervals. The 2-item Medication and 
Adherence (MA) questionnaire measured medication and adherence to DMDs at 1-month 
intervals. The Expanded Disability Status Scale (EDSS) score was administered once via 
telephone by an experienced nurse. For both the self-assessment schedules, completion 
adherence (i.e. percentage of patients who completed all the questionnaires in the first 2 
years) and interval adherence (i.e. the percentage of patients who completed all the 
questionnaires within a set time frame) were calculated. We also assessed whether there 
was a relationship between adherence and the timing of EDSS assessment. Over a 2-year 
period, no difference was found in the proportion of patients completing all scheduled 
assessments between the two less frequent long questionnaires (perceived disabilities and 
HRQoL) and the more frequent short questionnaire, but patients completed the low-
frequency long questionnaires more often (85.5%) within a predefined time frame than the 
high-frequency short questionnaire (25.5%). If a nurse administered the EDSS within 6 
months after baseline, completion adherence was higher than if the EDSS was administered 
later (OR 1.810, 95% CI 0.999-3.280), suggesting that long-term completion adherence in 
direct-to-patient studies may be positively affected if patients are personally contacted by 
a member of the research team regarding early in the study. 
 
The last chapter of this dissertation (Chapter 7) summarizes the main findings, and discusses 
the methodological considerations. Moreover, implications for further development and 
research into the patient decision aid and implications for clinical practice and policy are 
discussed. Overall, this dissertation described the systematic and rigorous development of 
a patient decision aid for DMDs for MS. However, further development and research into 
its effects is warranted, starting with optimization of the content and delivery of the 
decision aid and a beta pilot test to optimize implementation strategy of the patient 
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decision aid. These studies should be followed by a (cost-) effectiveness study to establish 
the value for clinical practice and provide grounds for wide implementation. 
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Patiënten met multiple sclerose (MS) kunnen verschillende lichamelijke, cognitieve en 
mentale symptomen van hun ziekte ervaren. Deze symptomen hebben een aanzienlijke 
invloed op de kwaliteit van leven van deze patiënten. Door ontwikkeling van 
ziektemodulerende medicijnen voor MS kan verergering van de ziekte vertraagd worden. 
Momenteel zijn er in Nederland 12 verschillende ziektemodulerende medicijnen 
beschikbaar voor de relapsing-remitting vorm van MS (RRMS); vier van deze medicijnen zijn 
ook beschikbaar voor klinisch geïsoleerd syndroom (clinically isolated syndroom, CIS). Naar 
verwachting zullen er in de komende jaren meer nieuwe medicijnen beschikbaar komen. 
Dit groeiend aantal ziektemodulerende medicijnen maakt de keuze voor een medicijn ter 
behandeling van MS gecompliceerd. Dit komt met name door de verscheidenheid in 
eigenschappen van deze medicijnen, dat wil zeggen de positieve en negatieve 
consequenties van de behandeling. Bovendien is de keuze voor een ziektemodulerend 
medicijn ook afhankelijk van de voorkeuren van de individuele patiënt. Dit betekent dat er 
niet één duidelijk “beste” keuze bestaat. Met name voor MS, waarbij er zoveel 
verscheidenheid is in zowel de symptomen die patiënten ervaren als in de medicijnen die 
beschikbaar zijn, is het van belang om de voorkeuren van de patiënt mee te nemen in het 
maken van een keuze. Dit vraagt om actieve participatie door de patiënt in het keuzeproces: 
Samen Beslissen met de zorgverlener.  
 
Samen Beslissen is een gezamenlijk proces tussen de zorgverlener en de patiënt: de patiënt 
wordt door de zorgverlener geïnformeerd over de ziekte, de prognose en de 
behandelmogelijkheden, zodat de patiënt voorkeuren kan ontwikkelen voor de 
verschillende behandelmogelijkheden, en deze voorkeuren meegenomen kunnen worden 
in de keuze. Keuzehulpen hebben als doel om dit proces te ondersteunen. Om de kwaliteit 
van het ontwikkelingsproces van keuzehulpen te waarborgen beveelt de International 
Patient Decision Aid Standards aan, om de volgende stappen te doorlopen in de 
ontwikkeling: 1) vaststellen van het doel en de doelgroep voor de keuzehulp; 2) vormen van 
een stuurgroep bestaande uit klinische experts en patiënten; 3) in kaart brengen van de 
informatie die patiënten nodig hebben om een keuze te kunnen maken, ook volgens 
zorgverleners; 4) in kaart brengen van de behandelmogelijkheden op basis van 
wetenschappelijk en klinisch bewijs; 5) ontwikkelen van een prototype; 6) testen van de 
begrijpelijkheid en bruikbaarheid van het prototype (alfa-pilot test), en 7) testen van de 
haalbaarheid van het implementeren van de keuzehulp in de klinische praktijk (bèta-pilot 
test).  
 
Deel I van dit proefschrift beschrijft de ontwikkeling en pilot test van een keuzehulp die 
dient om patiënten met RRMS of CIS en hun zorgverleners te ondersteunen in het Samen 
Beslissen over de behandeling met ziektemodulerende medicijnen. Hierbij zijn de 
aanbevolen stappen van de International Patient Decision Aid Standards gevolgd.  
 
Hoofdstuk 2 brengt in kaart welke informatie over ziektemodulerende medicijnen patiënten 
nodig hebben om een keuze voor een behandeling te kunnen maken. Dit om te bepalen 
141878 Ingrid Kremer BNW.indd   210 19-02-20   09:50
S A M E N V A T T I N G  
211 
 
welke informatie opgenomen moet worden in de keuzehulp. Verschillende stappen zijn 
doorlopen. Door middel van drie focusgroepen met RRMS-patiënten (N=19) is 
geïdentificeerd welke eigenschappen van ziektemodulerende medicijnen de keuze van 
patiënten beïnvloeden. Een nominale groepstechniek is toegepast in deze focusgroepen om 
een volledige lijst van eigenschappen samen te stellen. Vervolgens is een best-worst scaling 
vragenlijst ontwikkeld om de geïdentificeerde eigenschappen te prioriteren aan de hand 
van hun belangrijkheid bij de keuze. Deze vragenlijst bestond uit 17 keuzevragen. In elke 
vraag is aan de patiënt gevraagd om uit een rijtje van vijf eigenschappen te kiezen welke 
hij/zij het belangrijkst en minst belangrijkst vindt om mee te nemen in de keuze voor een 
ziektemodulerend medicijn. Op basis van de antwoorden is een relatieve 
belangrijkheidsscores per eigenschap berekend.  
Op basis van de resultaten uit de focusgroepen werden 27 eigenschappen geïdentificeerd 
en opgenomen in de best-worst scaling vragenlijst. Relatieve belangrijkheidsscores waren 
het hoogst voor effect van het medicijn op ziekteachteruitgang (gemiddelde score: 9.64, 
95% betrouwbaarheidsinterval [9.48-9.81]), de kwaliteit van leven (score: 9.21 [9.00-9.42]), 
het aantal relapses (score: 7.76 [7.39-8.13]), ernst van de bijwerkingen (score: 7.63 [7.33-
7.94]) en ernst van de relapses (score: 7.39 [7.06-7.73]. Er zijn verschillen gevonden in de 
belangrijkheidsscores voor eigenschappen op basis van verschillende subgroepen van 
patiënten met bepaalde karakteristieken, zoals hun ervaring met ziektemodulerende 
medicijnen. Exploratieve subgroepanalyses lieten zien dat de belangrijkheidsscores voor 
eigenschappen gerelateerd aan bijwerkingen statistisch hoger waren voor patiënten die 
geen ervaring hadden met het gebruik van ziektemodulerende medicijnen dan voor 
patiënten die wel eerder al een medicijn gebruikt hadden (p<.001). Deze studie laat zien, 
dat patiënten effectiviteit en bijwerkingen, gemiddeld, het belangrijkst vinden om in hun 
overweging mee te nemen bij het maken van een keuze voor een ziektemodulerend 
medicijn, maar ook dat er sprake is van heterogeniteit in de patiëntvoorkeuren.  
 
In Hoofdstuk 3 van dit proefschrift is beschreven welke informatie over ziektemodulerende 
medicijnen in de keuzehulp opgenomen moet worden volgens zorgverleners, dus volgens 
neurologen en MS-verpleegkundigen. Zorgverleners kunnen namelijk mogelijk niet juist 
inschatten wat de voorkeuren van de individuele patiënt zijn. Daarom vergelijkt de studie 
beschreven in Hoofdstuk 3 het perspectief van zorgverleners met het perspectief van 
patiënten, zoals verkregen in Hoofdstuk 2. Multivariabele lineaire regressieanalyses zijn 
uitgevoerd om de relatieve belangrijkheidsscores per eigenschap te vergelijken volgens de 
verschillende perspectieven. Volgens 27 neurologen en 33 MS-verpleegkundigen was 
veiligheid van het ziektemodulerend medicijn (gemiddelde belangrijksheidsscore 
(standaarddeviatie): 9.29 (±0.92)) de belangrijkste eigenschap in de keuze voor de 
behandeling, op de voet gevolgd door het effect op ziekteachteruitgang (score: 9.27 
(±1.58)), kwaliteit van leven (score: 9.19 (±0.83)) en het aantal relapses (score: 8.89 (±0.88)). 
Weinig verschillen zijn gevonden tussen de perspectieven van neurologen en MS-
verpleegkundigen, maar een vergelijking van hun gezamenlijke perspectief met het 
perspectief van patiënten liet zien dat de belangrijkheidsscore voor veiligheid significant 
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lagers was volgens de groep patiënten (b=-2.59, p<.001). Deze studie suggereert daarom 
dat de perspectieven van neurologen en MS-verpleegkundigen onderling over het belang 
van de eigenschappen van ziektemodulerende medicijnen in het algemeen 
overeenstemmen, net als met het perspectief van patiënten, met uitzondering van het 
belang van veiligheid.  
 
De systematische ontwikkeling van de keuzehulp is verder beschreven in Hoofdstuk 4. De 
online keuzehulp is ontwikkeld om patiënten met RRMS en CIS te ondersteunen in het 
maken van de behandelkeuze voor één van de ziektemodulerende medicijnen, beschikbaar 
in Nederland. Een stuurgroep bestaande uit neurologen, MS-verpleegkundigen, 
patiëntvertegenwoordigers en experts in de ontwikkeling van keuzehulpen is gevormd. 
Deze stuurgroep gaf op verschillende momenten gedurende de ontwikkeling van de 
keuzehulp advies. Een online format voor de keuzehulp was noodzakelijk om de benadering 
van multi-criteria decision analysis (MCDA) in de keuzehulp in te bouwen. MCDA kan de 
cognitieve belasting verminderen: het afwegen van een groot aantal verschillende 
behandelmogelijkheden met ieder zijn eigen eigenschappen, die ook nog kunnen 
conflicteren kan een moeilijke taak zijn. In de MCDA-keuzehulp voert de patiënt 
persoonlijke en medische informatie, zoals geslacht en type MS. Deze informatie kan 
namelijk van invloed zijn op de medicijnen waarvoor de patiënt in aanmerking komt. Op 
basis van deze informatie worden de medicijnen, waarvoor de patiënt niet in aanmerking 
komt, uitgefilterd. Ook selecteert de patiënt welke eigenschappen van ziektemodulerende 
medicijnen hij/zij van belang vindt in de keuze voor een medicijn en geeft iedere eigenschap 
een weging door een belangrijksheidsscore toe te kennen. De patiënt kan hierbij kiezen uit 
eigenschappen die op basis van de onderzoeken uit Hoofdstukken 2 en 3 geselecteerd zijn. 
Een uitgebreide literatuurstudie naar de effecten en nadelige gevolgen van het gebruik van 
ziektemodulerende medicijnen is uitgevoerd. De resultaten van deze studie zijn gevalideerd 
door de stuurgroep. Daarna zijn deze resultaten in de keuzehulp opgenomen om de 
verschillende ziektemodulerende medicijnen te beschrijven aan de hand van hun 
eigenschappen. De keuzehulp vergelijkt het belang van de eigenschap (zoals gescoord door 
de patiënt) met de mate waarin elk medicijn presteert op iedere eigenschap. Op basis van 
deze vergelijking geeft de keuzehulp een ranking weer van de medicijnen die het best tot 
het minst overeenkomen met wat de patiënt belangrijk vindt. Bovendien kan de patiënt de 
prestatie van elk medicijn op een specifieke eigenschap vergelijken met de andere 
medicijnen beschikbaar voor deze patiënt.  
Nadat de ontwikkeling van een initieel prototype van de keuzehulp was afgerond, is een 
alfa pilot test uitgevoerd onder MS-patiënten en zorgverleners in drie rondes van interviews 
(Hoofdstuk 4). Zowel patiënten als zorgverleners hadden een positieve houding over het 
potentieel van de keuzehulp om het proces van Samen Beslissen te ondersteunen, maar zij 
rapporteerden ook verschillende verbeterpunten. Deze verbeterpunten betroffen de 
inhoud en verwoording, de methoden die gehanteerd werden om de belangrijkheid van 
eigenschappen te scoren en de presentatie van de eindresultaten van de keuzehulp. Op 
basis van de opmerkingen is de keuzehulp aangepast. Verdere ontwikkeling van de 
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keuzehulp is vereist om de rankings van de keuzehulp te verifiëren, inclusief de onzekerheid 
over de puntschattingen, en de begrijpelijkheid van de keuzehulp te verbeteren door 
evaluatie van de benodigde gezondheidsvaardigheden en adaptatie van de manier waarop 
de keuzehulp aangeboden wordt aan de patiënt. Vervolgens dient de haalbaarheid van de 
implementatie in de klinische praktijk onderzocht te worden in een bèta-pilot test.  
 
Deel II van dit proefschrift had als doel om de ontwikkeling van en onderzoek naar 
gezondheidsdiensten voor MS, - die online worden aangeboden - zoals 
zelfmanagementapplicaties en keuzehulpen, te informeren.  
 
Hoofdstuk 5 beschrijft een vroege economische evaluatie om de potentiële 
kosteneffectiviteit van Samen Beslissen voor behandeling van RRMS in vergelijking met 
reguliere zorg te bepalen. Deze modelmatige economische evaluatie is uitgevoerd over een 
levenslange tijdshorizon vanuit een maatschappelijk perspectief.  Een eerder ontwikkeld 
model dat de kosteneffectiviteit van verschillende ziektemodulerende medicijnen voor 
RRMS vergeleek met geen behandeling (ofwel ondersteunende zorg zonder medicatie) is 
aangepast om drie potentiële effecten van Samen Beslissen te modelleren: 1) een 
verandering in de keuze voor het initiële ziektemodulerende medicijn; 2) verbeterde 
volharding door patiënten met het gekozen medicijn; en 3) een verbetering in 
therapietrouw aan het gekozen medicijn. Resultaten van een scenario dat de drie effecten 
combineert zijn verder geëvalueerd in sensitiviteitsanalyses. Een referentiewaarde-analyse 
(threshold analysis) is uitgevoerd om te schatten wat de maximale kosten van Samen 
Beslissen per patiënt mogen zijn, wil de interventie Samen Beslissen nog kosteneffectief 
zijn. Elk effect apart en gecombineerd resulteerde in een toename in het aantal voor 
kwaliteit van leven gecorrigeerde levensjaren (quality-adjusted life years, QALYs) en een 
toename in de kosten wanneer Samen Beslissen zou worden toegepast in plaats van 
reguliere zorg. De toename in kosten werd primair veroorzaakt door een toename in het 
gebruik van ziektemodulerende medicijnen. Het gecombineerde scenario resulteerde in 
een toename van 1,12 QALYs en €20.009 meer kosten gerelateerd aan de 
gezondheidstoestand van de patiënt. De incrementele kosteneffectiviteitsratio (IKER) was 
17.875 per extra QALY. Bij een referentiewaarde waarbij de maatschappij maximaal 
€50.000 extra zou willen betalen voor een extra QALY is er een kans van 98.5% dat Samen 
Beslissen kosteneffectief is, ofwel dat de IKER lager of gelijk aan de referentiewaarde is. De 
IKER bleek echter gevoelig voor veranderingen in medicijnkosten, risico op ziekteprogressie, 
de disconteringsvoet en het perspectief. Samen Beslissen mag maximaal €23.639 kosten bij 
een referentiewaarde van €50.000 per extra QALY. Geconcludeerd is dat Samen beslissen 
de potentie heeft om kosteneffectief te zijn als interventie om keuzes te maken in 
ziektemodulerende medicijnen. Als apart gekeken wordt naar de drie mogelijke effecten 
van Samen Beslissen, dan wordt de kosteneffectiviteit meest beïnvloed door een toename 
in de volharding van patiënten met het gekozen medicijn. Nu nieuwe initiatieven worden 
onderzocht om een toename in het toepassen van Samen Beslissen te bewerkstelligen, 
informeert deze studie clinici en beleidsmaker over de potentiële economische waarde van 
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investeringen in Samen Beslissen. Daarnaast laat deze studie zien dat data over het effect 
van Samen Beslissen op voortijdig stoppen met medicatie, verzameld buiten 
gecontroleerde studies om, nodig is.  
 
Hoofdstuk 6 focust op het optimaliseren van direct-to-patient onderzoek dat plaatsvindt via 
online vragenlijsten. Patiënten kunnen zichzelf opgeven voor dit type onderzoek, zonder 
tussenkomst van een zorgverlener. Omdat MS-patiënten over het algemeen relatief actief 
zijn op internet, kan online afname van vragenlijsten een optie zijn in onderzoek. Dit 
resulteert in efficiënte verzameling en verwerking van data. Missende data of het te laat 
invullen van vragenlijsten door patiënten kan de kwaliteit van de studieresultaten 
beïnvloeden. Data van de Nederlandse MS studie zijn geanalyseerd om na te gaan in 
hoeverre patiënten zelfevaluatievragenlijsten van verschillende frequenties en tijdsduur 
invullen volgens het vooraf bepaalde invulschema. In het onderzoek werden twee typen 
invulschema’s gehanteerd die verschilden ten aanzien van lengte van de vragenlijst en de 
frequentie waarmee de vragenlijst ingevuld dient te worden. De vragenlijst MS Impact 
Profile (MSIP) met 36 items brengt functioneringsproblemen in kaart. De MS Quality of Life-
54 (MSQoL-54) met 54 items meet gezondheidsgerelateerde kwaliteit van leven. Beide 
vragenlijsten typeerden het eerste invulschema en werden in het onderzoek elke zes 
maanden ingevuld. De Medication and Adherence vragenlijst brengt in kaart welke 
medicijnen een patiënt gebruikt en in welke mate de patiënt therapietrouw is in het gebruik 
van het medicijn. Deze vragenlijst typeerde het tweede invulschema en werd elke maand 
ingevuld door patiënten. Daarnaast is de Expanded Disability Status Scale (EDSS) eenmalig 
telefonisch afgenomen door een ervaren verpleegkundige. Voor beide invulschema’s is 
nagegaan in hoeverre patiënten het invulschema naleefden. Dat wil zeggen dat het 
percentage patiënten dat alle vragenlijsten in de eerste twee jaar van het onderzoek 
ingevuld heeft in kaart is gebracht en het percentage patiënten dat alle vragenlijsten 
ingevuld heeft binnen een vooraf vastgestelde tijdslimiet. Ook is nagegaan of er een relatie 
is tussen het naleven van het invulschema en het moment van afnemen van de EDSS. Er is 
geen verschil gevonden tussen de twee typen invulschema’s in het percentage patiënten 
dat alle vragenlijsten had ingevuld over een periode van twee jaar. Patiënten vulden de 
laagfrequente lange vragenlijst (functioneringsproblemen en gezondheidsgerelateerde 
kwaliteit van leven) wel vaker (85,5%) binnen de vooraf vastgestelde tijdslimiet in dan de 
hoogfrequente korte vragenlijst (25,5%). Daarnaast lieten de studieresultaten zien dat 
patiënten vaker alle vragenlijsten invulden indien zij binnen 6 maanden na starten met het 
onderzoek contact hadden gehad met een verpleegkundige ten behoeve van de afname van 
de EDSS (OR 1,810, 95% CI 0,999-3,280). Dit suggereert dat persoonlijk contact met een 
onderzoeker aan het begin van direct-to-patient studies mogelijk de naleving van de 
invulschema’s positief beïnvloedt. 
 
Het laatste hoofdstuk van dit proefschrift (Hoofdstuk 7) vat de belangrijkste bevindingen 
samen en bediscussieert methodologische overwegingen en beperkingen. Daarnaast zijn de 
implicaties voor verdere ontwikkeling en onderzoek over keuzehulpen en implicaties voor 
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de klinische praktijk en beleid weergegeven. Samenvattend beschrijft dit proefschrift de 
systematische ontwikkeling van een keuzehulp voor ziektemodulerende medicijnen voor 
MS.  Verdere ontwikkeling en onderzoek in de effecten van de keuzehulpen is echter nodig. 
Hierbij dient begonnen te worden bij het optimaliseren van de inhoud van de keuzehulp, 
gevolgd door bèta-pilot testen, om de inhoud en implementatiestrategie verder te kunnen 
optimaliseren. Vervolgens dient een (kosten-)effectiviteitsstudie uitgevoerd te worden om 
de waarde van de keuzehulp voor de klinische praktijk vast te stellen, dat uiteindelijk kan 
motiveren tot brede implementatie van de keuzehulp.  
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This chapter discusses the societal value of the results found in this thesis for three groups 
of stakeholders: patients and healthcare professionals, policy makers, and the scientific 
community. Moreover, the efforts made to disseminate the knowledge gained from this 
thesis and the additional actions to be taken are described.  
Societal value of this dissertation 
Patients and healthcare professionals 
The number of treatment options for reducing the number of relapses and/or delay disease 
progression for patients with multiple sclerosis (MS) has been increasing rapidly. Patients 
with the relapsing-remitting type of MS (RRMS) or clinically isolated syndrome (CIS) often 
have often two or more options of treatment with disease-modifying drugs (DMDs). 
Therefore, an adequate treatment decision needs to be made; no single treatment option 
is the dominant choice, as the most suitable option can differ according to the patient’s 
situation and preferences. Consequently, international recommendations for MS treatment 
have highlighted the importance of involving patient preferences in the treatment decision 
[1, 2]. Accordingly, the different characteristics of treatment options need to be considered 
and weighed. This can be a difficult process for patients and healthcare professionals. The 
patient needs to capture all of the information, develop preferences and communicate 
these preferences with the healthcare professional. The healthcare professional needs to 
educate the patient about the treatment options, balance the information provided and 
elicit the patient’s preferences.  
This dissertation aims to develop a patient decision aid to facilitate shared decision making 
for DMDs for MS. Patient decision aids help patients to feel informed, to have more 
confidence in the decision, and, importantly, to achieve more congruence between the 
treatment chosen and the patient’s preferences [3]. The online patient decision aid 
proposed in this dissertation is based on the principles of multi-criteria decision analysis 
(MCDA). This patient decision aid enables the filtering of treatment options based on the 
patient’s personal and medical characteristics, elicitation of the patient’s preferences for 
specific characteristics of treatments, and ranking of the treatments for which the patient 
is eligible from most to least fitting with the patient’s individual preferences. The ranking 
can be used to focus the deliberation process of studying and discussing the treatment 
options, i.e., based on the ranking, the patient can identify a small number of treatment 
options to read more about. Accordingly, in contrast with other approaches for patient 
decision aids, such as schematic summaries of treatment options according to frequently 
asked questions, in which the patient needs to grasp the characteristics of all available 
treatment options, an MCDA-based approach for patient decision aids may relieve the 
cognitive burden of considering the treatments in situations with many options and many 
varying characteristics. The proposed patient decision aid is one of the first MCDA-based 
patient decision aids for MS, and the first patient decision aid for MS in the Netherlands.  
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During the development of our tool, alpha pilot testing of the developed patient decision 
aid enabled the identification and resolution of problems regarding patients’ 
comprehension and the usability of the decision aid for patients and healthcare 
professionals. Further development and evaluation of our patient decision aid for 
optimizing the content and implementation strategy and assessing whether the patient 
decision aid results in the effects on the quality of the decision and of the decision making 
process as reported for patient decision aids for other decisions [3]. Both patients and 
healthcare professionals expressed a positive attitude towards the potential use of of our 
patient decision aid for supporting shared decision making about DMDs.  
The implementation of shared decision making supported with the patient decision aid in 
clinical practice could improve the quality of care for patients, and could also result in 
improved persistence and adherence levels in taking prescribed medication, and 
consequently in improved health outcomes and quality of life, as our early economic 
evaluation of the cost effectiveness of shared decision making for MS suggested. 
Policy makers 
Healthcare policy makers and healthcare insurance companies decide on the allocation of 
funds for the implementation and reimbursement of new interventions based on a number 
of factors, including cost effectiveness [4]. Like all assessments of consequences in terms of 
the costs of an intervention and benefits gained, policy makers need to make decisions in 
the face of uncertainties [4]. This dissertation informs policy makers about the potential 
cost-effectiveness of implementing a shared decision aid in clinical practice in order to 
determine whether shared decision making should be implemented and reimbursed. The 
early economic evaluation demonstrated a favourable incremental cost-effectiveness ratio 
in different scenarios, which supports arguments for implementation and reimbursement. 
This study suggests that if shared decision making improves persistence and adherence to 
treatment with DMD, shared decision making could potentially be cost-effective in 
achieving improved health outcomes.  
Scientific community 
Both parts of this dissertation, i.e. the chapters focusing on the development of the patient 
decision aid and the chapters exploring how web-based health services and research for MS 
can be optimized, are of added value for researchers in the field of patient decision aid 
development, and in the assessment of shared decision making and MS. First, 
methodologies which have been increasingly applied in health technology assessment, i.e. 
best-worst scaling surveys and MCDA, have been applied successfully in the development 
of patient decision aids. Researchers could therefore consider using stated preference 
research to prioritize which information should be included in a patient decision aid. 
Moreover, MCDA can be considered as an approach for the development of a decision aid 
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in situations with many different options and/or many characteristics which must be 
considered or for patients with impaired cognitive abilities.  
In part two of this dissertation, the adherence of patients to assessment schedules in web-
based research was examined. Long assessments at low frequency are more often 
completed within a set time frame in comparison with highly frequent short assessments. 
In addition, personal contact with a researcher shortly after commencing participation in 
the study could positively affect patient adherence to assessment schedules. Researchers 
considering web-based measurement schedules could consider these findings in the design 
of protocols for direct-to-patient research.  
Dissemination of knowledge 
Several efforts have been undertaken to disseminate the findings from this dissertation to 
the various stakeholders [Table 1]. Dissemination among researchers and policy makers has 
been stimulated through publication of the study results in scientific journals and by 
publication of this dissertation. Three articles have already been published in open access 
peer-reviewed journals, and the two remaining articles have been submitted to open access 
journals. In addition, the results of the studies described in this dissertation have been 
presented at several international conferences, such as the conferences of the Society for 
Medical Decision Making, the International Shared Decision Making Society, the European 
Committee for Treatment and Research in Multiple Sclerosis, and ISPOR- the Professional 
Society for Health Economics and Outcomes Research.  
Moreover, patients and healthcare professionals have been involved in a number of phases 
of the developmental process. An advisory committee was formed consisting of patient 
representatives from two patient organizations (Nationaal MS Fonds, MS Vereniging 
Nederland) as well as neurologists and nurses from several hospitals in the Netherlands. 
This collaboration brought about continuous contact with patient organizations regarding 
the progress of the development of the patient decision aid, and led to interest in the 
patient decision aid from patient and professional magazines. Two articles about the patient 
decision aid for MS were published in these magazines (i.e. Nieuwslijn, 2017 and Medidact 
Neurologie, 2019), creating awareness among patients and healthcare professionals about 
the future availability of the patient decision aid, and stimulating both patients and 
healthcare professionals to participate in the decision aid’s development.  
The attention paid to the patient decision aid by these magazines also highlights for policy 
makers the need for its implementation in clinical practice. The implementation of patient 
decision aids in hospitals is not straightforward, due to the initial investments needed by 
hospitals to acquire licenses, train staff and adjust structures to facilitate the use of patient 
decision aids [5]. Moreover, shared decision making could result in longer consultation time 
and in more expensive or cheaper treatments being chosen [6]. The successfulness of 
securing sustainable implementation of patient decision aids in clinical practice is reported 
to be, in part, dependent on available financing [5], i.e. who is paying for it. We are currently 
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examining the feasibility of different financial structures and incentives to achieve 
organizational and financial sustainability for the implementation in clinical practice and to 
optimize the uptake of implementation across hospitals in the Netherlands, in collaboration 
with a partner experienced in the implementation of patient decision aids. We have been 
working on acquiring research and implementation grants from consortiums formed by the 
pharmaceutical industry and government grants to overcome the initial financial barriers 
for hospitals, such as training staff and acquiring licenses. Other structures, such as 
healthcare insurers’ reimbursement of shared decision making, could also be considered, 
aiming at achieving sustainable implementation of shared decision making supported with 
patient decision aids on a large scale for all treatment and screening decisions. For example, 
the National Healthcare Authority’s policy “Experiments” allows conditional reimbursement 
by a healthcare insurer if both healthcare insurer and healthcare provider want an 
innovation to be embedded for limited time [7]. After the experiment is terminated, a 
decision could be made about structural reimbursement for the innovation [7].  
Before the initiation of such structures, further information about the consequences for 
patients and healthcare budgets is needed. This information enables determining the cost-
effectiveness of shared decision making supported with a patient decision aid for MS and 
its budgetary impact for budget holders, i.e. policy makers from healthcare providers and/or 
healthcare insurers. Moreover, a business case should be developed, which summarizes the 
costs and benefits in monetary and non-monetary terms for each stakeholder, including the 
effects on the quality of healthcare and the benefits for patients. A business case and 
budget impact analysis could provide grounds that support implementation of the new 
intervention, and convince budget holders that these investments are worthwhile in 
improving quality of care.   
Additional research concerning the patient decision aid is planned. Before implementation 
in hospitals, we will optimize and update the patient decision aid in terms of content, user-
friendliness and health literacy, and test the feasibility of implementing the patient decision 
aid in a before-and-after pilot study. Moreover,  a controlled trial is planned to research the 
effects of the patient decision aid on the quality of the decision, the decision making 
process, on adherence, persistence and treatment choice, health outcomes, quality of life 
and costs.  
Other research areas of value are optimization of risk communication for patients with MS, 
setting up an international network of patient decision aid developers for MS to possibly 
develop an international tool, and to embed the patient decision aid in a multicomponent 
intervention to support patients in the management of their MS. Pending the update of the 
Dutch clinical guidelines for MS, we will also strive to connect the patient decision aid to 
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Table 1. Completed and intended activities for dissemination of knowledge 
Patients and healthcare professionals 
 Involvement during the developmental process, involvement in advisory 
group 
 Continuous contact with patient organizations 
 Article in patient and professional magazines (Nieuwslijn, 2017; Medidact 
Neurologie, 2019) 
o Optimize and update content, user-friendliness (e.g. risk communication) 
and health literacy of patient decision aid 
o Increase commitment of intended users to implementation 
o Connect patient decision aid with guidelines for clinical practice 
o Embed patient decision aid in a multicomponent intervention for MS 
management 
Policy makers 
 Publications of papers in scientific journals and of dissertation 
 Presentation of studies during (inter)national conferences 
o Mapping structures to ensure financial sustainability of implementation 
o Conduct a controlled trial to determine the (cost-)effectiveness, perform 
budget impact analysis and develop a business case 
Scientific community 
 Publications of papers in scientific journals and of dissertation 
 Presentation of studies during (inter)national conferences 
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Dan zijn bijna alle hoofdstukken geschreven en rest nu nog dit laatste hoofdstuk. Een 
hoofdstuk dat ik niet makkelijk vind om te schrijven, want ik ben niet iemand die haar hart 
op de tong heeft. Maar wat een mooie kans om – na deze jaren – de mensen te bedanken 
die me op welke manier dan ook geholpen, geïnspireerd, geadviseerd en meegedacht 
hebben bij het schrijven van dit proefschrift. Dankjewel. Ik waardeer dit zeer. Ik wil een 
aantal mensen in het bijzonder bedanken.   
 
Ten eerste wil ik iedereen bedanken die instemden om mee te doen aan de focusgroepen, 
interviews en vragenlijstonderzoeken en via deze weg hun kennis en inzichten hebben 
gedeeld. Jullie hulp was onmisbaar voor dit proefschrift.  
 
Ik wil mijn promotieteam Silvia, Mickaël en Sjef bedanken voor jullie begeleiding. Al in het 
eerste jaar van de research master schreef ik onder jullie begeleiding een subsidievoorstel, 
dat ik in het tweede jaar verder uitwerkte naast het onderzoek voor mijn afstudeerthesis. 
Uiteindelijk heeft dit subsidievoorstel eraan bijgedragen dat ik bij jullie kon beginnen aan 
mijn promotieonderzoek. Zo heb ik dus een aantal jaren onder jullie begeleiding en met 
jullie steun mogen werken en zullen we onze samenwerking in de toekomst ook 
voortzetten. Bedankt voor jullie betrokkenheid, de constructieve feedback, het delen van 
jullie kennis en het vertrouwen dat jullie in mij hadden.  
Silvia, ik waardeer hoe jij bij problemen meteen in oplossingen denkt. Het kwam meer dan 
eens voor dat ik twijfelde hoe ik verder moest en dat je me weer op weg hielp, onder andere 
door me te verbinden met anderen. Daarnaast heb je mij meer dan eens gestimuleerd om 
ook aan de grote lijnen van het onderzoek te denken wanneer ik mezelf verloor in details, 
om bewust te worden van mijn eigen kwaliteiten en die ook uit te stralen. 
Mickaël, onze gezamenlijke wekelijkse overleggen en jouw kritische blik op mijn werk 
hebben mij veel geholpen bij het uitvoeren van dit promotieonderzoek. Ik waardeer je 
nuchtere kijk en de rust die je altijd uitstraalt, ook als ik zelf beren op de weg zie. Ook was 
jij het die vroeg of ik een paar maanden in Canada wilde gaan werken, waar ik uiteindelijk 
unieke (werk-) ervaringen heb opgedaan. Dankjewel! 
Sjef, je passie voor onderzoek en specifiek voor MS, is aanstekelijk. Ik kon altijd rekenen op 
jouw kritische feedback. Jij hielp me om mijn project in een bredere context te plaatsen en 
stimuleerde me om ook vooruit te denken. Dank voor je betrokkenheid en de vele 
telefoontjes tussen de overleggen door. Ik kijk ernaar uit om onze samenwerking ook na 
mijn promotie voor te zetten.  
 
Graag zou ik de leden van de beoordelingscommissie, bestaande uit prof. dr. Manuela Joore, 
dr. Elske van den Akker-van Marle, prof. dr. Rik Crutzen, prof. dr. Joep Killestein en dr. 
Ghislaine van Mastrigt, hartelijk willen bedanken voor het lezen en beoordelen van mijn 
proefschrift.  
 
During my PhD, I had the opportunity to work with people in the Netherlands and abroad. 
I would like to thank all coauthors of the articles in this dissertation for their collaboration 
and their contribution to the articles: Nick Bansback, Josh Carlson, Erwin Hoogervorst, Elena 
Hristodorova, Ilona van de Kolk, Anton Kool, Esther van Noort, Svenja Petersohn, Xavier 
Pouwels, Wim Verhagen, Trudy van der Weijden and Marita Zimmerman.  
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Hartelijk dank aan de leden van de adviesgroep, Martijn Beenakker, Karin Hameetman, 
Erwin Hoogervorst, Tiny Janssen, Manita Karman, José Savelkoul, Laura van der Velde en 
Wim Verhagen, die gedurende de ontwikkeling van de keuzehulp verschillende keren bereid 
waren om tijd vrij te maken en hun deskundigheid met mij te delen. Daarnaast ook hartelijk 
dank aan Trudy van der Weijden voor je advies ten aanzien van de ontwikkeling van de 
keuzehulp. Thank you to Jack Dowie and Mette Kaltoft for you critical remarks and guidance 
during the development of the research protocol and the conduct of the protocol for the 
development of the MCDA-based patient decision aid.  
 
I also had the opportunity to travel to Canada and work with experts in the field of patient 
decision aids and MS and economic evaluations, which was made possible by the Student 
Research Award 2018 from the Association for Canada Studies in the Netherlands. Thank 
you to Nick Bansback, Larry Lynd and Mark Harrison for hosting me at the University of 
British Columbia in Vancouver, and to everyone at the departments of the Collaboration for 
Outcomes Research and Evaluation and Centre for Health Evaluation & Outcomes Sciences 
for your kindness and hospitality. Nick, thank you for collaboration and academic guidance 
on the economic evaluation during and after my stay in Vancouver, and for the lovely dinner 
with your family and colleagues during the last days of my visit to UBC. Larry and Mark, 
thank you for welcoming me at your department and giving me the opportunity to learn 
from you are your teams.  
 
Dank aan alle partijen, waaronder PATIËNT+ en Adriana Berlanga van het Knowledge 
Transfer Office, voor jullie samenwerking en het meedenken met hoe de keuzehulp in de 
klinische praktijk uitgerold zou kunnen worden.  
 
Op mijn eerste dag als junior onderzoeker kwam ik terecht op kamer 0.015 en over de jaren, 
ook gedurende mijn promotieonderzoek, heb ik met een heel aantal mensen deze kamer 
mogen delen. Wat zijn jullie allemaal belangrijk geweest om de leuke en minder leuke 
kanten van promoveren mee te delen.  
Daan, Sofie, Linda en Willemine, als eerste kwam ik bij jullie op de kamer en kon ik bij jullie 
afkijken hoe zo’n promotieonderzoek nu eigenlijk in zijn werk gaat. Een dikke dankjewel dat 
jullie mij een beetje wegwijs hebben gemaakt, maar ook voor alle kameruitjes naar de Lidl 
en gezellige lunches. Daan, van jou heb ik ook geleerd dat ik chocoladeletters nooit te lang 
moet laten liggen. Linda, de donderdag was de gezelligste dag van de week! Dit kwam de 
productiviteit niet altijd ten goede, maar de leuke gesprekken over van alles en nog wat 
waren de inhaaluren zeker waard . Sofie, wat vond ik het fijn dat we een aantal jaren een 
kamer hebben gedeeld: het sparren over onze onderzoeken, klagen over de problemen die 
we tegen kwamen in de projecten, en bijkletsen na het weekend. Ik ben zo blij voor je dat 
je – al weer twee jaar geleden - een baan hebt gevonden waar je helemaal je draai in hebt 
gevonden en ik vind het onwijs knap hoe je hebt doorgezet om je promotie af te ronden 
naast je baan én je mooie gezin. Maar eigenlijk had ik niet anders verwacht .  
Jullie konden niet eeuwig PhD studenten blijven, dus één voor één promoveerden jullie, 
verlieten jullie kamer 0.015 en kwamen er nieuwe PhD’ers in de plaats.  
Inge, met jouw komst naar 0.015 kwam er ook een heleboel gezelligheid mee, ook in de 
styling van de kamer. Je bent altijd bereid om te helpen, adviezen te geven, te sparren over 
stellingen, en je hebt een talent voor organiseren en coördineren: knap hoe jij alle ballen in 
A
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de lucht houdt. Zo fijn dat we voorlopig nog een kamer zullen blijven delen en op mekaars 
steun kunnen blijven rekenen. 
Viviënne, we hebben niet zo heel lang een kamer gedeeld, maar lang genoeg om er een 
vriendschap aan over te houden. Jouw promotieonderzoek is zeker niet zonder zijn 
uitdagingen. Knap hoe jij je door die uitdagingen heen vecht. Je positiviteit en sportiviteit 
zijn aanstekelijk, zo erg dat je me hebt laten beloven om in april een tour van 65 km te gaan 
fietsen! Super fijn dat je mijn paranimf zult zijn bij de verdediging van mijn proefschrift.  
Ruth, jouw enthousiasme straalt overal in door. Jij ziet altijd de zon al schijnen, voordat het 
onweer is opgetrokken en ik denk dat dit jouw kracht is in het afronden van je PhD. Jammer 
dat je onze kamer gaat verlaten. Ook al ga je he-le-maal naar de andere kant van het 
gebouw, ik kijk uit naar onze geplande lunches om bij te kletsen. 
Robin, nog niet zo heel lang op 0.015 en helaas ga je al weer naar een ander kamer. Gelukkig 
om een hele leuke reden: je gaat ook promotieonderzoek doen! Ik denk dat jij dat met je 
nieuwsgierigheid en je motivatie helemaal gaat rocken.  Nog maar vier jaar en dan staan we 
bij jouw promotie ;). 
 
De buurvrouwen aan de overkant! Het ontstond toen Anne, Linda, Inge en ik een 
gezamenlijke liefde voor spelletjes ontdekten tijdens één van de HSR-uitjes. Sindsdien 
hebben we een heel aantal spelletjesavonden gehad, waarbij we allemaal heel competitief 
bleken, en het groepje steeds verder uitbreidde. Dankjewel voor deze leuke avonden! Al zal 
het nu stukken moeilijker worden om nog eens een avondje te plannen, hopelijk lukt het 
toch nog eens een keer nu iedereen zich langzaam verspreidt over het land.  
 
Collega’s van de vakgroep HSR, dankjewel voor jullie behulpzaamheid en jullie gezelligheid. 
Ik denk dat de laagdrempeligheid - het even kunnen binnen lopen met een vraag, voor 
advies of een praatje - de kracht is van onze vakgroep. De gezamenlijke lunches, HSR-uitjes 
en verjaardag vlaaien dragen hier alleen maar aan bij en zorgen voor een welkome 
onderbreking van de uren achter de pc. In het bijzonder ook dank aan Janet, Brigitte en Suus 
voor alle keren dat ik met kleine en grote vragen bij jullie binnen mocht lopen en ik op jullie 
hulp kon rekenen. Naast de ondersteuning die jullie geven, maken jullie de vakgroep ook 
nog eens zo veel gezelliger.  
 
Daarnaast heb ik me ook met heel veel plezier ingezet voor de ISPOR Student Chapter. Dank 
aan de (oud-)leden van het bestuur van de ISPOR Student Chapter, Adrienne, Xavier, Ben, 
Kei Long, Marije, Inge, HoiYau, Svenja, Luca en Irina voor de workshops en seminars die we 
samen hebben mogen organiseren. Ook dank aan de collega’s van KEMTA voor de 
inhoudelijke discussies tijdens de (HTA-) seminars.  
 
Iedereen, vrienden, collega’s en kennissen, die soms bewust, maar meestal onbewust 
geholpen hebben bij het zoeken van afleiding door het juist helemaal niet over mijn werk 
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Ik heb al een hele lieve familie, en nu heb ik er ook nog een hele leuke familie bijgekregen. 
Miguel, Monique, Susan en Wilbert, dank jullie wel voor jullie hartelijke ontvangst in jullie 
familie, jullie betrokkenheid en jullie lieve woorden toen ik mijn proefschrift ingediend had 
bij de beoordelingscommissie. Muchas Gracias!  
 
Denise, Marcel, Ize, Jarne en de kleine mup die er op het moment van mijn verdediging 
misschien al net wel of net niet is. De hectiek van jullie gezin, de schaterlachen en pretoogjes 
van Ize en Jarne zorgden ervoor dat ik niet anders kon dan mijn gedachten verzetten van 
mijn proefschrift als we samen waren.  
 
Daphne en Sander, ook al kon ik niet iedere keer zeggen dat ik grote stappen had gemaakt 
– want onderzoek gaat nu vaak eenmaal langzaam - jullie altijd oprechte interesse in de 
vorderingen van mijn proefschrift was heel fijn. Nog fijner zijn de gezellige avonden samen, 
vaker met spelletjes dan zonder. Ik hoop dat daar nog veel van mogen volgen.  
 
Lieve pap, wat ik me nog goed kan herinneren is dat je uren en uren helemaal kon opgaan 
in het uitpluizen van onze stamboom. Mijn nieuwsgierigheid en drive om iets tot op het bot 
uit te zoeken, moet ik dus wel van jou hebben. Ook al ben je er al zo lang niet meer, zo heb 
je me toch geholpen om dit proefschrift te schrijven. Ik hoop dat je dit op de één of andere 
manier toch mee krijgt… 
 
Lieve mam, mijn voorbeeld op meerdere vlakken. Het was allesbehalve makkelijk toen jij er 
alleen voor kwam te staan met vier meiden. Jouw doorzettingsvermogen, jouw 
vastberadenheid om je mannetje te staan en jouw lieve en goede zorgen voor de mensen 
om je heen, bewonder ik. Dankjewel dat je er altijd voor me bent en dat je me altijd de 
vrijheid hebt gegeven om zelf uit te zoeken wat ik wilde. En hoe bijzonder was het om mijn 
tijd in Canada af te sluiten met een roadtrip door de Canadese Rockies samen met jou!  
 
Lieve Kirsten, wat ben ik blij dat ik een zus en vriendin als jij heb. We zijn er voor elkaar in 
de leuke, minder leuke en spannende perioden. Daarom ben ik ook zo ontzettend blij dat je 
mijn paranimf wilt zijn en naast mij zult staan bij de verdediging van mijn proefschrift! 
Dankjewel dat je altijd wilde luisteren naar mijn verhalen over mijn onderzoek en probeerde 
om mijn geratel te ontcijferen.  
 
Lieve Frank, al kennen wij elkaar nu pas bijna een jaar, het voelt als zo veel langer en zo 
vertrouwd. In deze korte periode ben je ook van onschatbare waarde geweest in de laatste 
maanden van het afronden van mijn proefschrift. Jouw steun in mijn werk, maar ook op alle 
andere vlakken, was en is zo ontzettend fijn, en maakt het allemaal net wat makkelijker. 
Dankjewel! Ik kan niet wachten op wat we nog allemaal samen gaan beleven, de mooie 
reizen die we gaan maken, alle momenten die we samen gaan doorbrengen en om ons eigen 
huisje te vinden. Ik houd van jou! 
A
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